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Abstract 
 
Introduction:  In patients who present with ST-elevation myocardial infarction 
(STEMI), primary percutaneous coronary intervention and the administration 
of dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) are recommended.  
This thesis aimed to determine the extent to which oral P2Y12 inhibitors 
(clopidogrel/prasugrel/ticagrelor) exert their antiplatelet effect during the acute 
phase of a STEMI compared to non-ST elevation myocardial infarction 
(NSTEMI). 
Methods:  The degree and time-course of platelet inhibition following oral 
administration of P2Y12 inhibitors was determined in 87 patients from their 
pharmacokinetic (plasma concentration) and pharmacodynamic (degree of 
platelet inhibition) profiles at 20 minutes, balloon inflation, 60 and 240 minutes 
using liquid chromatography/mass spectrometry, VerifyNow and VASP-
phosphorylation assays. 
Results: In STEMI patients, oral P2Y12 inhibitors do not provide adequate 
levels of platelet inhibition at the time of angioplasty and have a limited effect 
at 240 minutes. The NSTEMI group displayed a marked and rapid antiplatelet 
effect at all time points. A significant difference in the acute efficacy of oral 
P2Y12 inhibitors in STEMI vs NSTEMI patients (p < 0.001) was seen. 
Conclusion:  Oral P2Y12 inhibitors display delayed and attenuated 
antiplatelet effects in STEMI patients in the immediate period following 
administration of a loading dose when compared with NSTEMI patients.   
 
 
 
 
 
 iii 
 
 
Acknowledgements 
 
Firstly, I would like to thank my clinical supervisor, Professor James Cotton for 
the opportunities he has given me within the Cardiovascular Research Group 
and I am grateful for his support, guidance and encouragement throughout 
the duration of my thesis.  I would also like to thank Professor Ray Fitzpatrick 
for his support in allowing me to pursue my interest in research related 
activities. 
 
Extra special thanks to my family and in particular my mother, who is an 
amazing person, a true source of inspiration and someone who has always 
encouraged me to go the extra mile.  My brother Jawad has been supportive 
in every way possible, providing motivation, encouragement, laughter and 
occasional words of wisdom when necessary. 
 
I would also like to thank my academic supervisors, Dr Anthony Cox and 
Professor John Marriott  (University of Birmingham).  Much of my work would 
not have been possible without the support and assistance of Dr Vincent 
Amoah (Clinical Research Fellow), Dr Mike Cornes (Clinical Chemistry), Alan 
Nevill (statistician), Andrew Smallwood (Cardiovascular Research Group) and 
the Cardiac Assessment Team nurses (Fiona Shelley and Justin Lewis).  My 
pharmacy colleagues and friends, Gary Fletcher, Deborah Herriot, Jane Lewis 
and Pooja Sharma have been most helpful and supportive over the last four 
years. 
 
 iv 
 
Table of Contents 
Background .................................................................................................... 1 
Rationale behind thesis and research question ................................................ 1 
Thesis Structure .................................................................................................. 4 
Thesis layout ....................................................................................................... 7 
Publications ......................................................................................................... 8 
Chapter 1 – Introduction ............................................................................... 9 
1.1 Incidence and Prevalence of Cardiovascular Disease ............................. 9 
1.2 Risk Factors ................................................................................................. 10 
1.2.1 Modifiable risk factors: ............................................................................ 11 
1.2.2 Non-modifiable risk factors. .................................................................... 13 
1.3 Pathophysiology of ACS ............................................................................. 14 
1.4 Reperfusion Strategies for Acute Myocardial Infarction/STEMI ............... 17 
1.4.1 Thrombolysis .......................................................................................... 17 
1.4.2 Primary Percutaneous Coronary Intervention (PPCI) .............................. 18 
1.5 The Role of Platelets in ACS ....................................................................... 19 
1.6 Role of Antiplatelet Therapy ....................................................................... 22 
1.6.1 Aspirin .................................................................................................... 23 
1.6.2 Thienopyridines ...................................................................................... 25 
1.6.3 Glycoprotein IIb/IIIa Inhibitors (GPIs) ...................................................... 43 
1.7 Role of antithrombotic therapy ................................................................... 44 
1.7.1 Unfractionated heparin (UFH) ................................................................. 45 
1.7.2 Low Molecular Weight Heparin (LMWH) ................................................. 46 
1.7.3 Fondaparinux .......................................................................................... 46 
1.7.4 Bivalirudin ............................................................................................... 47 
Chapter 2 – Oral P2Y12 Inhibitors Administration and Outcomes in 
STEMI patients Undergoing PPCI -  A Single Tertiary Centre 
Retrospective Observational Analysis ....................................................... 51 
2.1 Introduction ................................................................................................. 51 
2.2 Rationale for Study ...................................................................................... 52 
2.3 Methods ....................................................................................................... 53 
2.3.1 Ethical Conduct of the Study ................................................................... 53 
2.3.2 Study Population .................................................................................... 53 
2.3.3 Study Design .......................................................................................... 53 
2.3.4 Outcome measures ................................................................................ 54 
2.4 Statistics and Data Analysis ....................................................................... 55 
2.4.1 Descriptive statistics ............................................................................... 55 
2.5 Results ......................................................................................................... 56 
2.5.1 Patient Demographics and Baseline Characteristics ............................... 56 
2.5.2 In-hospital Bleeding ................................................................................ 58 
2.5.3 In-hospital Mortality ................................................................................. 59 
2.5.4 Unadjusted 30 day Mortality ................................................................... 60 
2.5.5 Adjusted 30 day Mortality ........................................................................ 65 
2.6 Discussion ................................................................................................... 70 
2.6.1 In-hospital bleeding ................................................................................. 71 
2.6.2 Mortality .................................................................................................. 72 
2.6.3 Limitations .............................................................................................. 73 
2.7 Conclusions ................................................................................................. 73 
 v 
Chapter 3 - Pharmacokinetics and Pharmacodynamics of oral P2Y12 
inhibitors during the acute phase of a myocardial infarction: A 
Systematic Review. ...................................................................................... 75 
3.1 Introduction ................................................................................................. 75 
3.2 Study Objective ........................................................................................... 75 
3.3 Methods ....................................................................................................... 76 
3.3.1 Search Strategy ...................................................................................... 76 
3.3.2 Study Selection ....................................................................................... 76 
3.3.3 Data Synthesis ....................................................................................... 78 
3.4 Results ......................................................................................................... 78 
3.4.1 Study Selection and Data Extraction ....................................................... 78 
3.5 Discussion ................................................................................................... 82 
3.5.1 Phamacodynamic Studies ...................................................................... 82 
3.5.2 Pharmacokinetic Studies ........................................................................ 84 
3.5.3 Limitations .............................................................................................. 85 
3.6 Conclusion ................................................................................................... 85 
Chapter 4 – Materials and Methods describing the Pharmacokinetic and 
Pharmacodynamic assessment of Oral P2Y12 Inhibitors in Patients 
Undergoing Percutaneous Coronary Intervention (PCI) for Acute 
Myocardial Infarction ................................................................................... 87 
4.1 Introduction ................................................................................................. 87 
4.2 Study Objectives ......................................................................................... 88 
4.3 Study Design ............................................................................................... 89 
4.4 Study Outcome Measures ........................................................................... 89 
4.5 Materials and Methods ................................................................................ 90 
4.5.1 Subject Selection .................................................................................... 90 
4.5.2 Inclusion Criteria ..................................................................................... 91 
4.5.3 Exclusion Criteria .................................................................................... 92 
4.5.4 Withdrawal Criteria ................................................................................. 92 
4.5.6 Assessment and Follow-up ..................................................................... 93 
4.5.6.1 Subjects ............................................................................................... 93 
4.5.6.2 Sampling.............................................................................................. 93 
4.6 Pharmacodynamic Analysis ....................................................................... 95 
4.6.1 VerifyNow for aspirin and P2Y12 analysis ................................................ 95 
4.6.2 VASP Flow Cytometry ............................................................................ 98 
4.7 Pharmacokinetic Analysis ........................................................................ 100 
4.8 Statistics and Data Analysis ..................................................................... 102 
4.8.1 Interim Analyses ................................................................................... 102 
4.8.2 Number of subjects to be enrolled ........................................................ 103 
4.8.3 Definition of the end of the trial ............................................................. 103 
4.9 Ethical Considerations .............................................................................. 103 
4.9.1 Consent ................................................................................................ 103 
4.9.2 Ethics Approval ..................................................................................... 105 
Chapter 5 -  A Pharmacokinetic and Pharmacodynamic Assessment of 
Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention 
(PCI) for Acute Myocardial Infarction ....................................................... 107 
5.1 Introduction ............................................................................................... 107 
5.2 Objectives .................................................................................................. 107 
5.3 Ethical Considerations and Consent ....................................................... 107 
5.4 Materials and Methods .............................................................................. 107 
5.5 Statistics and Data Analysis ..................................................................... 107 
5.6 Results ....................................................................................................... 108 
 vi 
5.6.1 Pharmacodynamic analysis of the degree of platelet inhibition following 
clopidogrel loading (600mg) STEMI vs NSTEMI ............................................ 108 
5.6.2 Pharmacokinetic analysis of active metabolite generation following 
clopidogrel loading (600mg) STEMI vs NSTEMI ............................................ 111 
5.6.3 Correlation between platelet function assays (VerifyNow and VASP-PRI) 
and active metabolite generation. .................................................................. 113 
5.7 Discussion ................................................................................................. 114 
5.7.1 Pharmacodynamic analysis - VerifyNow ............................................... 115 
5.7.2 Pharmacodynamic analsysis – VASP-PRI(%) ....................................... 116 
5.7.3 Pharmacokinetic analysis – LC-MS/MS ................................................ 117 
5.7.4 General overview .................................................................................. 119 
5.8 Conclusion ................................................................................................. 124 
Chapter 6 - A Pharmacokinetic and Pharmacodynamic Assessment of 
Prasugrel in Patients Undergoing Percutaneous Coronary Intervention 
(PCI) for Acute Myocardial Infarction ....................................................... 127 
6.1 Introduction ............................................................................................... 127 
6.2 Objectives .................................................................................................. 127 
6.3 Ethical Considerations and Consent ....................................................... 127 
6.4 Materials and Methods .............................................................................. 127 
6.5 Statistics and Data Analysis ..................................................................... 127 
6.6 Results ....................................................................................................... 128 
6.6.1 Pharmacodynamic analysis of the degree of platelet inhibition following 
prasugrel loading (60mg) STEMI vs NSTEMI ................................................. 128 
6.6.1.1 VerifyNow Results ............................................................................. 128 
6.6.1.2 VASP-PRI (%) Results ......................................................................... 130 
6.6.2 Liquid Chromatography/Mass Spectrometry Results .......................... 132 
6.6.3 Correlation between platelet function assays, VerifyNow and VASP-PRI 
(%) and active metabolite generation/plasma concentration. ...................... 133 
6.7 Discussion ................................................................................................. 135 
6.7.1 Pharmacodynamic analysis - VerifyNow ............................................... 136 
6.7.2 Pharmacodynamic analysis -  VASP-PRI (%) ....................................... 137 
6.7.3 Pharmacokinetic analysis – LC-MS/MS ................................................ 139 
6.8 Conclusion ................................................................................................. 146 
Chapter 7 - A Pharmacokinetic and Pharmacodynamic Assessment of 
Ticagrelor in Patients Undergoing Percutaneous Coronary Intervention 
(PCI) for Acute Myocardial Infarction ....................................................... 148 
7.1 Introduction ............................................................................................... 148 
7.2 Objectives .................................................................................................. 148 
7.3 Ethical Considerations and Consent ....................................................... 148 
7.4 Materials and Methods .............................................................................. 148 
7.5 Statistics and Data Analysis ..................................................................... 148 
7.6 Results ....................................................................................................... 149 
7.6.1 Pharmacodynamic analysis of the degree of platelet inhibition following 
ticagrelor loading (180mg) in STEMI vs NSTEMI patients. ........................... 149 
7.6.1.1 VerifyNow Results ............................................................................. 149 
7.6.1.2 VASP-PRI Results ............................................................................. 151 
7.6.2 Pharmacokinetic analysis of ticagrelor and ticagrelor active metabolite 
(AR-C124910X) generation following ticagrelor loading (180mg) in STEMI vs 
NSTEMI patients. ............................................................................................. 153 
7.6.2.1 Liquid Chromatography/Mass Spectrometry Results – Ticagrelor Parent 
Compound (T-PC) ......................................................................................... 153 
7.6.2.2 Liquid Chromatography/Mass Spectrometry Results – Ticagrelor Active 
Metabolite (T-AM). ......................................................................................... 154 
 vii 
7.6.2.3 Relationship between the mean plasma concentration of ticagrelor 
parent compound and active metabolite in STEMI patients. ........................ 156 
7.6.2.4 Relationship between the mean plasma concentration of ticagrelor 
parent compound and active metabolite in NSTEMI patients. ..................... 157 
7.6.3 Correlation between platelet function assays (VerifyNow and VASP-PRI) 
and ticagrelor plasma concentration as assessed using LC-MS/MS. .......... 160 
7.7 Discussion ................................................................................................. 161 
7.7.1 Pharmacodynamic Analysis - VerifyNow ............................................... 162 
7.7.2 Pharmacodynamic analysis – VASP-PRI (%) ....................................... 163 
7.7.3 Pharmacokinetic Analysis – LC-MS/MS ................................................ 164 
7.8 Conclusion ................................................................................................. 167 
Chapter 8 -  A Pharmacodynamic Comparison of all Three Oral P2Y12 
Inhibitors in the context of STEMI vs NSTEMI in  Patients Undergoing 
Percutaneous Coronary Intervention (PCI) ............................................. 170 
8.1 Introduction ............................................................................................... 170 
8.2 Objectives .................................................................................................. 172 
8.3 Ethical Considerations and Consent ....................................................... 172 
8.4 Materials and Methods .............................................................................. 172 
8.5 Statistics and Data Analysis ..................................................................... 173 
8.6 Results ....................................................................................................... 173 
8.6.1 Pharmacodynamic analysis of the degree of platelet inhibition following 
aspirin loading (300mg) STEMI vs NSTEMI ................................................... 176 
8.6.1.1 VerifyNow Results – Aspirin ............................................................... 177 
8.6.2 Analysis of the degree of platelet inhibition following clopidogrel loading 
(600mg) compared with prasugrel loading (60mg) in STEMI and NSTEMI 
patients. ......................................................................................................... 180 
8.6.3 Analysis of the degree of platelet inhibition following clopidogrel loading 
(600mg) compared with ticagrelor loading (180mg) in STEMI and NSTEMI 
patients. ......................................................................................................... 187 
8.6.4 Analysis of the degree of platelet inhibition following prasugrel loading 
(60mg) compared with ticagrelor loading (180mg) in STEMI and NSTEMI 
patients. ......................................................................................................... 194 
8.7 Discussion ................................................................................................. 205 
8.7.1  Clopidogrel vs Prasugrel ...................................................................... 207 
8.7.2 Clopidogrel vs Ticagrelor ...................................................................... 210 
8.7.3 Prasugrel vs Ticagrelor ......................................................................... 212 
8.7.4 Clopidogrel vs Prasugrel vs Ticagrelor .................................................. 214 
8.8 Conclusion ................................................................................................. 219 
Chapter 9 – Overall Summary and Conclusions ..................................... 221 
9.1 Summary of key findings .......................................................................... 221 
9.2 General Discussion ................................................................................... 223 
9.2.1 Opioid based analgesia and antiplatelet drug interaction ...................... 228 
9.2.2 Alternative Treatment Options – antiplatelet therapy ............................. 230 
9.2.3 Alternative Treatment Options – analgesia ........................................... 232 
9.3 Limitations ............................................................................................... 233 
9.4 Future Research and Projects ................................................................. 235 
9.5 Changes in clinical practice ..................................................................... 237 
9.6 Conclusions ............................................................................................. 237 
9.7 Key messages ......................................................................................... 238 
10. Appendices........................................................................................... 240 
Appendix 1.  Case report form – antiplatelet registry data collection ......... 240 
Appendix 2. Systematic review - Inclusion and Exclusion Criteria ............. 241 
 viii 
Appendix 3. Screening questions to assess the quality and appropriateness 
of the final articles selected for scrutiny prior to inclusion in the systematic 
review. .............................................................................................................. 242 
Appendix 4. Case Report Form STEMI ........................................................... 243 
Appendix 5. Case Report Form NSTEMI ........................................................ 246 
Appendix 6. Process for sample collection from patients admitted following 
STEMI ............................................................................................................... 252 
Appendix 7. Process for sample collection from patients admitted following 
NSTEMI............................................................................................................. 253 
Appendix 8. Following approval of substantial amendment – process for 
sample collection from patients admitted following a STEMI ...................... 254 
Appendix 9. Following approval of substantial amendment - process for 
sample collection from patients admitted following a NSTEM ..................... 255 
Appendix 10 – Shortened Patient Information Sheet to obtain verbal assent 
STEMI ............................................................................................................... 256 
Appendix 11. Patient Information Sheet STEMI ............................................ 257 
Appendix 12. Patient Information Sheet NSTEMI .......................................... 260 
Appendix 13. Consent form ............................................................................ 263 
Appendix 14. Research Ethics Committee Approval Letter 2013 ................ 265 
Appendix 15. Research Ethics Committee Approval Letter 2015 ................ 271 
Appendix 16. Presentations, Publications and Abstracts ............................ 275 
Appendix 16.1 Presentations ......................................................................... 275 
Appendix 16.2 Publications arising from this thesis ....................................... 275 
Appendix 16.3 Abstracts presented following collation of results ................... 276 
Appendix 16.4 Work in Progress -  publications in preparation: ..................... 277 
11. References............................................................................................ 278 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
List of Figures 
Figure 1. Clinical manifestations of the acute coronary syndromes. .............. 15 
Figure 2. Process of atherothrombosis .......................................................... 16 
Figure 3. A pictorial description of the complex molecular and signaling 
pathways involved in platelet adhesion, activation and aggregation.  
(Adapted from Papp, Kenyeres et al 2013). ............................................ 22 
Figure 4. Absorption, biotransformation and mechanism of action of 
clopidogrel, prasugrel and ticagrelor. (Adapted from (Schomig 2009) .... 26 
Figure 5 Pathway leading to the formation of clopidogrel active metabolite ... 32 
Figure 6. Pathway leading to the formation of prasugrel active metabolite: ... 38 
Figure 7. Pathway leading to the onset of action of ticagrelor and formation of 
its active metabolite. ............................................................................... 42 
Figure 8. All cause mortality at 30 days - Kaplan-Meier Survival Curves -  
clopidogrel, prasugrel and ticagrelor. ...................................................... 61 
Figure 9. All cause mortality at 30 days - Kaplan-Meier Survival Curves – 
clopidogrel vs prasugrel .......................................................................... 62 
Figure 10. All cause mortality at 30 days - Kaplan-Meier Survival Curves – 
clopidogrel vs ticagrelor .......................................................................... 63 
Figure 11. All cause mortality at 30 days - Kaplan-Meier Survival Curves – 
prasugrel vs ticagrelor ............................................................................ 64 
Figure 12. Cox regression survival and hazard curves – clopidogrel vs 
prasugrel vs ticagrelor. ........................................................................... 66 
Figure 13. Cox regression survival and hazard curves – clopidogrel vs 
prasugrel ................................................................................................. 67 
Figure 14. Cox regression survival and hazard curves – clopidogrel vs 
ticagrelor ................................................................................................. 68 
Figure 15. Cox regression survival and hazard curves – prasugrel vs 
ticagrelor ................................................................................................. 69 
Figure 16. PRISMA-P Flow chart/Study Selection Process ........................... 81 
Figure 17.  VerifyNow mean PRUs (and standard error) after the 
administration of clopidogrel in STEMI vs NSTEMI patients. ................ 109 
Figure 18 Mean VASP-PRI (%) (and standard error) after the administration of 
clopidogrel 600mg in STEMI vs NSTEMI patients. ............................... 110 
Figure 19. Mean active metabolite generation (ng/ml) (and standard error) 
after administration of Clopidogrel in STEMI vs NSTEMI patients. ....... 112 
Figure 20. Mean VerifyNow PRUs (and standard error) following the 
administration of Prasugrel in STEMI vs NSTEMI patients ................... 129 
Figure 21. Mean VASP-PRI% (and standard error) following the 
administration of Prasugrel in STEMI vs NSTEMI patients. .................. 130 
Figure 22: Mean prasugrel active metabolite plasma concentration (ng/ml) 
(and standard error) following the administration of a prasugrel 60mg 
loading dose in STEMI vs NSTEMI patients. ........................................ 132 
Figure 23. Mean VerifyNow PRUs (and standard error) after administration of 
a 180mg ticagrelor loading dose in STEMI vs NSTEMI patients........... 150 
Figure 24. Mean VASP-PRI (%) (and standard error) following the 
administration of a 180mg ticagrelor loading dose in STEMI vs NSTEMI 
patients. ................................................................................................ 151 
Figure 25 Mean plasma concentration of ticagrelor parent compound ........ 153 
 x 
Figure 26. Mean plasma concentration of ticagrelor active metabolite (ng/ml) 
(and standard error) following administration of a loading dose in STEMI 
vs NSTEMI patients. ............................................................................. 155 
Figure 27. Mean plasma concentration (ng/ml) (and standard error) of T-PC 
vs T-AM in STEMI patients following the administration of a 180mg 
loading dose. ........................................................................................ 156 
Figure 28  Mean plasma concentration (ng/ml) (and standard error) of 
ticagrelor parent compound vs active metabolite in NSTEMI patients 
following the administration of a 180mg loading dose. ......................... 158 
Figure 29. Comparative pathways describing the absorption and metabolic 
biotransformation of oral P2Y12 inhibitors, clopidogrel, prasugrel and 
ticagrelor (adapted from Floyd et al 2012). ........................................... 172 
Figure 30. VerifyNow mean ARUs (and standard error) after administration of 
aspirin in STEMI vs NSTEMI patients. .................................................. 177 
Figure 31. VerifyNow mean PRUs (and standard error) following the 
administration of clopidogrel vs prasugrel in STEMI patients. .............. 180 
Figure 32. VerifyNow mean PRUs (and standard error) following the 
administration of clopidogrel vs prasugrel in NSTEMI patients. ............ 182 
Figure 33. Mean VASP-PRI(%) (and standard error) following the 
administration of clopidogrel vs prasugrel in STEMI patients. .............. 184 
Figure 34. Mean VASP-PRI(%) (and standard error) following the 
administration of clopidogrel vs prasugrel in NSTEMI patients. ............ 185 
Figure 35. VerifyNow mean PRUs (and standard error) following the 
administration of clopidogrel vs ticagrelor in STEMI patients. ............... 187 
Figure 36. VerifyNow mean PRUs (and standard error) following the 
administration of clopidogrel vs ticagrelor loading doses in NSTEMI 
patients. ................................................................................................ 189 
Figure 37. Mean VASP-PRI(%) (and standard error) following the 
administration of clopidogrel vs ticagrelor in STEMI patients. ............... 191 
Figure 38. Mean VASP-PRI(%) (and standard error) following the 
administration of clopidogrel vs ticagrelor in NSTEMI patients. ............ 192 
Figure 39. VerifyNow mean PRUs (and standard error) following the 
administration of prasugrel vs ticagrelor loading doses in STEMI patients.
 .............................................................................................................. 194 
Figure 40. VerifyNow mean PRUs (and standard error) following the 
administration of prasugrel vs ticagrelor loading doses in NSTEMI 
patients. ................................................................................................ 196 
Figure 41. Mean VASP-PRI(%) (and standard error) following the 
administration of prasugrel vs ticagrelor in STEMI patients. ................. 197 
Figure 42. Mean VASP-PRI(%) (and standard error) following the 
administration of prasugrel vs ticagrelor in NSTEMI patients. .............. 199 
Figure 43. VerifyNow mean PRUs (and standard error) following the 
administration of clopidogrel vs prasugrel vs ticagrelor loading doses in 
STEMI patients. .................................................................................... 200 
Figure 44. VerifyNow mean PRUs (and standard error) following the 
administration of clopidogrel vs prasugrel vs ticagrelor loading doses in 
NSTEMI patients. .................................................................................. 202 
Figure 45. Mean VASP-PRI% (and standard error) following the 
administration of clopidogrel vs prasugrel vs ticagrelor loading doses in 
STEMI patients. .................................................................................... 203 
 xi 
Figure 46. Mean VASP-PRI% (and standard error) following the 
administration of clopidogrel vs prasugrel vs ticagrelor loading doses in 
NSTEMI patients. .................................................................................. 204 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xii 
List of Tables 
Table 1. Modifiable and non-modifiable risk factors for coronary artery 
disease. .................................................................................................. 11 
Table 2. Baseline demographics and patient characteristics ......................... 56 
Table 3. Patient risk factors and co-morbidities ............................................. 57 
Table 4. Clinical parameters on admission. ................................................... 57 
Table 5. Procedural complications. ................................................................ 57 
Table 6. In-patient length of stay. ................................................................... 58 
Table 7. Discharge medications. .................................................................... 58 
Table 8. Bleeding complications. ................................................................... 58 
Table 9. Mortality outcomes (unadjusted). ..................................................... 59 
Table 10. Study and patient characteristics with key findings. ....................... 79 
Table 11. Patient allocation to treatment groups. ........................................... 91 
Table 12. Sample collection and sampling times. .......................................... 95 
Table 13. Patient allocations to treatment groups (prior to substantial 
amendment and REC re-submission). .................................................. 105 
Table 14. Baseline patient characteristics  - clopidogrel treatment group .... 108 
Table 15. Clopidogrel - VerifyNow (PRU) .................................................... 108 
Table 16. Clopidogrel - VASP-PRI (%) ........................................................ 110 
Table 17. Clopidogrel active metabolite plasma concentration (ng/ml) ........ 111 
Table 18. Correlation the degree of platelet inhibition observed using 
VerifyNow compared with VASP-PRI following the administration of a 
clopidogrel 600mg loading dose ........................................................... 113 
Table 19.  Correlation between the degree of platelet inhibition observed 
using VerifyNow compared with clopidogrel active metabolite plasma 
concentration following the administration of a 600mg loading dose. ... 114 
Table 20. Baseline patient characteristics – prasugrel treatment group. ...... 128 
Table 21. Prasugrel - VerifyNow (PRU) ....................................................... 128 
Table 22. Prasugrel – VASP-PRI (%) .......................................................... 130 
Table 23. Prasugrel active metabolite plasma concentration (ng/ml) ........... 132 
Table 24 Correlation the degree of platelet inhibition observed using 
VerifyNow compared with VASP-PRI following the administration of a 
prasugrel 60mg loading dose................................................................ 134 
Table 25.  Correlation between the degree of platelet inhibition observed 
using VerifyNow compared with prasugrel active metabolite plasma 
concentration following the administration of a 60mg loading dose. ..... 134 
Table 26. Baseline patient characteristics .................................................... 149 
Table 27. Ticagrelor VerifyNow (PRU) ......................................................... 149 
Table 28. Ticagrelor - VASP-PRI(%) ............................................................ 151 
Table 29. Ticagrelor parent compound plasma concentration (ng/ml) ......... 153 
Table 30. Ticagrelor active metabolite plasma concentration (ng/ml) .......... 154 
Table 31.  Mean plasma concentration (ng/ml) ticagrelor parent compound vs 
active metabolite in STEMI patients ...................................................... 156 
Table 32. Mean plasma concentration (ng/ml) ticagrelor parent compound vs 
active metabolite in NSTEMI patients. .................................................. 157 
Table 33. Correlation the mean plasma concentration (ng/ml) of T-PC 
compared with T-AM following the administration of a ticagrelor 180mg 
loading dose ......................................................................................... 159 
 xiii 
Table 34. Correlation the degree of platelet inhibition observed using 
VerifyNow compared with VASP-PRI following the administration of a 
ticagrelor 180mg loading dose .............................................................. 160 
Table 35.  Correlation between the degree of platelet inhibition observeusing 
VerifyNow compared with ticagrelor parent compound plasma 
concentration following the administration of a 180mg loading dose. ... 161 
Table 36.  Pharmacokinetic/Pharmacodynamic trend of ticagrelor over time
 .............................................................................................................. 167 
Table 37. Baseline characteristics of study population – STEMI vs NSTEMI
 .............................................................................................................. 173 
Table 38. Baseline characteristics - STEMI cohort ...................................... 173 
Table 39. Baseline Characteristics -  NSTEMI cohort. ................................. 174 
Table 40. Baseline characteristics of study population – Clopidogrel vs 
Prasugrel vs Ticagrelor ......................................................................... 175 
Table 41. Aspirin - VerifyNow (ARU) STEMI vs NSTEMI ............................. 177 
Table 42. VerifyNow (PRU) – Clopidogrel vs Prasugrel STEMI ................... 180 
Table 43. VerifyNow (PRU) – Clopidogrel vs Prasugrel NSTEMI ................ 182 
Table 44. VASP-PRI% – Clopidogrel vs Prasugrel STEMI .......................... 183 
Table 45. VASP-PRI% – Clopidogrel vs Prasugrel NSTEMI ........................ 185 
Table 46. VerifyNow (PRU) – Clopidogrel vs Ticagrelor STEMI .................. 187 
Table 47. VerifyNow (PRU) – Clopidogrel vs Ticagrelor NSTEMI ................ 189 
Table 48. VASP-PRI% – Clopidogrel vs Ticagrelor STEMI .......................... 190 
Table 49. VASP-PRI% – Clopidogrel vs Ticagrelor NSTEMI ....................... 192 
Table 50. VerifyNow (PRU) – Prasugrel vs Ticagrelor STEMI ..................... 194 
Table 51. VerifyNow (PRU) – Prasugrel vs Ticagrelor NSTEMI .................. 195 
Table 52. VASP-PRI% – Prasugrel vs Ticagrelor STEMI ............................ 197 
Table 53. VASP-PRI% – Prasugrel vs Ticagrelor NSTEMI .......................... 198 
Table 54. ANOVA descriptive statistics - Comparison of mean PRU over time 
following the administration of clopidogrel 600mg vs prasugrel 60mg vs 
ticagrelor 180mg in STEMI patients. ..................................................... 200 
Table 55. ANOVA descriptive statistics - Comparison of mean PRU over time 
following the administration of clopidogrel 600mg vs prasugrel 60mg vs 
ticagrelor 180mg in NSTEMI patients. .................................................. 201 
Table 56. ANOVA descriptive statistics - Comparison of change in mean 
VASP-PRI% over time following the administration of clopidogrel 600mg 
vs prasugrel 60mg vs ticagrelor 180mg in STEMI patients. .................. 203 
Table 57. ANOVA descriptive statistics - Comparison of change in mean 
VASP-PRI% over time following the administration of clopidogrel 600mg 
vs prasugrel 60mg vs ticagrelor 180mg in NSTEMI patients. ............... 204 
 
 
 
 
 
 
 
 
 
 
 
 xiv 
List of Abbreviations 
 
AA Arachadonic acid 
ACEI Angiotensin converting enzyme inhibitor 
ACS Acute coronary syndromes 
ADP Adenosine diphosphate 
A & E Accident and emergency 
AMI Acute myocardial infarction 
ANOVA Analysis of variance 
APTT Activated partial thromboplastin time 
ARB Angiotensin II receptor blocker 
ARU Aspirin response units 
AUC Area under the curve 
BARC Bleeding academic research consortium 
BMI Body mass index 
CABG Coronary artery bypass graft surgery 
C-AM Clopidogrel active metabolite 
cAMP Cyclic adenosine monophosphate 
CAD Coronary artery disease 
CARDAS Coronary artery disease database 
CASP Critical appraisal skills programme 
CHD Coronary heart disease 
CHF Congestive heart failure 
COPD Chronic obstructive pulmonary disease 
COX-1 Cyclo-oxygenase enzyme 1 
COX-2 Cyclo-oxygenase enzyme 2 
 xv 
Cmax Maximum plasma concentration 
cGMP Cyclic guanosine monophosphate 
CHD Coronary heart disease 
CRF Case report form 
CTIMP Clinical Trial of an Investigative Medicinal Product 
CVA Cerebrovascular accident 
CVD Cardiovascular disease 
CYPP450 Cytochrome P450 isoenzyme 
DAPT Dual antiplatelet therapy 
DTB Door to balloon time 
EDTA Ethylenediaminetetraacetic acid 
ECG Electrocardiogram 
ESC European Society of Cardiology 
GI Gastrointestinal 
GP IIb/IIIa Glycoprotein IIb/IIIa receptor 
GPI Glycoprotein IIb/IIIa receptor inhibitor 
GTN Glyceryl trinitrate 
Hb Haemaglobin 
HR Heart rate 
HRPR High residual platelet reactivity 
HTPR High on treatment platelet reactivity 
5-HT2A Serotinin receptor 
IPA Inhibition of platelet aggregation 
IRAS Integrated Research Applications System 
IV Intravenous 
 xvi 
LC-MS/MS Liquid chromatography in tandem with mass spectometry 
LDLC Low density lipoprotein cholesterol 
LMWH Low molecular weight heparin 
LRPR Low residual platelet reactivity 
LTA Light transmittance aggregometry 
MACE Major adverse cardiovascular event 
MACCE Major adverse cardiovascular and cerebrovascular event 
MHRA Medicines and Healthcare products Regulatory Agency 
MI Myocardial Infarction 
MBP 2-bromo-3'-methoxy acetophenone  
NICE National Institute for Health and Care Excellence 
NRES National Research Ethics Service 
NSTEMI Non-ST segment elevation myocardial infarction 
NO Nitrous oxide 
ONS Office for National Statistics 
P-AM Prasugrel active metabolite 
PAR1 Proteinase activated receptor 1 
PAR4 Proteinase activated receptor 4 
PD Pharmacokinetic 
PCI Percutaneous coronary intervention 
PGI2 Prostaglandin I2 (prostacyclin) receptor 
PGE2 Prostaglandin E2 receptor 
PGH2 Prostaglandin H2 receptor 
P-gp P-glycoprotein 
PK Pharmacokinetic 
 xvii 
PLA2 Phospolipase A2 receptor 
PO Per os 
PPCI Primary percutaneous coronary intervention 
PRI Platelet reactivity index 
PRISMA-P Preferred Reporting Items for Systematic review and Meta-
Analysis Protocols 
 
PRU P2Y12 reactivity units 
PVD Peripheral vascular disease 
REC Research ethics committee 
RLCCB Rate limiting calcium channel blocker 
RRR Relative risk reduction 
RWH The Royal Wolverhampton Hospitals NHS Trust 
SCAD Stable coronary artery disease 
SBP Systolic blood pressure 
STEMI ST segment elevation myocardial infarction 
TC Total cholesterol 
TIA Transient ischaemic attack 
T-AM Ticagrelor active metabolite 
Tmax Time taken to reach Cmax 
TP Thromboxane receptor 
T-PC Ticagrelor parent compound 
TXA2 Thromboxane A2 
UA Unstable angina 
UFH Unfractionated heparin 
UK United Kingdom 
 xviii 
VASP Vasodilator Stimulated Phosphoprotein 
VHD Valvular heart disease 
VN VerifyNow 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xix 
List of clinical trials 
 
ACCOAST-PCI A Comparison of prasugrel at the time of percutaneous 
Coronary intervention Or as pre-treatment At the time of 
diagnosis in patients with non-ST-segment elevation 
myocardial infarction. 
 
ATLANTIC-PCI Administration of Ticagrelor 
in the cath Lab or in the Ambulance for New ST 
elevation myocardial Infarction to open the Coronary 
artery. 
 
ATT Antithrombotics Trialists Collaboration 
 
CAPRIE A randomised, blinded, trial of clopidogrel versus aspirin in 
patients at risk of ischaemic events  
 
CLARITY-TIMI 
28 
Clopidogrel as Adjunctive Reperfusion Therapy -- 
Thrombolysis in Myocardial Infarction 28 
 
COGENT Clopidogrel with or without Omeprazole in Coronary Artery 
Disease 
 
CREDO Early and sustained dual oral antiplatelet therapy following 
percutaneous coronary intervention: a randomized 
controlled trial. 
 
CURE Clopidogrel in Unstable angina to prevent Recurrent 
Events (CURE) trial  
 
CURRENT 
OASIS 7 
Double-dose versus standard-dose clopidogrel and high-
dose versus low-dose aspirin in individuals undergoing 
percutaneous coronary intervention for acute coronary 
syndromes (CURRENT-OASIS 7): a randomised factorial 
trial. 
 
DISPERSE Pharmacodynamics, pharmacokinetics, and safety of the 
oral reversible P2Y12 antagonist AZD6140 with aspirin in 
patients with atherosclerosis: a double-blind comparison 
to clopidogrel with aspirin 
 
DISPERSE-2 Safety, tolerability, and initial efficacy of AZD6140, the first 
reversible oral adenosine diphosphate receptor 
antagonist, compared with clopidogrel, in patients with 
non-ST-segment elevation acute coronary syndrome. 
 xx 
 
GRAVITAS Gauging Responsiveness With A VerifyNow Assay-Impact 
On Thrombosis And Safety 
 
HORIZONS-AMI Harmonizing Outcomes with Revascularization and Stents 
in Acute Myocardial Infarction  
 
JUMBO-TIMI 26 Joint Utilization of Medications to Block Platelets 
Optimally-Thrombolysis In Myocardial Infarction 26  
 
ISAR-CHOICE 
Intracoronary Stenting and Antithrombotic Regimen: 
Choose Between 3 High Oral Doses for Immediate 
Clopidogrel Effect 
 
ISIS-2 Randomised trial of intravenous streptokinase, oral 
aspirin, both, or neither among 17,187 cases of suspected 
acute myocardial infarction: ISIS-2. ISIS-2 (Second 
International Study of Infarct Survival) 
 
PCI-CLARITY PCI-Clopidogrel as Adjunctive Reperfusion Therapy 
(CLARITY) study 
 
PCI-CURE Effects of pretreatment with clopidogrel and aspirin 
followed by long-term therapy in patients undergoing 
percutaneous coronary intervention: the PCI-CURE study. 
 
PLATO Ticagrelor versus Clopidogrel in Patients with Acute 
Coronary Syndromes 
 
PRINCIPLE-
TIME 44 
The Prasugrel in Comparison to Clopidogrel for Inhibition 
of Platelet Activation and Aggregation–Thrombolysis in 
Myocardial Infarction 44 Trial 
 
TRILOGY-ACS Targeted Platelet Inhibition to Clarify the Optimal Strategy 
to Medically Manage Acute Coronary Syndromes 
 
Background   
 
Rationale behind thesis and research question 
 
In the UK alone, up to 2.3 million people have a diagnosis of coronary heart 
disease; of this number approximately 175,000 will experience a heart attack 
or myocardial infarction.  Despite advances in both pharmacological and non-
pharmacological management, mortality following a myocardial infarction 
remains high; 11% of men and 15% of women who are admitted to hospital 
following a heart attack die within 30 days (BHF 2016).  
 
A heart attack occurs when the arteries that supply oxygen rich blood to the 
heart muscle become suddenly blocked.   Clotting blood cells called platelets 
become activated and clump together to form a clot (thrombus) within the 
narrowed vessel. If the blockage in the coronary artery is partial this leads to a 
non-ST-elevation myocardial infarction (NSTEMI) or minor heart attack.  
However, if the blockage is complete, this will lead to an ST-elevation 
myocardial infarction (STEMI) or a major heart attack. 
 
The first approach to treatment for a patient who presents with a myocardial 
infarction (MI) is to administer anti-platelet agents.  Aspirin is the first agent 
used in this context, and a second antiplatelet, such as clopidogrel, prasugrel 
or ticagrelor (P2Y12 receptor antagonists) is prescribed in combination with 
aspirin (dual anti-platelet therapy) following a heart attack.  These agents are 
administered in tablet form. 
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The second mode of treatment for a heart attack is to restore blood flow 
(reperfusion) as quickly as possible to the affected part of the heart.  A patient 
admitted following a major heart attack (STEMI) is treated with Primary 
Percutaneous Coronary Intervention (PPCI), a procedure, in which a wire and 
balloon are used to reopen the coronary artery and then a stent (a slotted 
meshed metal tube) is placed to keep the artery open.  Ninety four percent of 
all STEMIs are treated with PPCI, the mortality rate or death following a 
STEMI has fallen from 12.4% to 8.1% following the introduction of PPCI 
services within the UK (MINAP 2014). 
 
PPCI is an emergency procedure, which should be performed within 90 
minutes of a patient’s arrival at hospital (MINAP 2014).  Data derived from 
healthy volunteers or those with stable coronary artery disease indicates that 
the oral P2Y12 inhibitors take at least two hours to exert a therapeutic effect 
and provide sufficient levels of platelet inhibition (Brandt, Payne et al. 2007, 
Gurbel, Bliden et al. 2009). 
 
Until recently, the clinical efficacy of oral P2Y12 inhibitors, during the acute 
phase of a myocardial infarction was largely an under investigated area. In 
addition to the short timescales involved for PPCI, it is possible that the 
condition of STEMI itself, with the effects of concomitant treatments might limit 
the effectiveness of oral P2Y12 inhibitors.   
The physiological state of STEMI coupled with effects of severe pain and co-
administration of opioid-based analgesia may well lead to a reduction in drug 
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absorption and metabolism through direct effects on hepatic and splanchnic 
blood flow and gut motility. 
 
At the time of the conception of my research question and hypothesis there 
were little clinical human data available exploring the way in which oral P2Y12 
inhibitors are handled by the body in the immediate period following a 
myocardial infarction.   
 
The principle aims and objectives of my thesis were therefore to: 
1. Determine the degree and time course of platelet inhibition by 
clopidogrel, prasugrel and ticagrelor administered acutely prior to 
emergency PPCI, during the procedure and in the following four hours. 
2. Determine whether the state of acute STEMI reduces the absorption 
and/or subsequent clinical efficacy of oral P2Y12 inhibitors when 
compared with other acute coronary syndromes.  
 
My research will therefore aim to answer two key questions: 
 Is the speed of onset of action of oral P2Y12 inhibitors and the degree 
of platelet inhibition achieved following administration adequate for 
patients undergoing PPCI following a STEMI? 
 Is drug absorption during an acute MI the same as that during other 
less acute ACS at presentation e.g, STEMI vs NSTEMI/UA? 
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Thesis Structure 
 
Chapter 1: 
Provides a general introduction into the pathophysiology of acute coronary 
syndromes as well as describing the intricate relationship between platelet 
activation and subsequent atherothombosis.  This chapter will summarise the 
role of platelets in ACS, the reperfusion strategies adopted in the 
management of ACS and recent advances in the armamentarium of 
antithrombotic and in particular antiplatelet therapies. 
 
Chapter 2: 
Will provide a review of all STEMI patients treated at our PPCI centre over a 
five-year period to assess our local mortality and compare this against 
national figures.  In addition, this work will not only provide context with 
regards to our local patient demographic and the characteristics of the local 
population who present with and are treated for STEMI but will also form the 
basis from which the PK/PD study patient population is recruited in chapter 4. 
The work undertaken in this chapter will also allow me to map drug utilisation 
(following the administration of oral clopidogrel, prasugrel and ticagrelor) 
against clinical outcomes such as in-hospital bleeding episodes 
(cerebrovascular events, gastrointestinal bleeds and blood transfusions), in-
hospital and 30-day mortality. I independently collected all patient specific 
data, managed and maintained the patient registry and independently 
completed all statistical analyses of the results generated. 
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Chapter 3: 
I completed a systematic review to evaluate currently available evidence 
relating to the pharmacokinetics and pharmacodynamics of oral P2Y12 
inhibitors during the acute phase of a myocardial infarction; the findings of 
which further support the need to undertake and complete our research 
proposal.  The systematic review has since been published in a leading peer 
reviewed journal. 
 
Chapter 4: 
The principal aim of my thesis was to determine and quantify the 
pharmacokinetic and pharmacodynamics profiles of oral P2Y12 inhibitors 
during the acute phase of a myocardial infarction using both platelet function 
assays (pharmacodynamics) and liquid chromatography in tandem with mass 
spectrometry (pharmacokinetics). 
This chapter describes the considerations given to the trial protocol to ensure 
our practice with regards to patient recruitment; sample collection, data 
storage and analysis were in line with ethical principles.  The methodology 
used to undertake sample collection and subsequent analysis is also 
described in this chapter.  As a member of the Cardiovascular Research 
Group, I co-assisted with study management, patient identification, 
recruitment, sample collection, analysis and interpretation.  I independently 
completed all statistical analyses presented in the results sections of chapters 
5-8. 
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Chapters 5-8: 
These chapters describe pharmacokinetic and pharmacodynamic analyses 
and the results generated following the administration of clopidogrel, 
prasugrel and ticagrelor in STEMI and NSTEMI patients. 
 
Chapter 9: 
Provides a concise overview of the conclusions that can be drawn from the 
results generated and presented throughout the thesis write-up.  Limitations to 
the study design and the methods used to generate results are also discussed 
in addition to future research opportunities and proposed changes to clinical 
practice. 
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Thesis layout 
 
The pictorial outline below describes the structure of this thesis. 
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Publications 
 
The pace of change in terms of clinical and pharmacological developments in 
cardiology is so rapid, that there was a necessity to publish elements of my 
work prior to completion of my thesis.  As such the following sections of my 
thesis have been published and presented in various pharmacy and 
cardiology settings:  Chapter 1 (general review articles), chapter 3 (systematic 
review), chapter 4 (research protocol which was registered with Research 
Ethics Committee), chapters 5-9 (the findings of this thesis have been 
presented at a national cardiology meeting and published as part of the 
systematic review). 
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Chapter 1 – Introduction 
 
1.1 Incidence and Prevalence of Cardiovascular Disease 
 
Cardiovascular disease (CVD), an overarching term that encompasses 
coronary heart disease and stroke, remains the leading cause of death 
worldwide (Bhatnagar, Wickramasinghe et al. 2015).  Although survival from 
myocardial infarction (MI) has improved in England, data from the Global 
Burden of Disease Study indicates that CVD was responsible for 30% of all 
deaths worldwide and is the most common cause of death in the UK (Nichols, 
Townsend et al. 2014).  Health statistics data from 2016 indicates that in the 
UK alone, 2.3 million people have a current diagnosis of CHD, up to 188,000 
individuals will experience a heart attack, and approximately 11% of men and 
15% of women who are admitted to hospital following a heart attack will die 
within 30 days of presentation (BHF 2016).  The higher mortality observed in 
women is attributable to their older age at presentation in addition to the 
presence of a greater number of co-morbidities and risk factors, for example, 
diabetes, that may well contribute to their cardiovascular disease burden 
(Maas and Appelman 2010). 
 
CHD death rates vary according to age, gender, socioeconomic status and 
UK geographic location and ethnicity; people of South Asian origin have 
almost a 50% higher death rate compared to the general population (BHF 
2014). 
 
Despite advances over the last decade in both the interventional and 
pharmacological management of patients who present with coronary heart 
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disease (CHD), there is still significant morbidity and mortality associated with 
this condition.  Compared to 2003 where 30-day mortality for patients 
following an MI was 13% the mortality at 30 days in 2014 is 8% (MINAP 
2014). 
 
The economic burden associated with CHD is already considerable and 
continues to grow, predominantly because of improvements in the availability 
of and access to interventional strategies to manage CHD and greater uptake 
of secondary prevention measures, more and more people are surviving their 
heart attacks and living longer.  In addition, as a population the incidence of 
diabetes and obesity and their associated complications are also increasing, 
all of which contribute towards an individual’s cardiovascular disease burden.   
The economic burden of CHD relates not only to the direct healthcare related 
costs, but also to the provision of formal and informal care of patients and the 
loss of productivity that may occur following an adverse cardiac event (Leal, 
Luengo-Fernandez et al. 2006). 
1.2 Risk Factors 
The underlying cause of CVD is the presence of atherosclerosis, which refers 
to the build up of atheromatous plaques in the walls of blood vessels that 
supply the brain, heart and peripheral vasculature.  As described in table 1, a 
number of risk factors can contribute to and directly influence the 
development of atherosclerosis and in turn an individuals CVD burden. 
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Table 1. Modifiable and non-modifiable risk factors for coronary artery 
disease. 
Modifiable Non-modifiable 
Smoking Increasing age 
Dyslipidaemia Male sex 
Diabetes mellitus Family history 
Hypertension Ethnic origin 
Obesity and the metabolic 
syndrome 
Chronic kidney disease 
High calorie, high fat diet  
Physical inactivity  
 
1.2.1 Modifiable risk factors: 
Although current UK statistics indicate that the prevalence of smoking in 
adults has reduced from 46% in the early seventies to 19% in 2014, it is still 
thought to be the single most notable contributor to the development of CHD 
(HSCIC 2016).  Smoking leads to a significant 50% increase in risk of 
developing CHD and mortality from any CVD is thought to be 60% higher in 
smokers (BHF 2014).  Smoking cessation is associated with almost 
immediate benefit and as such individuals with established atherosclerosis or 
at an increased risk of developing atherosclerosis should be advised to stop 
smoking. 
 
Obesity is known to adversely affect an individuals cardiovascular health and 
increase their risk of developing CHD (Lavie, Milani et al. 2009).  The 
prevalence of obesity is increasing rapidly on a global scale; in the UK alone, 
adult obesity has increased by more than 50% in less than 10 years (BHF 
2016).  In addition, childhood obesity is on the rise also; this will in turn 
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exacerbate the problem in adulthood and will adversely contribute to an 
individuals CVD burden. 
 
Studies have demonstrated that overweight and obese people tend to be less 
physically active and often tend to consume a lower quality diet, which 
contributes further to their atherogenic risk (Buttar, Li et al. 2005).  A balanced 
healthy diet and exercise should be considered first line interventions together 
with careful surveillance for and aggressive management of diabetes, 
hypertension and dyslipidaemia to mitigate against the development and 
progression of CVD. 
 
Diabetes, is known to significantly increase an individuals risk of developing 
CVD, since hyperglycaemia and insulin resistance contribute directly to the 
development of atherosclerosis and it’s associated complication.  A strong 
positive correlation is also observed between the onset of type 2 diabetes and 
obesity, this, in turn triggers a series of complex pathways involving 
inflammatory mediators, which ultimately leads to insulin resistance (Paneni, 
Beckman et al. 2013). The development of insulin resistance secondary to 
obesity and type 2 diabetes leads to endothelial dysfunction and platelet 
aggregation thereby contributing to the development of atherothrombosis and 
the clinical manifestations of CVD (Lavie, Milani et al. 2009). 
 
Dyslipidaemias, and disorders of lipid metabolism, which result in an increase 
in low density lipoprotein cholesterol (LDLC) and total cholesterol (TC) levels 
and their subsequent contribution to the development of atherosclerosis, have 
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long been recognised as important risk factors in the development of CVD 
(Miller 2009).   
 
Hypertension is also known to increase an individuals CAD and stroke risk; 
uncontrolled and persistently elevated blood pressure (>140/90 mmHg) is 
known to cause adverse changes in peripheral and coronary vasculature in 
addition to changes in the cardiac conduction system and myocardial 
structure and function.  These changes eventually manifest as cardiac 
dysrhythmias such as atrial fibrillation, systolic or diastolic dysfunction of the 
myocardium or coronary artery disease in the form of unstable angina or 
myocardial infarction.  The latter association between hypertension and 
myocardial infarction is well documented in that persistently elevated blood 
pressures are known to not only initiate, but also accelerate the process of 
atherosclerosis, causing endothelial dysfunction and subsequent 
atherosclerotic plaque rupture (Dunn 1983, Rakugi, Yu et al. 1996). 
 
Often time, modifiable risk factors tend to present simultaneously in an 
individual; modification of risk factors through implementing dietary and 
lifestyle changes and optimising the management of co-morbidities can lead 
to a significant reduction in an individuals CVD burden. 
1.2.2 Non-modifiable risk factors. 
Atherosclerosis is a natural consequence of aging, and aging is a major risk 
factor for atherosclerotic disease.  As such, advancing age is considered to be 
an important determinant of an individual’s risk of developing CVD.  This is in 
part due to the cumulative impact of a worsening risk factor profile in 
 14 
combination with the degenerative processes that are associated with aging 
(National Institute for Health and Care Excellence 2014).  Gender is also 
significant in terms of risk; CAD is more common and often presents earlier in 
men than in women.  The incidence of CAD in women increases rapidly once 
they become menopausal, at which point their risk profile is similar to that 
seen in men (BHF 2016).  An individual’s family history is considered to be 
significant when atherosclerotic disease and/or an adverse cardiac event 
manifests in a first-degree male relative before the age of 55 years or female 
relative before the age of 65 years.  Such an individual then has a positive 
family history of premature CAD.   
 
Ethnicity is also known to impact an individuals CVD risk; mortality from CAD 
is 50% higher in individuals from South Asian origin living in the UK.  Afro-
caribbeans on the other hand have a lower prevelance of CHD, but greater 
incidence of stroke and end-stage renal failure.  Although increased 
prevalence of risk factors, including dyslipidaemias, insulin resistance and 
reduced physical activity explain much of this risk, genetic factors in both 
ethnicities and are thought to contribute significantly to their CVD risk (BHF 
2016). 
 
1.3 Pathophysiology of ACS 
Cardiovascular disease can present as a variety of clinical syndromes that are 
either cerebrovascular or coronary in origin.  Cardiovascular manifestations of 
CHD are described using the umbrella term of the acute coronary syndromes 
(ACS), which refers to a spectrum of clinical presentations of the same 
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underlying disease process (atherosclerosis) and encompasses conditions 
such as unstable angina (UA), non ST-elevation myocardial infarction 
(NSTEMI) and ST-elevation myocardial infarction (STEMI) as described in 
figure 1.  Disease severity and prognosis often worsens as we progress from 
UA through to STEMI. 
  
Figure 1. Clinical manifestations of the acute coronary syndromes. 
 
Atherosclerosis is the common underlying cause of ACS, the onset of which 
and speed of progression will vary between individuals and will be influenced 
by the presence of risk factors such as smoking, family history and presence 
of co-morbidities such as diabetes.  As the atheromatous plaques grow in size 
they can become unstable and rupture; the subsequent endothelial and 
vascular damage that occurs acts as a stimulus to platelet adherence, 
activation and aggregation, leading to thrombus formation at the site of 
damage (figures 2 and 3) (Hall and Mazer 2011). 
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Figure 2. Process of atherothrombosis 
 
 
 
The development of atherosclerosis is associated with significant morbidity 
and mortality in patients with cardiovascular disease (Alexander and Peterson 
2010).  The exact nature of the relationship between atherosclerosis, platelets 
and thrombosis was first described in the early 70’s (Steele, Weily et al. 
1973).  Steele et al proposed the concept of “platelet survival time” as a 
measure of the interaction of platelets with a vascular surface; the idea being 
that a reduction in platelet survival time would occur in the following 
scenarios; rupture of an atherosclerotic plaque, in response to turbulent blood 
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flow induced by an irregular lumen (endothelial dysfunction) or due to 
excessive circulating catecholamines (Steele, Weily et al. 1973).  Platelet 
exposure to such endothelial dysfunction will lead to platelet aggregation and 
subsequent thrombus formation; which can lead to a partial obstruction 
(NSTEMI) or complete obstruction of a coronary artery (STEMI).  The 
corresponding reduction in the delivery of oxygenated blood to the area of the 
myocardium usually supplied by the infarcted artery leads to myocardial cell 
death/necrosis and is characterised by ECG changes and the presence of 
cardiac biomarkers that are released as a result of myocardial cell 
death/necrosis. 
 
1.4 Reperfusion Strategies for Acute Myocardial Infarction/STEMI 
The principal aim of treatment for patients who present following a myocardial 
infarction is to ensure timely, rapid and complete restoration of blood flow to 
the affected section of the myocardium to limit the extent and degree of 
myocardial cell death and thereby limit infarct size, preserve left ventricular 
function and ultimately improve long-term survival (Keeley, Boura et al. 2003). 
 
1.4.1 Thrombolysis 
The role of thrombolytic agents such as streptokinase became firmly 
established as a reperfusion strategy in the early 90’s following publication of 
the landmark ISIS-2 study.  As part of ISIS-2, 17,187 participants with 
suspected acute myocardial infarction were randomised to treatment with 
either streptokinase monotherapy, aspirin monotherapy, a combination of 
streptokinase and aspirin or placebo.  The results of ISIS-2 demonstrated that 
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in the context of acute MI, administration of streptokinase or aspirin was 
associated with a significant reduction in mortality of 25% and 24% 
respectively, however, the combination was associated with a statistically 
significant reduction in mortality of 42% (P<0.001) (ISIS-2CollaborativeGroup 
1988). 
Whilst thrombolysis proved to be an effective treatment option, the risk of 
early reinfarction following its administration is associated with adverse 
outcomes and increased mortality (Barbash, Birnbaum et al. 2001).  In 
addition, there are a number of contra-indications, which must be considered 
prior to its use; recent trauma, gastro-instestinal bleed within the last month, 
ischaemic stroke within the last 6 months, recent intracranial haemorrhage 
(Lyengar and Godbole 2011).  
 
1.4.2 Primary Percutaneous Coronary Intervention (PPCI) 
Pecutaneous coronary intervention (PCI) refers to a process in which the 
infarct related artery is viewed via angiography and a wire and balloon are 
used to reopen the artery (angioplasty) and a coronary artery stent is 
implanted to maintain artery patency and prevent re-occlusion. 
Primary PCI (PPCI) is defined as “an emergent percutaneous coronary 
intervention in the setting of a STEMI” (Steg, James et al. 2012). In order to 
ensure the maximum amount of myocardial salvage and ensure optimal 
benefit in terms of survival, PPCI should be completed within 120 minutes of 
the onset of chest pain (Steg, James et al. 2012).   
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A quantitative review conducted by Keeley et al found that PPCI when 
compared with thrombolysis was shown to be associated with clear benefits in 
terms of reducing the incidence of major adverse cardiovascular events 
(MACE), such as non-fatal reinfarction and stroke, as well as improving both 
short and long term survival/mortality.  The combined end point of death, non-
fatal MI and stroke was statistically significantly lower when patients were 
treated with PPCI compared to thrombolytic therapy with a reduction of 8% 
and 14% respectively (p <0.0001) (Keeley, Boura et al. 2003).   
1.5 The Role of Platelets in ACS 
Platelets are anucleate cells produced in the bone marrow, and have a life 
span of approximately 10 days (Papp, Kenyeres et al. 2013).  They are 
important components in the process of normal haemostasis as well as 
pathological thrombus formation (Michelson 2011). 
 
Platelet adhesion, activation and subsequent aggregation, secondary to 
endovascular injury or plaque rupture are key stages that contribute to the 
underlying pathophysiology of the acute coronary syndromes (Libby 2013).    
The content of the atherosclerotic plaque contains both inflammatory cells and 
thrombogenic materials such as tissue factor, a potent procoagulant molecule 
which stimulates thrombin generation.  Vascular injury secondary to 
atherosclerotic plaque rupture exposes subendothelial collagen and von 
Willebrand factor, in addition to releasing tissue factor.  All three acts as 
powerful agonists, which stimulate the process of platelet adhesion and 
subsequent activation (Libby 2013, Papp, Kenyeres et al. 2013).  In addition, 
a complex series of signal transduction/activation pathways that complement 
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this initial process (figure 3), also occur, for example adenosine diphosphate 
(ADP) binds to P2Y1 and P2Y12 receptors, thromboxane A2 binds to the 
thromboxane receptor (TP), thrombin binds to the proteinase-activated 
receptor, PAR1 and PAR4, serotonin binds to the 5-HT2A receptor and 
epinephrine via the alpha-adrenergic receptor (Papp, Kenyeres et al. 2013).  
As shown in figure 3, the binding of these agonists to their corresponding 
receptors results in an increase in intracellular calcium, which in turn reduces 
cyclic AMP levels, causing the activation of phospholipase A2.  
Phospholipase A2, cleaves arachadonic acid from membrane lipids, which will 
first be converted to prostaglandin H2 by the ubiquitous cyclo-oxygenase 1 
enzyme and then to thromboxane A2 (TXA2) by thromboxane synthase 
(Jennings 2009, Papp, Kenyeres et al. 2013).  TXA2 is a potent 
vasoconstrictor and platelet agonist, which amplifies the process of platelet 
activation through releasing intracellular granules, which stimulate the binding 
of other agonists to receptors on the platelets surface.  In addition, this 
process results in a rapid change in platelet morphology such that the platelet 
itself changes from a smooth disk like structure into an irregular spheroid, 
thereby facilitating the process of platelet aggregation and perpetuating 
thrombus formation (Davi and Patrono 2007, Papp, Kenyeres et al. 2013). 
 
The binding of agonists such as ADP, thrombin and serotonin to their 
corresponding extracellular receptors on the platelet surface, stimulates an 
increase in intracellular calcium, which in turn decreases levels of cAMP, 
resulting in a decrease in the phosphorylation of vasodilator activated 
phosphoprotein (VASP).  Dephosporylated VASP facilitates conformational 
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changes that lead to the activation of the integrin GP IIb/IIIa receptor (Papp, 
Kenyeres et al. 2013).  The activated GP IIb/IIIa receptor binds fibrinogen 
which allows for bridging and cross-linking between activated platelet and 
allows for further thrombus formation as well as maintaining the stability of the 
thrombus formed (Davi and Patrono 2007, Jennings 2009).   This is a 
haemostatic mechanism designed to limit the degree of vascular 
injury/damage and allow for vascular repair.  However, within the confines of 
the affected coronary artery, this healing process leads to partial/complete 
coronary occlusion and subsequent myocardial cell death/necrosis, which 
manifests as a myocardial infarction. 
 
The role of ADP as a potent platelet agonist is well established and is the 
target of pharamacological intervention.  ADP is known to stimulate two G-
protein coupled receptors; P2Y1 and P2Y12.  While the P2Y12 receptor is the 
main target of drug therapy, co-activation of both P2Y1 and P2Y12 receptors 
is necessary for ADP-induced platelet aggregation to occur (Jennings 2009). 
 
The complex molecular and signaling pathways involved in the process of 
platelet adhesion, activation and subsequent aggregation are described in 
figure 3 (Papp, Kenyeres et al. 2013) .   
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Figure 3. A pictorial description of the complex molecular and signaling 
pathways involved in platelet adhesion, activation and aggregation.  
(Adapted from Papp, Kenyeres et al 2013). 
 
 
 
1.6 Role of Antiplatelet Therapy 
In view of the underlying pathophysiology of ACS and significant contribution 
of platelets, antiplatelet agents are an integral component of the 
pharmacological management of patients who present following an ACS. 
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Antithrombotic therapies and in particular antiplatelet therapies play a pivotal 
role in preventing further ischaemic complications and major adverse 
cardiovascular and cerebrovascular events (MACCE) secondary to 
atherothrombosis as well as reducing the likelihood of stent thrombosis 
following PCI (Angiolillo, Guzman et al. 2008).   Stent thrombosis, although 
rare with an incidence of 1-2%, is associated with a mortality of 40% and is 
considered to be a potentially fatal complication of the procedure which can 
be mitigated against through the appropriate use of antithrombotic therapies 
(Curzen 2012). 
 
1.6.1 Aspirin 
Aspirin is the most commonly prescribed antiplatelet agent in clinical practice, 
and when prescribed at low doses (75-150mg daily) irreversibly inhibits cyclo-
oxygenase-1, which subsequently inhibits thromboxane A2 (TXA2), which is a 
potent platelet activator (Angiolillo, Guzman et al. 2008).  The mechanism of 
action of aspirin is outlined in figures 3 and 5; when administered at low doses 
(75mg – 150mg once daily) it acts as an indirect inhibitor of the cyclo-
oxygenase 1 (COX-1) enzyme, which in turn inhibits the production of 
thromboxane A2 (TXA2) a potent platelet agonist stimulating platelet 
activation (Angiolillo, Guzman et al. 2008). 
 
The clinical benefit and efficacy of aspirin as an antiplatelet became apparent 
following the publication of the landmark ISIS-2 trial, in which aspirin 
monotherapy was associated with a 23% reduction in mortality in the context 
of AMI (ISIS-2CollaborativeGroup 1988), this positive finding was further 
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supported by the results of a meta-analysis undertaken by the Antithrombotics 
Trialists Collaboration, which demonstrated that aspirin was associated with a 
25% reduction in serious adverse events without any increase in bleeding 
events (Antithrombotic Trialists 2002).  
 
In view of the significant benefits in terms of reduction in cardiovascular and 
cerebrovascular events, aspirin is now recommended for long-term use in 
patients who present with atherosclerotic vascular disease and, as such, the 
place of aspirin in the context of secondary prevention is well defined. This 
recommendation is further supported by the National Institute for Health and 
Care Excellence (NICE) guidelines for secondary prevention following an MI 
in which it is stipulated that all patients should be offered aspirin following a 
heart attack and that it should be continued indefinitely (NICE CG 167 2013). 
  
In terms of primary prevention, aspirin is no longer recommended in patients 
with a low-to-moderate cardiovascular risk; that is those with a calculated 
lifetime risk of <20% over 10 years (Antithrombotic Trialists' (ATT) 
Collaboration 2009).  In this patient group, aspirin results in only a 1.5% 
reduction in the incidence of vascular events but is associated with a two-to-
three fold increase in bleeding risk, such that the marginal cardiovascular 
benefit seen is far outweighed by the increase in the risk of adverse effects, 
particularly that of gastrointestinal bleeds/irritation (Antithrombotic Trialists' 
(ATT) Collaboration 2009). 
 
Whilst a robust body of evidence supports the use of aspirin in the context of 
ACS, prescribing aspirin alone will not be sufficient to prevent against further 
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adverse cardiac events during the acute of phase of an ACS or following 
coronary artery stent implantation, since multiple pathways are involved in the 
process of platelet activation (figure 3) (Libby 2013). 
 
The need to target these alternative platelet signaling pathways resulted in the 
development of the thienopyridines; a group of agents that inhibit the process 
of platelet activation and aggregation through blockade of the ADP/P2Y12 
receptor found on the platelet surface (Gurbel and Tantry 2009).  Preventing 
the binding of ADP to its receptor on the platelet surface stops activation of 
the glycoprotein IIb/IIIa complex and thereby inhibits platelet aggregation 
(Gurbel and Tantry, 2009). 
 
1.6.2 Thienopyridines 
 
The thienopyridines are a class of antiplatelet agents, which exert their 
therapeutic effect through blockade/inhibition of the platelet P2Y12 receptor, 
as shown in figures 3 and 4. 
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Figure 4. Absorption, biotransformation and mechanism of action of 
clopidogrel, prasugrel and ticagrelor. (Adapted from (Schomig 2009) 
 
 
1.6.2.1 Clopidogrel 
Clopidogrel, a second-generation thienopyridine, is a selective and 
irreversible inhibitor of the P2Y12 receptor and is indicated for the prevention 
of atherothrombotic events in patients with peripheral arterial disease, 
following an ischaemic stroke, a myocardial infarction or after elective PCI 
(Khan 2015).  In the context of secondary prevention following an ACS or 
following coronary artery stent implantation, dual antiplatelet therapy (aspirin 
in addition to clopidogrel) has been the pharmacological standard of care 
since the early nineties.  Numerous clinical trials have demonstrated a 
significant reduction in MACCE and in particular stent thrombosis in patients 
who receive a coronary artery stent following NSTEMI and STEMI (Mehta, 
Yusuf et al. 2001, Yusuf, Zhao et al. 2001, Sabatine, Cannon et al. 2005, 
Sabatine, Morrow et al. 2005).  
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1.6.2.1.1 Clopidogrel – Clinical Efficacy 
CAPRIE, a randomised, blinded, international trial, was the first to 
demonstrate long-term benefits of clopidogrel administration in comparison to 
aspirin in terms of reducing combined risk of myocardial infarction, ischaemic 
stroke, or vascular death in patients with atherosclerotic vascular disease 
(Committee 1996).  Whilst the outcomes of CAPRIE were able to support 
long-term safety and efficacy of clopidogrel, its benefits in terms of pre-
treatment and maintenance therapy following a myocardial infarction became 
apparent following publication of CLARITY-TIMI 28.  CLARITY-TIMI 28 was 
able to demonstrate that pre-treatment with clopidogrel in addition to aspirin 
and thrombolytic therapy, in patients under the age of 75 years, was 
associated with a significant reduction in cardiovascular death, recurrent 
myocardial infarction and stroke, without any increase in bleeding 
complications (Sabatine, Morrow et al. 2005). PCI-CLARITY; a planned pre-
specified sub-group analysis of CLARITY-TIMI 28, was the first study to 
provide clinical justification for pre-treatment with clopidogrel prior to PCI in 
STEMI patients. Pre-procedural administration of a clopidogrel 300mg loading 
dose was associated with a reduction in cardiovascular death and ischaemic 
events prior to and after PCI (Sabatine, Cannon et al. 2005).  
Further benefits of clopidogrel pre-treatment in addition to long-term 
maintenance therapy were proven in the PCI-CURE study (a sub-group 
analysis of the CURE trial) and subsequent CREDO study. 
 
In PCI-CURE, the primary study end-point, a composite of CV death, MI or 
urgent target vessel revascularisation at 30 days was significantly lower (p = 
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0.03) in the clopidogrel arm compared with placebo (Mehta, Yusuf et al. 
2001).  However, it should be noted that the patient cohort recruited to PCI-
CURE consisted of NSTEMI patients and that they received treatment with 
clopidogrel for a median of 6 days prior to PCI (Mehta, Yusuf et al. 2001).   
 
This strategy is not reflective of current UK based practice, since a loading 
dose is administered immediately prior to PCI and the recommended time 
from diagnosis to mechanical reperfusion for NSTEMIs is now 24 to 72 hours 
and for STEMIs 120 minutes (MINAP 2014).  The benefits of pre-treatment 
and long-term therapy post-PCI were again demonstrated in the CREDO trial, 
in which dual antiplatelet therapy (clopidogrel plus aspirin) for a 12-month 
duration of treatment was associated with a 26.9% relative reduction in a 
composite of death, MI and stroke (Steinhubl, Berger et al. 2002).  With 
regards to pre-treatment, a loading dose of 300mg was utilised during the 
study, and the investigators were able to provide some insights into the 
optimal timing of administration.  A pre-specified sub-group analysis of 
patients who received clopidogrel 6 hours before PCI was able to 
demonstrate a RRR of 38.6% compared with no reduction in primary end-
point when administered less than 6 hours before PCI. 
 
In view of such robust and unequivacol clinical trial data, the place in therapy 
of clopidogrel in combination with aspirin is firmly established and spans the 
entire spectrum of ACS, inclusive of patients who are medically managed as 
well as though who undergo revascularisation with PCI.  As such, DAPT has 
become the cornerstone of management for patients who present with ACS 
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(Mehta, Yusuf et al. 2001, Yusuf, Zhao et al. 2001, Steinhubl, Berger et al. 
2002). 
 
However, despite this overwhelming evidence of efficacy following the 
administration of clopidogrel in addition to aspirin, up to 20% of patients will 
experience recurrent ischaemic events (Curzen and Sambu 2011).  This 
apparent treatment failure has been extensively investigated and attributed to 
not only physiological changes that occur during a STEMI, but also secondary 
to suboptimal characteristics of clopidogrel. 
 
As described in figures 4 and 5, clopidogrel is an inactive prodrug which itself 
does not effect platelet inhibition (Hall and Mazer 2011).  Following a two-step 
hepatic metabolic conversion process, dependent on the cP450 3A4 and 
2C19 enzymes, it is converted to an active metabolite which exerts an 
antiplatelet effect through preventing binding of ADP to the P2Y12 receptor on 
the platelet surface (Gurbel and Tantry 2009). 
 
However, owing to significant heterogeneity in the activity of the 2C19 allele in 
the general population, this process of biotransformation is subject to marked 
inter-patient variability in terms of the degree of platelet inhibition achieved 
(Hall and Mazer 2011).  Up to 30% of patients will have defective 2C19 alleles 
(genetic polymorphisms) and will be unable to convert clopidogrel to its active 
form, such patients are at increased risk of further MACCE and 
atherothrombotic/ischaemic complications such as stent thrombosis 
(Contractor and Ruparelia 2012). Whilst genetic testing might provide insights 
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into those who may have a defective 2C19 allele prior to treatment with 
clopidogrel, the test requires considerable expertise and skill to carry out, is 
expensive and time consuming, all of which render its use impractical in a 
clinical setting (Curzen and Sambu 2011).   
 
Clopidogrel is also relatively slow in terms of its speed of onset; even after 
administration of a 600mg loading dose in healthy volunteers, only 
approximately 40% inhibition of platelet aggregation (IPA) is seen after 4-6 
hours (Tapp, Shantsila et al. 2010), which is a particular disadvantage in the 
context of STEMI managed by PPCI, since optimal levels of platelet inhibition 
are required at the time of the procedure. 
 
ST-segment elevation myocardial infarction (STEMI) is a highly prothrombotic 
state such that there is an increase in intrinsic platelet reactivity even before 
the administration of clopidogrel contributes to the high platelet reactivity seen 
while on treatment, which is an occurrence known as, high residual platelet 
reactivity (HRPR) (Frelinger, Michelson et al. 2011).  This intrinsic platelet 
reactivity in conjunction with the limitations faced with clopidogrel are 
responsible for the recurrent ischaemic complications seen particularly 
following PCI (Aradi, Vorobcsuk et al. 2010, Alexopoulos 2013). 
 
A number of strategies have been investigated in an attempt to overcome the 
limitations experienced with clopidogrel and address the issue of HRPR. 
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As demonstrated by the outcomes of the GRAVITAS study, increasing the 
maintenance dose of clopidogrel to compensate for HRPR did not yield any 
increase in the degree of IPA (Price, Angiolillo et al. 2011).  Furthermore, the 
findings of ISAR-CHOICE indicate that increasing the loading dose of 
clopidogrel beyond 600mg did not offer any additional IPA due to the limited 
absorption of clopidogrel from the gut (von Beckerath, Taubert et al. 2005).  
 
The outcomes of CURRENT-OASIS 7 demonstrated that alternative treatment 
regimes (600mg loading followed by 150mg daily for 7 days then 75mg daily 
therafter) may result in a significant reduction in the incidence of stent 
thrombosis, but at the expense of increased bleeding (Mehta, Tanguay et al. 
2010).  Whilst increasing the loading and maintenance doses proved to be 
beneficial in terms of achieving slightly faster and moderately greater degrees 
of IPA, these advantages were not apparent in those patients in whom 
clopidogrel could not be converted to its active form i.e. the clopidogrel non-
responders.   
 
1.6.2.1.2 Clopidogrel – Mechanism of Action 
Clopidogrel selectively and irreversibly binds to the P2Y12 receptor and 
prevents the binding of the agonist adenosine diphosphate (ADP) and thereby 
inhibits further platelet aggregation (Park, Franchi et al. 2015).  Clopidogrel is 
an inactive prodrug, of which, following oral ingestion and subsequent 
gastrointestinal absorption, approximately 85% of the parent compound 
undergoes enzymatic degradation by esterases into an inactive carboxylic 
acid derivative (Heestermans, van Werkum et al. 2008, Frelinger, Bhatt et al. 
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2013).  As a result only 15% of the orally ingested parent compound is 
available to undergo the two-step metabolic biotransformation process 
(dependent upon the cytochrome P450 3A4 and 2C19 isoenzymes) to 
generate the active thiol metabolite that is capable of binding to the ADP 
P2Y12 receptor to exert its therapeutic effect leading to inhibition of platelet 
aggregation (figure 5). 
 
Figure 5 Pathway leading to the formation of clopidogrel active 
metabolite 
 
In terms of absorption, in vitro experiments undertaken using colonic 
adenocarcinoma (Caco-2) cell lines have demonstrated that the absorption of 
clopidogrel via intestinal epithelial cells is dependent upon the P-glycoprotein 
(P-gp) efflux transporter (Floyd, Passacquale et al. 2012).  Variability in the 
expression of P-gp within the small intestine can affect intestinal permeability 
and subsequent oral bioavailability of clopidogrel.  This in combination with 
genetic polymorphisms of the CYP isoenzymes can have a profound effect on 
the ability of an individual to convert the inactive parent compound into the 
active metabolite. 
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In summary, the non-uniform and inconsistent levels of platelet inhibition 
observed following the administration of clopidogrel are attributable to several 
sub-optimal characteristics; inter-individual variability in response following 
oral administration, secondary to impaired gastric absorption and hepatic 
biotransformation as well as genetic polymorphisms of the 2C19 allele are 
known to limit the clinical efficacy of clopidogrel in practice.  To address these 
limitations, alternative therapeutic agents were investigated. 
 
1.6.2.2 Prasugrel 
 
Prasugrel, a third generation thienopyridine, is a selective and irreversible 
inhibitor of the P2Y12 receptor and its mechanism of action is outlined in 
figures 4 and 6.  Like clopidogrel it is also a prodrug that requires metabolic 
conversion to its active form, however, this process relies on a single step 
only, making it less prone to genetic polymorphism and inter-individual 
variability in response.  Consequently, prasugrel is able to achieve far more 
rapid (80% IPA achieved within 30 minutes), greater and more consistent 
levels of IPA compared to clopidogrel (Payne, Li et al. 2007, Wiviott, 
Braunwald et al. 2007) (Brandt, Payne et al. 2007). 
1.6.2.2.1 Prasugrel – Clinical Efficacy 
Following the positive outcomes of the TRITON-TIMI 38 study, in which 
prasugrel demonstrated superiority over clopidogrel in terms of reducing 
MACCE and ischaemic complications such as ST, the National Institute for 
Health and Care Excellence (NICE) and the European Society of Cardiology 
(ESC) recommend the use of prasugrel in patients who present following a 
STEMI and are suitable for PPCI.  In addition, based on the outcomes of 
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TRITON-TIMI 38, NICE also recommend the use prasugrel in diabetic 
NSTEMI patients who receive a coronary artery stent and in those who 
present with stent thrombosis whilst receiving treatment with clopidogrel 
(Wiviott, Braunwald et al. 2007, NICE TAG 317 2014). 
 
While prasugrel demonstrates favourable outcomes in STEMI patients 
undergoing PPCI and those who are diabetic NSTEMIs treated with PCI, a 
post-hoc sub group analysis of TRITON-TIMI 38 identified three patient 
groups in whom the administration of prasugrel resulted in little net clinical 
benefit and increased bleeding risk; those aged over 75 years and under 60 
kg and in those with a history of previous stroke or TIA. In this latter group, 
prasugrel administration resulted in harm and is therefore contraindicated 
(Wiviott, Braunwald et al. 2007).  
 
In order to determine the safety and efficacy of prasugrel in patients who are 
medically managed, the TRILOGY-ACS study was conducted.  The findings 
of TRILOGY-ACS demonstrate that the administration of prasugrel to patients 
presenting with unstable angina (UA)/NSTEMI who were to be managed 
without revascularization, does not lead to improved clinical outcomes when 
compared with clopidogrel and was associated with a similar bleeding risk 
(Roe, Armstrong et al. 2012).   The findings of TRILOGY-ACS in combination 
with TRITON-TIMI 38 very much inform the place in therapy of prasugrel and 
restrict its use to only in those who undergo mechanical reperfusion with PCI. 
 
In line with standard practice, some cardiac centres pretreat UA/NSTEMI 
patients with prasugrel prior to PCI. However, findings from the recently 
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published ACCOAST-PCI study indicate that pretreatment with prasugrel 
does not reduce the rate of major ischaemic events but does increase the 
incidence of major bleeding complications (Montalescot, Collet et al. 2014).     
As a consequence, the manufacturer’s advice and recommendation from 
NICE regarding the management of NSTEMI patients who are scheduled to 
undergo PCI has been updated to reflect these findings and indicate that the 
loading dose for UA/NSTEMI patients should be given at the time of PCI and 
not beforehand (NICE TAG 317 2014, eMC 2016a). 
 
Whilst the place in therapy of clopidogrel became firmly established following 
the publication of a number of clinical trials demonstrating efficacy across the 
spectrum of ACS, limitations associated with its use, as described earlier led 
to the development of alternative antiplatelet agents.  Prasugrel, a third 
generation thienopyridine is a suitable alternative to clopidogrel in certain 
clinical settings providing rapid, greater and more consistent levels of platelet 
inhibition (Wiviott, Braunwald et al. 2007). 
 
The current dosing strategy for prasugrel was determined following 
completion of the JUMBO-TIMI 26 study; a randomised phase II dose finding 
study in which various loading and maintenance doses of prasugrel were 
compared with clopidogrel in order to determine the most effective dose and 
assess the safety of prasugrel in patients undergoing PCI (Wiviott, Antman et 
al. 2005).  This was not an outcome driven study, but rather one in which the 
incidence of TIMI minor or major bleeding complications and adverse cardiac 
events were assessed after 30 days of treatment.  With regards to safety, 
there were no differences in terms of bleeding complications between 
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prasugrel and clopidogrel groups, in addition, a numerically lower incidence of 
complications such as myocardial infarction, clinical target vessel thrombosis 
and recurrent ischaemia was observed in prasugrel treated patients (Wiviott, 
Antman et al. 2005).  The findings of JUMBO-TIMI 26 formed the foundation 
of the pivotal phase III TRITON-TIMI 38 clinical trial in which the safety and 
efficacy of prasugrel was assessed. 
 
The subsequent adoption and uptake into clinical practice of prasugrel was 
driven by the outcomes of the landmark TRITON-TIMI 38 in which prasugrel 
was found to be superior to clopidogrel in patients undergoing PCI leading to 
statistically significant reductions in myocardial infarction, urgent target vessel 
revascularisation and stent thrombosis (Wiviott, Braunwald et al. 2007).  The 
primary efficacy end-point of non-fatal MI was found to be statistically 
significantly lower in the prasugrel group compared with the clopidogrel group; 
7.3% vs 9.5% (p < 0.001), however, there was no significant difference in the 
rates of death (2.4% vs 2.1% p = 0.31) or stroke (1% vs 1% p = 0.93).  The 
incidence of stent thrombosis was found to be statistically significantly lower in 
the prasugrel group compared with the clopidogrel group (1.1% vs 2.4%, p 
<0.0001).  Whilst the reduction in non-fatal MI and stent thrombosis were 
beneficial clinical outcomes, their occurrence was accompanied by an 
increase in serious and non-fatal bleeding episodes particularly in prasugrel 
treated patients (Wiviott, Braunwald et al. 2007). Whilst TRITON-TIMI 38 
provides insights into the superiority of prasugrel, it should be noted that the 
comparative loading dose of clopidogrel was 300mg administered after 
angiography.   
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The PRINCIPLE-TIMI 44 study, undertaken in healthy subjects or patients 
with stable CAD (SCAD) was designed to assess the degree of platelet 
inhibition of prasugrel 60mg against clopidogrel 600mg in patients undergoing 
PCI. The findings showed superiority of prasugrel in terms of platelet inhibition 
when compared with even a 600mg loading and 150mg daily maintenance 
dose of clopidogrel, indicating that, increasing the maintenance and loading 
doses of clopidogrel is still not able to overcome inherent limitations such as 
inter-individual variability in response, genetic polymorphisms of CYP2C19 or 
the slow and variable onset of action (Wiviott, Trenk et al. 2007). 
 
Whilst the outcomes of TRITON-TIMI 38 were compelling enough to lead to a 
change in national and international guideline recommendations regarding its 
place in therapy, a major limitation to it use lies in the fact that its superiority is 
restricted to a niche group of patients; STEMI or diabetic NSTEMIs 
undergoing PCI or those who present with stent thrombosis (Steg, James et 
al. 2012).  As such, prasugrel is a drug that is mainly restricted for use in the 
context of PCI only and not in those who are to be medically managed. 
1.6.2.2.2  Prasugrel – Mechanism of Action 
Prasugel, a third generation thienopyridine prodrug, which following 
conversion to its metabolically active form results in irreversible inhibition of 
the platelet P2Y12 receptor and subsequent inhibition of platelet aggregation. 
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Figure 6. Pathway leading to the formation of prasugrel active 
metabolite: 
 
Although prasugrel is a prodrug like clopidogrel, the pathways leading to the 
generation of the active metabolite differ between the two drugs.  As 
described in figure 6, hydrolysis by intestinal esterases result in a large 
proportion of orally administered clopidogrel (85%) being converted into an 
inactive metabolite (Floyd, Passacquale et al. 2012).  In contrast, however, 
intestinal esterases are essential for the conversion of all orally administered 
prasugrel to its active metabolite, as described in figure 20 above.   
 
Following oral administration, prasugrel undergoes rapid and complete 
gastrointestinal absorption, hydrolysis via intestinal esterases leads to the 
generation of an inactive intermediate compound (R-95913), which then 
undergoes rapid metabolic conversion to the active metabolite, R-138727 
(Wallentin 2009, Floyd, Passacquale et al. 2012).  This is a process that 
occurs predominantly in the intestine as opposed to the liver.   
 
The key cytochrome P450 isoenzymes responsible for this metabolic 
biotransformation are CYP3A4, CYP2B6 and CYP2C19 (Floyd, Passacquale 
et al. 2012).  This is in contrast to clopidogrel, which relies predominantly on 
CYP2C19 in both the intestine and liver to facilitate conversion of the inactive 
parent compound into its active metabolite.  As discussed, in chapter 5, 
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genetic polymorphisms within the 2C19 allele, render it inactive in up to 30% 
of patients leading to significant variability in response (Contractor and 
Ruparelia 2012).   
 
Since the pathways involved in the generation of the prasugrel active 
metabolite (P-AM) are not solely reliant on the CYP2C19 allele, its 
pharmacokinetic and pharmacodynamic profile is more efficient, streamlined 
and predictable when compared with clopidogrel.  The one step conversion 
process following oral administration results in greater and more consistent 
levels of P-AM generation and levels of platelet inhibition; prasugrel is also 
much faster in terms of its onset of action resulting in approximately 80% 
inhibition of platelet aggregation (IPA) within 2 hours of administration in 
healthy patients (Brandt, Payne et al. 2007, Payne, Li et al. 2007). 
 
 
1.6.2.3 Ticagrelor 
Ticagrelor, as described in chapter 1, is a novel first in class antiplatelet agent 
belonging to the cyclopentyltriazolopyrimidine (CPTP) family. 
It has a number of distinguishing pharmacokinetic and pharmacodynamic 
characteristics when compared to the thienopyridines; it is a directly acting, 
reversible inhibitor of the P2Y12 receptor (Floyd, Passacquale et al. 2012).  
As well as allowing for greater and more consistent levels of platelet inhibition, 
like prasugrel, ticagrelor is subject to rapid and complete gastrointestinal 
absorption following oral administration (Wallentin 2009, Wallentin, Becker et 
al. 2009).  
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Since ticagrelor does not require biotransformation to its active form and as 
such it is rapid in terms of its speed of onset and is able to achieve far greater 
and more consistent level of IPA compared to clopidogrel (Wallentin, Becker 
et al. 2009).   
1.6.2.3.1 Ticagrelor – Clinical Efficacy 
The findings of the PLATO study in which ticagrelor was compared to 
clopidogrel demonstrated improved clinical outcomes (reduction in MACE and 
stent thrombosis) across the spectrum of ACS patients; those who were 
medically managed and those undergoing PCI following an NSTEMI/STEMI.  
In addition, ticagrelor is the first antiplatelet since aspirin that has shown a 
mortality benefit in AMI/STEMI patients as demonstrated by a 22% relative 
risk reduction in all cause mortality (Wallentin, Becker et al. 2009). 
 
During PLATO, a number of “off-target” side effects of ticagrelor were noted 
and thought to be attributable to ticagrelor-induced blockage of adenosine re-
uptake into red blood cells (eMC 2016b).   Dyspnoea, the first of these side 
effects, was found to be a troublesome, yet transient effect experienced on 
treatment initiation, in approximately 13.8% of patients (eMC, 2014b).  As a 
consequence, ticagrelor should be prescribed with caution in patients with a 
history of asthma or chronic obstructive pulmonary disorder (COPD) (eMC, 
2014b). The administration of ticagrelor is also associated with an increase in 
the incidence of asymptomatic ventricular pauses; however, these are self-
limiting and do not require any intervention. Following initiation, ticagrelor can 
also cause an increase in creatinine and uric acid levels, however, the former 
is not associated with a decline in renal function (eMC, 2014b).  Although, not 
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a strict contraindication, the use of ticagrelor in patients with a with a history of 
cerebrovascular accident (CVA)/ stroke, should be undertaken with caution, 
since its administration is associated with an increase in non- CABG-related 
and, in particular, intracranial bleeding (Wallentin, Becker et al. 2009, eMC 
2016b). 
 
The superiority of ticagrelor over clopidogrel has been verified by the 
outcomes of a number of phase II studies, the first of which, a dose finding 
study (DISPERSE) was able to demonstrate that ticagrelor administration is 
associated with less variable and more rapid inhibition of platelet aggregation 
compared with clopidogrel (Husted, Emanuelsson et al. 2006).  As a follow on 
from this initial dose finding study, a subsequent study, DISPERSE II, was 
undertaken to establish the safety and efficacy of ticagrelor when compared 
with clopidogrel in patients with NSTEMI.  In terms of efficacy, ticagrelor was 
able to provide levels of platelet inhibition that were far greater than those 
achieved with clopidogrel.  From a safety and tolerability perspective, there 
was no statistically significant difference in the incidence of minor or major 
bleeding events between the two groups.  Although, patients assigned to 
treatment with ticagrelor experienced a greater incidence of dyspnoea and 
asymptomatic ventricular pauses; neither of which was significant enough to 
warrant the discontinuation of treatment (Cannon, Husted et al. 2007). 
The findings of DISPERSE and DISPERSE II acted as a platform for the 
pivotal phase III study, PLATO, which was a randomised double blind parallel 
group study in which the safety and efficacy of ticagrelor was compared with 
clopidogrel in ACS patients.  As described in chapter 1, ticagrelor was found 
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to be superior to clopidogrel in reducing the incidence of the primary efficacy 
end point, which was a composite of myocardial infarction, stroke or death 
from a vascular cause (Wallentin, Becker et al. 2009).  The benefits are 
largely driven by the improved pharmacokinetic and pharmacodynamic profile 
of ticagrelor compared to clopidogrel. 
 
1.6.2.3.2 Ticagrelor - Mechanism of Action 
The mechanism of action by which ticagrelor is able to exert its antiplatelet 
effect is not dependent on the cytochrome P450 pathway, as such the parent 
compound does not require metabolic bioactivation in order to exert its 
antiplatelet effect (figure 7).  A major advantage of this being that ticagrelor is 
not subject to genetic polymorphisms, as observed with clopidogrel.  Despite 
this advantage, ticagrelor-parent compound (T-PC) is subject to enzymatic 
degradation, which is driven predominantly by the cytochrome P450 3A4 
isoenzyme, leading to the generation of T-AM, which is present at a third of 
the concentration of T-PC and is comparable in terms of its potency at the 
P2Y12 receptor (Husted, Emanuelsson et al. 2006, Wallentin 2009, Teng, 
Oliver et al. 2010). 
 
Figure 7. Pathway leading to the onset of action of ticagrelor and 
formation of its active metabolite. 
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In terms of onset of action, the administration of a 180mg loading dose of 
ticagrelor is able to provide 40% IPA within 30 minutes of administration 
compared to 5% IPA following the administration of clopidogrel 600mg loading 
dose; these values increased to 80% and 20% respectively after one hour 
(Gurbel, Bliden et al. 2009).  These data support previous findings which state 
that ticagrelor allows for greater, more rapid, consistent and predictable levels 
of IPA when compared to clopidogrel. 
 
The non-competitive binding of ticagrelor to the P2Y12 receptor also allows 
for its reversibility of action; following discontinuation of the drug, ticagrelor 
displays faster offset and recovery of platelet function when compared with 
clopidogrel.  Within 24 hours of cessation, a 50% recovery of platelet function 
is observed, and it is this reversibility and rapid offset of effect that warrants 
twice daily dosing of ticagrelor (Gurbel, Bliden et al. 2009). 
 
1.6.3 Glycoprotein IIb/IIIa Inhibitors (GPIs) 
As shown in figures 3 and 5, the final common pathway of platelet 
aggregation involves activation of the glycoprotein IIb/IIIa receptor, which is 
located on the platelet surface.  Binding of fibrinogen to the GPIIb/IIIa 
receptor, allows for cross-linking between platelets, which subsequently leads 
to platelet aggregation and thrombus formation (Saucedo 2010). 
The glycoprotein IIb/IIIa inhibitors (GPIs) are administered as an adjunctive 
intravenous antiplatelet agent, since they allow for greater levels of platelet 
inhibition to be achieved prior to and at the time of PCI.  Failure to achieve 
optimal levels of IPA has been shown to be associated with procedural MI and 
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catheter related thrombosis albeit at an increased risk of bleeding (Quinn, 
Plow et al. 2002, Van de Werf, Bax et al. 2008, Alexander and Peterson 
2010). 
 
In recent years, particularly following the introduction into clinical practice of 
the more potent P2Y12 inhibitors, the use of GPIs has diminished since both 
prasugrel and ticagrelor allow for greater and more consistent levels of 
platelet inhibition.  This reduction in usage has also been influenced by 
studies that question the additive value of these agents to DAPT, in view of 
the extra bleeding complications that may arise secondary to such potent 
antiplatelet combinations (De Luca, Suryapranata et al. 2005, Mehilli, Kastrati 
et al. 2009).  Although a rare phenomenon, thrombocytopaenia has also been 
reported following the administration of GPIs, and is thought to be mediated 
by the formation of antibodies that are stimulated by conformational changes 
in the GP IIb/IIIa receptor induced by the medication.  Although an immune-
mediated response, the development of antibodies does not diminish the 
efficacy of subsequently administered doses (Stangl and Lewis 2010, 
Kristensen, Wurtz et al. 2012). 
1.7 Role of antithrombotic therapy 
 
The administration of anticoagulant therapy during PCI performs two 
functions; firstly it prevents further thrombotic complications secondary to 
plaque rupture following angioplasty and/or stenting e.g periprocedural MI, 
and secondly it prevents periprocedural thrombus formation on intravascular 
catheters and PCI equipment e.g. catheter related thrombosis (Rao and 
Ohman 2010).  Therefore, anticoagulants are important adjuncts in the 
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management of patients who undergo emergent or elective PCI.  Since the 
procedure itself can also cause endovascular damage, which as described 
above, increases the stimulation of the procoagulant tissue factor, leading to 
the activation of the coagulation cascade and activated factor Xa.  Factor Xa 
leads to thrombin generation, the conversion of fibrinogen to fibrin and 
subsequent thrombus formation.  This process occurs simultaneously to that 
of platelet adhesion, activation and aggregation as described in figure 5. 
 
In view of the significant contribution of thrombin to thrombus formation, as a 
result of its pro-inflammatory effects and ability to stimulate platelet activation 
and enhance aggregation, it is also an important target for antithrombotic 
therapies, particularly for patients who present following an ACS. 
 
1.7.1 Unfractionated heparin (UFH) 
Anticoagulation with heparin has been the mainstay of treatment for decades 
in PCI.  UFH has a very short, dose-dependent half-life such that heparin is 
administered as a continuous infusion and the dose administered is dictated 
by the activated partial thromboplastin time (APTT) or activated clotting time 
(ACT).  In view of the short half-life, discontinuation of the infusion is sufficient 
to allow for reversal of its anticoagulant effect.   
While UFH is an effective thrombin inhibitor, monotherapy is not sufficient to 
protect against further ischaemic complications, since heparin administration 
itself can cause induce platelet activation and contribute to the formation of 
further platelet aggregates (Xiao and Theroux 1998).  However, in the era of 
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modern PCI, the administration of potent oral antiplatelet agents and 
concomitant administration of GPIs mitigate against this complication. 
1.7.2 Low Molecular Weight Heparin (LMWH) 
The LMWHs carry less risk of bleeding than UFH and do not require any 
monitoring since they can be administered as simple and convenient 
once/twice daily sub-cutaneous injections depending on the indication. The 
safety and efficacy of enoxaparin compared with UFH has been investigated 
as part of a meta-analysis.  The authors found that in the context of ACS, 
there was a marginally significant reduction in the composite end point of 
death at 30 days or MI in those treated with enoxaparin, but no statistically 
significant difference in the incidence of major bleeding events (Murphy, 
Gibson et al. 2007).  A more recent systematic review and meta-analysis 
reported the superiority of enoxaparin over UFH in reducing bleeding 
complications and mortality following PPCI (Silvain, Beygui et al. 2012). 
Despite these encouraging outcomes, the uptake of LMWH into clinical 
practice in the context of peri-procedural administration during PCI remains 
low. 
 
1.7.3 Fondaparinux 
Fondaparinux, a synthetic pentasacchiride, is an irreversible inhibitor of factor 
Xa (figure 8) with a half-life of 17 to 21 hours (Rao and Ohman 2010). 
Fondaparinux has been investigated in the context on NSTEMI/UA in the 
OASIS-5 study, in which it was compared against enoxaparin.  The study 
demonstrated that in the short term, fondaparinux was comparable to 
enoxaparin in the prevention of death, MI or recurrent ischeamia in those 
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presenting within 24 hours with symptoms of UA/NSTEMI.  Fondaparinux also 
demonstrated a reduced risk of bleeding, which was associated with lower, 
long-term mortality (Fifth Organization to Assess Strategies in Acute Ischemic 
Syndromes, Yusuf et al. 2006). 
 
However, it should be noted that during the study there was an increase in the 
incidence of catheter related thrombus during PCI (Rao and Ohman 2010).  In 
addition, fondaparinux is known to accumulate in patients with renal 
impairment, such that its use is contra-indicated in patients with a CrCl < 
20ml/min (eMC 2014). 
 
While OASIS-5 supports the use of fondaparinux in NSTEMI/UA, the OASIS-6 
trial, which investigated fondaparinux administration and outcomes in STEMI 
patients reported a significantly higher rate of reinfarction and death at 30 
days in those assigned to the fondaparinux arm.  For this reason the 
administration of fondaparinux during primary PCI is not recommended 
(Yusuf, Mehta et al. 2006). 
 
 
1.7.4 Bivalirudin 
Bivalirudin, as described in figure 8, is a reversible direct thrombin inhibitor 
with additional antiplatelet activity, that is recommended for use in 
combination with aspirin and clopidogrel in patients who present following a 
STEMI and are to undergo primary PCI (NICE TAG 230 2011). 
The main study on which the NICE recommendation is based, is HORIZONS-
AMI, in which patients presenting with STEMI intended for PPCI were 
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assigned to bivalirudin or heparin plus a glycoprotein IIb/IIIa inhibitor.  Both 
treatment arms received aspirin and clopidogrel (NICE TAG 230 2011). 
 
The findings of HORIZONS-AMI demonstrated that bivalirudin alone, as 
compared with heparin plus glycoprotein IIb/IIIa inhibitors, led to a significant 
reduction in major bleeding and an overall reduction in net adverse clinical 
events at 30 days.  There was however, an increase in the incidence of acute 
stent thrombosis (Stone, Witzenbichler et al. 2008).  In clinical practice 
however, clopidogrel is rarely administered during PPCI and as such the use 
of more potent agents such as prasugrel and ticagrelor may well mitigate 
against the risk of acute stent thrombosis (Khan 2015). 
 
Following the publication of HEAT-PPCI, the clinical efficacy of bivalirudin in 
PPCI/STEMI patients has recently been called into question. Patients were 
recruited following an admission for PPCI and were assigned to either 
bivalirudin plus bail-out GP IIb/IIIa inhibitor (abxicimab) or heparin plus bail out 
GP IIb/IIIa inhibitor (abciximab).  The investigators found that bivalirudin was 
inferior to UFH, and was associated with an increase in adverse 
cardiovascular events, due to increased incidence of myocardial infarction 
and stent thrombosis.  In addition, the administration of bivalirudin did not lead 
to a reduction in major bleeding as claimed in HORIZONS-AMI (Shahzad, 
Kemp et al. 2014).  As a consequence, the use of bivalirudin has very much 
fallen out of favour in clinical practice. 
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Figure 8. Antithrombotic drugs used in the treatment of ACS.  This 
figure outlines the targets of antithrombotic drugs used to inhibit 
coagulation and platelet aggregation during and after thrombus 
formation. 
 
 
 
 
Combinations of antithrombotic therapies are necessary to target all pathways 
that may lead to further ischaemic and thrombotic complications in patients 
who are treated with PCI following an ACS, figure 9 outlines the place in 
therapy of the many drugs available for use in this context. 
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Figure 9. The place in therapy of anticoagulant and antiplatelet agents 
utilised in the management of patients who undergo PCI following 
presentation. 
 
The information in this chapter provides some background to the complexities 
of antithrombotic management of patients who present with cardiovascular 
disease; the remainder of my thesis will focus on the role of oral antiplatelet 
therapies and their clinical efficacy in the context of ACS. 
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Chapter 2 – Oral P2Y12 Inhibitors Administration and 
Outcomes in STEMI patients Undergoing PPCI -  A Single 
Tertiary Centre Retrospective Observational Analysis 
 
2.1 Introduction 
The contemporary management of ST-elevation myocardial infarction 
(STEMI) patients has evolved considerably in the last decade with primary 
percutaneous coronary intervention (PPCI) being the default revascularisation 
strategy of choice in this setting (Keeley, Boura et al. 2003, Thomas and 
French 2014, De Luca, Danchin et al. 2015).  In this time we have also seen 
an evolution in stent technologies with each generation of stents promising 
improved biocompatibility and reduced thrombogenicity, leading to a reduction 
in the incidence of stent thrombosis; a rare yet potentially fatal complication 
associated with coronary artery stent implantation (Curzen and Sambu 2011, 
Mehran, Giustino et al. 2015, Riegger, Byrne et al. 2015). 
The success of mechanical reperfusion is also dependent on the 
administration of antithrombotic therapies, prior to, during and post stent 
implantation (as described in chapter 1, figure 9).  To this end, early treatment 
with dual antiplatelet therapy consisting of aspirin plus an oral P2Y12 inhibitor 
forms the cornerstone of management for patients who not only present with 
STEMI but all forms of acute coronary syndromes (De Luca, Danchin et al. 
2015).  STEMI, the most malignant manifestation of this clinical syndrome 
requires the administration of oral P2Y12 inhibitors that are rapid in terms of 
their onset, as well as providing adequate and consistent levels of platelet 
inhibition at the time of angioplasty and stent deployment.  Although, a robust 
clinical evidence base supports clopidogrel, its use in clinical practice has 
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been superseded by the introduction of newer more potent agents, prasugrel 
and ticagrelor. With the latter agents providing a superior pharmacological 
profile which translates into improved clinical outcomes such as reduction in 
cardiovascular death, recurrent MI and stroke (Wiviott, Braunwald et al. 2007, 
Wallentin, Becker et al. 2009) National and international guideline 
recommendations indicate the use of all three agents in the context of STEMI, 
however, the place in therapy of prasugrel and ticagrelor is assigned a higher 
class/level of recommendation (NICE TAG 236 2011, Steg, James et al. 2012, 
NICE CG 167 2013, NICE TAG 317 2014).   
 
2.2 Rationale for Study 
Cardiovascular medicine is a dynamic and rapidly evolving field in which the 
timescales from the publication of clinically sound and robust evidence to 
implementation into clinical practice are often short.  Our tertiary referral 
centre has used all three agents in the last five years as part of the PPCI 
pathway. We aimed to determine the effect of clopidogrel, prasugrel and 
ticagrelor in a “real-world, all comers” STEMI population on the incidence of 
in-hospital and 30 day mortality in addition to their impact on the incidence of 
in-hospital major bleeding. 
In addition, this data will form the basis from which our patient population in 
subsequent chapters in which the pharmacokinetic and pharmacodynamic 
activity of the oral P2Y12 inhibitors in the context of acute myocardial 
infarction will be investigated. 
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2.3 Methods 
2.3.1 Ethical Conduct of the Study 
Data were collated as part of a service evaluation and clinical audit; all patient 
identifiable information was anonymised prior to analysis.  Since all analyses 
were undertaken on anonymised patient data, ethics approval and patient 
consent was not required as advised by our local ethics committee and 
Caldicott Guardian. 
 
2.3.2 Study Population 
The Heart and Lung Centre is the tertiary specialist cardiac centre for the 
Black Country and surrounding areas serving a population of approximately 
1.2 million and carrying out approximately 500 PPCI cases per year. Data 
were collected for 2,200 patients who were treated at the The Royal 
Wolverhampton Hospitals NHS Trust (RWH) Heart and Lung Centre following 
activation of the primary percutaneous coronary intervention (PPCI) pathway 
(2010-2015).  This time period was selected since it is reflective of the 
temporal changes in and uptake of guideline recommendations with regards 
to the use of oral P2Y12 inhibitors in the context of STEMI at our centre. 
2.3.3 Study Design 
This was a single centre retrospective observational analysis of specified 
outcomes following the administration of oral P2Y12 inhibitors prior to PPCI.  
Data relating to patient clinical characteristics/demographics, clinical 
presentation and procedural outcomes were collated from multiple data 
sources by a single individual (myself) to minimise bias and maintain the 
quality of data collected.  Information sources utilised included, local coronary 
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artery disease databases (CARDAS), Office for National Statisitics (ONS) 
data, pharmacy systems and patient health records. 
 
2.3.4 Outcome measures 
The primary outcome measure for this study was to assess 30-day mortality 
(all cause and cardiovascular only) following the administration of an oral 
P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) in patients presenting 
with ST-elevation myocardial infarction (STEMI) immediately prior to primary 
percutaneous coronary intervention (PPCI).   
 
Secondary endpoints were, in-hospital mortality and in-hospital major 
bleeding.  Major bleeding was assessed using the BARC score and was 
defined as a gastrointestinal, intracerebral or a bleed requiring a blood 
transfusion (Mehran, Rao et al. 2011). 
 
Patients were categorised into three treatment groups based on the choice of 
oral P2Y12 inhibitor administered immediately prior to angioplasty/PPCI.  
These groups were: (1) clopidogrel group, (2) prasugrel group and (3) 
ticagrelor group.  Background and peri-procedural antithrombotic therapy 
consisted of aspirin, unfractionated heparin +/- bivalirudin and/or a 
glycoprotein IIb/IIIa receptor antagonist (abciximab/eptifibatide/tirofiban).   
 
Mortality data were retrieved from the UK Office for National Statistics (ONS) 
using the patient’s NHS number to track status (alive/dead).  This was further 
linked to the patient’s unique hospital identifier to collate information relating 
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to pre-, peri-procedural and post-procedural drug administration and 
outcomes such as in-hospital complications e.g. bleeding.  Local databases, 
CARDAS, pharmacy systems and electronic patients records were utilised to 
retrieve this data.  All data were recorded in a case report form (CRF) which 
can be viewed in appendix 1. 
2.4 Statistics and Data Analysis 
2.4.1 Descriptive statistics 
Continuous variables are described as a mean ± standard deviation (± SD).  
Categorical data are expressed as frequencies and percentages.  Continuous 
variables were analysed using student’s independent samples t-test or 
analysis of variance where appropriate.  Categorical variables were assessed 
using chi-square (Pearson’s chi square) test as appropriate. 
 
The unadjusted effect of oral P2Y12 inhibitor administration on overall 
survival/mortality was determined through construction of Kaplan-Meier 
survival curves and compared using the log-rank test.  In order to correct for 
known confounders, the effect of oral P2Y12 inhibitor administration on overall 
survival was also assessed using a Cox regression analysis, which was 
adjusted/standardised for age, gender, weight, diabetes, previous MI/PCI, call 
to balloon time and systolic blood pressure, heart rate and haemaglobin on 
admission.  Other co-morbidities included in the standardised analysis were 
peripheral vascular disease, congestive heart failure, atrial fibrillation, chronic 
obstructive pulmonary disease, family history, hypercholesterolaemia and 
hypertension. 
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I undertook all statistical calculations and analyses using SPSS (SPSS 
Version 21; SPSS, Inc, Chicago, Il, USA).  A p-value < 0.05 (2-sided) was 
considered statistically significant. 
2.5 Results 
 
The study population comprised 2,200 patients with a confirmed diagnosis of 
ST-elevation myocardial infarction who underwent PPCI at our centre. 
2.5.1 Patient Demographics and Baseline Characteristics 
 
Table 2. Baseline demographics and patient characteristics 
 Clopidogrel  
(n = 570) 
Prasugrel  
(n = 1058) 
Ticagrelor 
 (n = 592) 
p-value 
Age (mean) years 70.51 ±13.36 59.36 ± 10.84 63.04 ± 12.72 < 0.0001 
Sex Male 338 (68) 848 (80) 446 (75) < 0.0001 
Sex Female 182 (32) 210 (20) 146 (25) < 0.0001 
Ethnicity 
Caucasian 
519 (91) 961 (91) 533 (90) 0.765 
Ethnicity Asian 46 (8.1) 87 (8.2) 56 (9.5) 0.765 
Ethnicity Black 5 (0.9) 10 (0.9) 3 (0.5) 0.765 
(Continous variables are expressed as a mean ± SD. Categorical data are expressed as frequencies 
and percentages) 
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Table 3. Patient risk factors and co-morbidities 
 Clopidogrel 
(n = 570) 
Prasugrel  
(n = 1058) 
Ticagrelor  
(n = 592) 
p-value 
Previous MI 81 (14) 107 (10) 67 (11) 0.056 
Previous CABG 14 (2.5) 17 (1.6) 8 (1.4) 0.314 
Previous PCI 61 (10.7) 90 (8.5) 51 (8.6) 0.256 
Diabetes Mellitus 88 (15) 129 (12.2) 73 (12.3) 0.298 
Diabetes Insulin 22 (3.9) 41 (3.9) 29 (4.9) 0.298 
BMI 26.62 ± 
4.84 
28.20  ± 
5.51 
27.92 ± 5.30 < 0.0001 
PVD 38 (6.7) 48 (4.5) 20 (3.4) 0.028 
CHD 161 (28) 190 (18) 141 (24) < 0.0001 
Previous 
Stroke/TIA/CVA 
92 (16) 20 (1.8) 22 (3.7) < 0.0001 
CHF 15 (2.6) 8 (0.8) 9 (1.5) 0.010 
Atrial Fibrillation 64 (11.2) 37 (3.5) 24 (4.0) < 0.0001 
COPD/Asthma 60 (10.5) 98 (9.3) 77 (13) 0.060 
VHD 41 (7.2) 21 (2) 15 (2.5) < 0.0001 
Family History CAD 182 (32) 398 (37.6) 190 (32) < 0.0001 
Current Smoker 166 (29) 487 (46) 228 (38.5) < 0.0001 
Ex Smoker 158 (28) 221 (21) 121 (20) < 0.0001 
Hypercholesterolaemia 378 (66) 795 (75) 425 (72) 0.001 
Hypertension 312 (55) 430 (41) 277 (47) < 0.0001 
 
 
Table 4. Clinical parameters on admission. 
 Clopidogrel  
(n = 570) 
Prasugrel  
(n = 1058) 
Ticagrelor  
(n = 592) 
p-value 
Total Cholesterol 4.80 ±1.27 5.21 ± 1.23 5.13 ±1.33 < 0.0001 
SBP 121.64 ±23.48 123.51± 23.38 125.3 ±23.74 0.034 
HR 77.28 ±15.55 77.44 ±15.63 78.74 ± 18.40 0.229 
Hb 134.5 ±19.25 142  ±16.61 139.4 ±20.13 < 0.0001 
Glucose 8.39 ± 3.66 8.34 ± 3.30 8.98  ± 4.43 0.005 
Creatinine 102.1 ± 64.3 89.41 ±48.76 89.13 ±33.02 < 0.0001 
 
 
Table 5. Procedural complications. 
 Clopidogrel  
(n = 570) 
Prasugrel  
(n = 1058) 
Ticagrelor  
(n = 592) 
p-value 
CVA Embolic 3 (0.5) 4 (0.4) 1 (0.2) 0.591 
CVA Bleed 1 (0.2) 0 (0) 0 (0) 0.235 
Blood Transfusion 30 (5.3) 19 (1.8) 26 (4.4) < 0.0001 
GI Bleed 8 (1.4) 4 (0.4) 7 (1.2) 0.061 
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Table 6. In-patient length of stay. 
  Clopidogrel  
(n = 570) 
Prasugrel  
(n = 1058) 
Ticagrelor  
(n = 592) 
p-value 
Days 5.34 ± 7.15 3.62 ± 5.46 4.50 ± 6.93 <0.0001 
 
The average length of stay (LOS) following a STEMI in our centre is 3 days, 
our results indicate a significant difference in LOS between the three groups 
with clopidogrel treated patients having the highest and prasugrel the lowest 
LOS (5.34 ±7.15 vs 3.62 ± 5.46, p = 0.000).   
 
 
Table 7. Discharge medications. 
  Clopidogrel  
(n = 570) 
Prasugrel  
(n = 1058) 
Ticagrelor 
 (n = 592) 
p-value 
Aspirin 551 (97) 1034 (90) 576 (97) 0.443 
Clopidogrel 454 95 41 < 0.0001 
Prasugrel 77 927 0 < 0.0001 
Ticagrelor 23 15 535 < 0.0001 
Beta 
blocker/RLCCB 
452 (79) 920 (87) 535 (90) < 0.0001 
ACEI/ARB 446 (78) 950 (90) 522 (88) < 0.0001 
Statin 524 (92) 1014 (96) 570 (96) 0.001 
Aldosterone 
antagonist 
25 (4.4) 59 (5.6) 48 (8.1) 0.021 
 
The data in table 7 indicates that all patients following PPCI were discharged 
on the recommended combination of secondary prevention medications. 
2.5.2 In-hospital Bleeding 
 
Table 8. Bleeding complications. 
 Clopidogrel  
(n = 570) 
Prasugrel 
(n = 1058) 
Ticagrelor  
(n = 592) 
p-value 
CVA Embolic 3 (0.5) 4 (0.4) 1 (0.2) 0.591 
CVA Bleed 1 (0.2) 0 (0) 0 (0) 0.235 
Blood 
Transfusion 
30 (5.3) 19 (1.8) 26 (4.4) < 0.0001 
GI Bleed 8 (1.4) 4 (0.4) 7 (1.2) 0.061 
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Our data indicates that across the three treatment groups there is no 
significant difference in bleeding complications relating to CVA events and GI 
bleeds as demonstrated in table 8.  However, there is a highly statistically 
significant difference (p = 0.000) in the number of patients who required a 
blood transfusion in the clopidogrel treatment arm.  This again is most likely 
attributable to the age of patients who were assigned to treatment with 
clopidogrel (as described in table 2). 
 
 
Table 9. Mortality outcomes (unadjusted). 
 Clopidogrel  
(n = 570) 
Prasugrel  
(n = 1058) 
Ticagrelor  
(n = 592) 
p-value 
All cause in-
hospital mortality 
52 (9.1) 42 (4.0) 30 (5.1) < 0.0001 
All cause 30 day 
mortality 
59 (10.4) 46 (4.3) 34 (5.7) 0.032 
The numbers for cardiovascular only and all-cause mortality for both in-hospital and 
30 day mortality are comparable, as such only all-cause will be considered in the 
final analysis. 
 
2.5.3 In-hospital Mortality 
 
Our data indicates that the unadjusted in-hospital mortality is statistically 
significantly different between the three treatment groups (p = 0.000).  This 
significance however, is driven by the increased mortality observed in the 
clopidogrel group. When comparing clopiogrel to prasugrel and ticagrelor in 
terms of in-hospital mortality, the latter agents demonstrate superiority over 
clopidogrel with p values of p = 0.000 (clopidogrel vs prasugrel) and p = 0.002 
(clopidogrel vs ticagrelor) which is indicative of higher in-hospital mortality 
following treatment with clopidogrel.  However, when comparing the incidence 
of in-hospital mortality between prasugrel and ticagrelor, there is no significant 
difference in outcome as demonstrated by p = 0.438. 
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The patients assigned to clopidogrel according to our patient demographic are 
older and have increased number of co-morbidities which may well account 
for the increased mortality observed in our clopidogrel treatment arm. 
2.5.4 Unadjusted 30 day Mortality 
Unadjusted mortality data for the three treatment groups are presented as 
Kaplan-Meier survival curves, which demonstrate the number of indviduals 
who are still alive over a 30-day period and includes data regarding those 
patients in whom the survival outcome may be unknown i.e is censored 
(figures 8 - 11).  This is a crude analysis however, since the variables 
included are not adjusted for any confounders.  Unadjusted thirty-day all-
cause and cardiovascular only mortality is lower for both prasugrel and 
ticagrelor when compared to clopidogrel. Log-rank testing confirmed 
significantly lower mortality following the administration of prasugrel and 
ticagrelor (p < 0.001 for prasugrel vs clopidogrel and ticagrelor vs clopidogrel).  
There was a non-significant difference in mortality when comparing prasugrel 
with ticagrelor (log rank test, p = 0.785)
 Figure 8. All cause mortality at 30 days - Kaplan-Meier Survival Curves -  clopidogrel, prasugrel and ticagrelor.  
 
 
61 
 62 
 
Figure 9. All cause mortality at 30 days - Kaplan-Meier Survival Curves – clopidogrel vs prasugrel 
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Figure 10. All cause mortality at 30 days - Kaplan-Meier Survival Curves – clopidogrel vs ticagrelor 
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Figure 11. All cause mortality at 30 days - Kaplan-Meier Survival Curves – prasugrel vs ticagrelor 
 
 
2.5.5 Adjusted 30 day Mortality 
A cox-regression analysis was also undertaken and mortality outcomes were 
standardised/adjusted for the following variables; age, sex, ethnicity, weight, 
previous MI, diabetes, PVD, CHD, CHF, atrial fibrillation, COPD, VHD, family 
history, hypercholesterolaemia, hypertension, systolic blood pressure, heart 
rate and call to balloon time (CBT).  The nationally mandated CBT is 150 
minutes and relates to the time from the patients call for help to reperfusion 
and is the benchmark against which all PPCI centres are measured (MINAP 
2014).  The survival curves (figures 12 - 15) differ once adjusted for 
confounders; following adjustment ticagrelor appears to be numerically 
superior to prasugrel in terms of surivival, however, this difference is not 
significant (p = 0.438).  Both prasugrel and ticagrelor are numerically superior 
to clopidogrel, however, again this difference is not of significance with p 
values of p = 0.746 and p = 0.169 respectively 
65 
Figure 12. Cox regression survival and hazard curves – clopidogrel vs prasugrel vs ticagrelor. 
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Figure legends -  the y-scale does not begin at zero 
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Figure 13. Cox regression survival and hazard curves – clopidogrel vs prasugrel 
 
  
Figure legends -  the y-scale does not begin at zero 
 68 
Figure 14. Cox regression survival and hazard curves – clopidogrel vs ticagrelor 
 
 
Figure legends -  the y-scale does not begin at zero 
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Figure 15. Cox regression survival and hazard curves – prasugrel vs ticagrelor 
 
Figure legends -  the y-scale does not begin at zero 
 2.6 Discussion 
 
Observations from the antiplatelet registry data indicate that the patient 
demographic presenting with STEMI to be treated with PPCI at our centre 
consists mainly of Caucasian people with an average BMI ranging from 26 to 
28 indicating that our population is predominantly overweight.  A statistically 
significant difference in BMI is seen between our three treatment groups (p = 
0.000) with patients with the highest BMI receiving treatment with prasugrel.  
This is due to prasugrels licensing restrictions, which state that it should not 
be administered to patients under 60kg in view of the increased incidence of 
bleeding complications that can occur in patients with low body weight.  There 
are statistically significant differences in the age at presentation between the 
three groups (p = 0.000), with younger patients receiving treatment with 
prasugrel and older patients clopidogrel.  Which is again reflective of the 
licensed indications for prasugrel, administration in patients  > 75 years is not 
recommended due to the increased bleeding risk in older patients. 
Baseline characteristics in terms of risk factors and co-mordibities differ 
between the three treatment groups; there are statistically significantly greater 
incidences of CHD, atrial fibrillation, VHD and hypertension in our clopidogrel 
treated group.  However, this seems reasonable in view of the older age of 
patients in this particular group; advancing age is known to be associated with 
increased number of co-morbidities. 
The patient demographic described in this chapter provides some insights into 
the population from which patients for the pharmacokinetic/pharmacodynamic 
study have been selected (chapters 5-8).  
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2.6.1 In-hospital bleeding  
The increased bleeding complications in older patients in TRITON-TIMI 38 
resulted in the recommendation to avoid the use of prasugrel in patients over 
the age of 75 years (Wiviott, Braunwald et al. 2007).  Ticagrelor is also 
associated with higher rates of non-CABG related major bleeding (Wallentin, 
Becker et al. 2009).  Such adverse effects are expected since prasugrel and 
ticagrelor provide greater levels of platelet inhibition when compared to 
clopidogrel resulting in a reduction in both ischaemic and thrombotic 
complications following an ACS event. 
 
Data regarding the optimal use of P2Y12 inhibitors in older patients are 
limited.  Pharmacokinetic and pharmacodynamic drug handling in older 
patients is markedly different to that seen in younger patients with often 
greater exposure to the antiplatelet drug which can contribute to the increased 
risk of bleeding complications that are seen in this patient group (Wiviott and 
Mega 2010). 
 
The prevalence of co-morbidities such as atrial fibrillation requiring 
concomitant anticoagulation and the incidence of renal impairment and 
anaemia in combination with the age-related changes in drug handing are 
known to contribute to the increased bleeding risk seen in older patients 
treated with P2Y12 inhibitors (Kinnaird, Stabile et al. 2003, Moscucci, Fox et 
al. 2003). 
 
This antiplatelet registry data demonstrates increased bleeding complications 
(GI bleeds) and need for the blood transfusions in our clopidogrel treated 
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patients.  This patient group is older (mean age 70.51 ± 13.36) and presented 
with a statistically significantly higher incidence of renal dysfunction (p = 
0.000) and anaemia (p = 0.000) when compared to the prasugrel and 
ticagrelor treated groups (refer to tables 4 and 8). 
2.6.2 Mortality  
The publication of large clinical trials have demonstrated that the 
administration of both prasugrel and ticagrelor versus clopidogrel leads to a 
reduction in the composite of cardiovascular death, myocardial infarction and 
stroke (Wiviott, Braunwald et al. 2007, Wallentin, Becker et al. 2009) 
 
Although ticagrelor is associated with a mortality benefit in patients who 
present with an acute MI, this benefit is not seen in our patient population.  
With regards to survival outcomes, this data indicates that all three oral 
P2Y12 inhibitors are associated with comparable levels of in-hospital and 30 
day mortality. Suggesting that survival outcomes are not solely determined by 
the antiplatelet drug administered, but are also related to the condition of 
STEMI itself which has an impact on drug handling and subsequent survival 
outcomes.  There may be additional/unknown factors that prevent the drugs 
from exerting their effect and benefit. 
 
The physiological changes that occur secondary to the disease state of 
STEMI, such as reduced gastric absorption and increased platelet reactivity 
may attenuate the benefit of all orally administered antiplatelet agents 
(Alexopoulos, Xanthopoulou et al. 2013).  
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2.6.3 Limitations 
The registry represents the daily practice of our PPCI centre and incorporates 
a “real world all-comers” population, which may introduce recruitment, 
selection or screening biases. 
This is a single centre study in which a relatively small sample size has been 
scrutinised. In addition, due to time constraints, it was not possible to compare 
the same outcomes in NSTEMI/UA patients who also received oral 
antiplatelets and were treated with PCI. 
Statistical analyses are conducted on unmatched/balanced populations since 
propensity matched analyses has not been undertaken at this stage. 
 
2.7 Conclusions 
This local registry data indicates that despite the rapid uptake into practice of 
newer more potent antiplatelet agents, in-hospital and 30 day mortality does 
not differ between the clopidogrel, prasugrel and ticagrelor groups.  Despite 
the use of newer agents, that offer enhanced pharmacological profiles, which 
should translate into improved therapeutic outcomes in clinical practice, this is 
not evident in our local patient population.  
 
We therefore postulate that all oral P2Y12 inhibitors have reduced clinical 
efficacy in the context of STEMI possibly secondary to gastric malabsorption 
and reduced hepatic perfusion.  This leads us to question whether the disease 
state rather than drug administration in the acute phase has more of an 
impact on clinical outcomes. 
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Although not an outcome driven trial, our pharmacokinetic/pharmacodynamic 
pilot study data, which will be discussed in the remainder of my thesis, will 
help to explore this question. 
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Chapter 3 - Pharmacokinetics and Pharmacodynamics of oral 
P2Y12 inhibitors during the acute phase of a myocardial 
infarction: A Systematic Review. 
 
3.1 Introduction 
The immediate administration of oral antiplatelet therapy in the form of aspirin 
plus a P2Y12 inhibitor is the mandated and universally recognised standard of 
care for patients who present with an acute myocardial infarction (Steg, 
James et al. 2012).  Despite such strong recommendations for their use, there 
are a paucity of data regarding their onset of action and clinical efficacy during 
the short time frames from confirmation of diagnosis to reperfusion with 
primary percutaneous coronary intervention.  In order to establish the current 
level of evidence regarding drug handling of oral P2Y12 inhibitors during the 
acute phase of a myocardial infarction I conducted a systematic review of the 
available literature. 
3.2 Study Objective  
To undertake a systematic review of the available evidence regarding the 
pharmacokinetic and pharmacodynamic drug handling of orally administered 
P2Y12 inhibitors (clopidogrel, prasugrel and ticagrelor) during the acute phase 
of a ST-elevation myocardial infarction (STEMI) (that is from symptom 
onset/diagnosis to the time of angioplasty) to determine whether their 
administration allows for and/or achieves adequate levels of platelet inhibition 
in patients undergoing primary percutaneous coronary intervention. 
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3.3 Methods 
This review has been conducted in line with the recommendations made 
within the PRISMA-P guideline and has been registered with the International 
Prospective Register of Systematic Reviews (PROSPERO - CRD 
42015023393) on June 19th 2015 (Khan 2015, Moher, Shamseer et al. 2015). 
Of note, the systematic review process was completed 36 months after the 
conception of the research project, formulation of the research question and 
initiation of the study as outlined in chapter 4 onwards. 
3.3.1 Search Strategy 
An initial literature search was undertaken to determine whether this research 
question had already been addressed.  At the time of review, there were no 
indications that a review of this nature had already been completed.  The 
main reviewer (NK) and secondary reviewer (AC) agreed the systematic 
review question, search terms, search strategy and inclusion/exclusion criteria 
for the final studies to be included. A structured and comprehensive literature 
search was performed in January 2014 using Pubmed (from inception to 
January 2014) and EMBASE (Ovid) (from 1974 to December week 3 2013).  
In addition, a search of the Cochrane database of systematic reviews was 
also undertaken, however, this did not reveal any relevant or related review 
topics. Secondary references found during the initial literature search were 
deemed to fall under the category of “grey” data/literature. 
 
3.3.2 Study Selection  
The key medical subheading search terms used during the literature search 
included, clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilique), P2Y12 
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inhibitors, myocardial infarction, STEMI, inhibition of platelet activity (IPA), 
gastrointestinal absorption, cardiogenic shock, pharmacokinetics and 
pharmacodynamics. 
 
As shown in figure 16, a total of 4,005 papers were retrieved following the 
literature search using PubMed and further 3,242 from EMBASE. A search of 
the Cochrane database did not yield any results. All search results were 
exported to a reference manager programme (EndNote Version X7.3 2015) 
where duplicate searches were excluded.  Of those searches that remained (n 
= 4,532), a title and abstract review was undertaken to determine whether the 
contents of the selection were in line with the inclusion and exclusion criteria 
stipulated at the outset (Appendix 2).  For the final title/abstracts selected, the 
full papers were retrieved and the contents scrutinised in more detail to 
determine their relevance in relation to the research question and inclusion 
criteria.  Any discrepancies in the search results identified were discussed by 
NK and AC, compared against the inclusion/exclusion criteria and screening 
questions and a decision made as to whether the paper should be included in 
the final review.  Where a decision regarding inclusion could not be made, the 
opinion of a third reviewer (JC) was sought.  In order to ensure the 
appropriateness of the final selections, a number of screening questions, 
based on the CASP and SURE checklists were devised and utilised 
(Appendix 3). A modified tool, incorporating only the key screening questions 
relevant to nature of the papers collated for my systematic review was 
developed to remove duplication and provide a more focused assessment of 
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the quality and robustness of the final randomised controlled trials and 
qualitative reviews included in the list of papers retrieved for scrutiny. 
3.3.3 Data Synthesis  
This review was able to provide insights in to whether sufficient levels of 
platelet inhibition are achieved at the time of primary percutaneous coronary 
intervention in patients who are administered loading doses of oral P2Y12 
inhibitors following a diagnosis of STEMI. The degree of platelet inhibition 
(pharmacodynamics) will be expressed as either percentage platelet reactivity 
index  (%PRI), P2Y12 reaction units (PRU), ADP-induced aggregation and 
whole blood aggregation.  Pharmacokinetic assessment will be determined 
through the amount of active metabolite generated.  A narrative overview of 
the data extracted from studies included in the final review will be given.   
3.4 Results 
3.4.1 Study Selection and Data Extraction 
The process of screening and selection of the final citations included in the 
systematic review are outlined in figure 16. We reviewed the full text of 101 of 
the 4,532 records identified through the initial database search.  Of these, a 
final eight papers were selected for inclusion in our analysis; six relate to 
pharmacodynamic studies and one relates to both pharmacodynamic and 
pharmacokinetic and the remainder is a pharmacokinetic study only. 
A summary of patient and study characteristics along with key study findings 
is included in table 10. 
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Table 10. Study and patient characteristics with key findings. 
Reference Study 
type 
Populatio
n 
Intervention Comparators Platelet Function 
Test/Analysis 
Findings 
Alexopoulos 
(Alexopoulos, 
Xanthopoulou et 
al. 2012) 
PD STEMI 
(n = 55) 
PPCI Prasugrel 60mg  
(n = 28) 
Ticagrelor 180mg  
(n = 27) 
VerifyNow and 
Multiplate Analyzer at 
baseline, 1,2,6, 24 hrs 
and 5 days post 
loading 
VerifyNow PRU at 1hr prasugrel 257 and 
ticagrelor 231. 
(PRU ≥ 230 indicates HTPR).  There is an 
initial delay in antiplatelet effect; taking 
approx. 2hrs to see sufficient levels of IPA 
(PRU <208) 
Background antithrombotic therapy: 
unspecified 
Beigel (Beigel, 
Fefer et al. 
2013) 
PD STEMI 
(n = 79) 
PPCI Clopidogrel 600mg  
(n = 49) 
Prasugrel 60mg  
(n = 30) 
LTA at baseline, at 
PPCI and after 72hrs 
Mean DTB – 48 +/-20 mins 
At baseline, ADP induced aggregation – 
comparable between prasugrel and 
clopidogrel. 
At PPCI -  ADP induced platelet 
aggregation significantly less in the 
prasugrel group compared with clopidogrel 
group; but less than 50% of prasugrel 
treated patients achieve IPA < 70%. 
Background antithrombotic therapy: 
aspirin 100mg (PO) +/- GPI (tirofiban) 
Heestermans 
(Heestermans, 
van Werkum et 
al. 2008) 
PK STEMI vs 
healthy 
controls 
(n = 21) 
PPCI STEMI clopidogrel 
600mg (n = 11) 
Healthy controls 
clopidogrel 600mg  
(n = 10) 
LC-MS/MS pre-dose, 
0.5, 1, 1.5,2,3,4,6 and 
24 hrs post-loading 
Plasma concentration of the active thiol 
metabolite of clopidogrel is significantly 
lower in STEMI patients compared to the 
healthy controls.   
Impaired bioavailabilty of clopidogrel in 
STEMI patients leads to suboptimal levels 
of IPA. 
 
Background antithrombotic therapy: 
aspirin 900mg (IV) + UFH 70IU/kg 
Hobl (Hobl, 
Stimpfl et al. 
2014) 
PK/ 
PD 
Healthy 
subjects  
(n =  24) 
None Clopidogrel 600mg 
+ morphine 5mg 
Clopidogrel 600mg 
+ placebo 
PD assessment: VASP 
phosphorylation assay 
PK assessment: 
LC-MS/MS 
PD: morphine administration is associated 
with a 2hr delay in achieving maximal IPA 
PK: morphine administration significantly 
reduces the maximal concentration on the 
active thiol metabolite (Cmax) and prolongs 
the time taken to reach maximal 
concentration (Tmax) 
A clinically significant drug/drug interaction 
Background antithrombotic therapy: 
none administered 
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is apparent following the co-administration 
of morphine and clopidogrel. 
Orban (Orban, 
Mayer et al. 
2014) 
PD STEMI 
(complicat
ed by 
cardiogen
ic shock) 
(n = 145) 
PPCI Clopidogrel 600mg  
(n = 95) 
Prasugrel 60mg (n 
=  50) 
Multiplate Analyser 42% of patients showed HTPR following 
loading doses of either clopidogrel or 
prasugrel.  All-cause mortality lower at 30 
days in patients treated with prasugrel 
without any increase in bleeding risk. Background antithrombotic therapy: 
aspirin 500mg (IV) + UFH 5,000IU 
Osmancik 
(Osmancik, 
Jirmar et al. 
2010) 
PD STEMI 
(critically 
ill) 
(n = 40) 
PPCI Clopidogrel 600mg 
unstable STEMI 
(n=20) 
Clopidogrel 600mg 
stable STEMI 
(n=20) 
VASP phosphorylation 
assay at baseline, 4, 
24 and 48 hrs post 
clopidogrel loading 
PRI >53% is indicative of clopidogrel 
unresponsiveness.  A greater reduction in 
%PRI was observed in stable compared to 
unstable STEMI patients. 
Background antithrombotic therapy: 
aspirin 500mg (IV) + UFH 150IU/kg +/- 
GPI 
Parodi (Parodi, 
Valenti et al. 
2013) 
PD STEMI 
(n =  50) 
PPCI Prasugrel 60mg (n 
= 25) 
Ticagrelor 180mg 
(n = 25) 
VerifyNow at baseline, 
2,4,8 and 12hrs post 
loading 
Only 50% of patients demonstrate effective 
levels of IPA at 2hrs and at least 4 hrs is 
required to see sufficient IPA in the majority 
of patients. 
The administration of morphine is an 
independent predictor of HRPR at 2 hrs 
Background antithrombotic therapy: 
aspirin 500mg (IV) + bivalirudin only 
Background antithrombotic therapy: 
aspirin 300-500mg + bivalirudin only 
         
AMI – acute myocardial infarction, DTB –door to balloon time, PPCI - primary percutaneous coronary intervention, PD - pharmacodynamics PK – 
pharmacokinetic  UFH – unfractionated heparin GPI – Glycoprotein IIb/IIIa inhibitor  PRU – P2Y12 reactivity units PRI – platelet reactivity index IPA – 
inhibition of platelet activity  HTPR – high on treatment platelet reactivity  LTA – light transmission aggregometry  LC-MS/MS – liquid chromatography 
tandem mass spectrometry
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Figure 16. PRISMA-P Flow chart/Study Selection Process 
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3.5 Discussion 
Although the place in therapy and longer-term benefits of DAPT are well 
established, there are very little data regarding the clinical utility of these 
agents during the acute phase of a STEMI. This systematic review has 
highlighted a potential gap in the evidence base regarding the use of 
antiplatelet agents, since it is apparent that the speed of onset, degree of 
platelet inhibition and clinical efficacy of the currently available oral P2Y12 
inhibitors has not been fully assessed during the narrow door to balloon times 
that are necessary to allow for successful PPCI following a STEMI.  
 
3.5.1 Phamacodynamic Studies 
The pharmacodynamic studies included compared the administration of 
clopidogrel, prasugrel or ticagrelor in various patient populations; healthy 
volunteers, STEMI patients who are haemodynamically stable and unstable, 
or STEMI complicated by cardiogenic shock.   A number of platelet function 
assays were utilised and the time points at which samples were collected in 
relation to the administration of the loading dose were variable. Irrespective of 
the differences in study designs, drugs administered and platelet function 
assays used, a number of key themes are apparent.  
 
Firstly, despite the administration of prasugrel or ticagrelor loading doses, 
there is an initial delay in their onset of action, with an increase intrinsic 
platelet reactivity/HRPR is present at 2 hours indicated by PRU  ≥ 230, 
indicating that neither agent has a particularly potent antiplatelet effect at the 
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time of PPCI (Alexopoulos, Xanthopoulou et al. 2012, Parodi, Valenti et al. 
2013)  
 
Secondly, STEMI is a clinical state which is often accompanied by 
haemodynamic instability and complications such as cardiogenic shock, the 
administration of catecholamines, systemic vasoconstriction, adrenergic 
activation and shunting of blood flow away from non-essential organs leads to 
impaired perfusion of the gut and liver with subsequent impairment of 
gastrointestinal absorption and metabolic biotransformation of orally 
administered drugs into their pharmacologically active forms.  The impact of 
such physiological changes on the pharmacological effect of the oral P2Y12 
inhibitors has also been investigated and quantified for clopidogrel and 
prasugrel, with both agents being subject to HRPR as demonstrated by %PRI 
> 50%  (Osmancik, Jirmar et al. 2010, Parodi, Valenti et al. 2013, Orban, 
Mayer et al. 2014). 
 
Thirdly, the co-administration of morphine introduces a potentially clinically 
significant drug-drug interaction, which leads to a delay in the onset of action 
of all three oral antiplatelet agents (clopidogrel, prasugrel and ticagrelor), with 
a consequent reduction in IPA and corresponding HRPR (Parodi, Bellandi et 
al. 2015).  The nature of the interaction will be described in more detail in 
chapter 8, but it is has been proposed that the administration of morphine 
reduces gastric emptying, which in turns leads to a delay in the absorption of 
orally administered antiplatelets and a consequent reduction in their 
antiplatelet effects (Parodi, Bellandi et al. 2015). 
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3.5.2 Pharmacokinetic Studies 
Only one study reports on pharmacokinetic data regarding clopidogrel and its 
active metabolite in the context of STEMI; there are no data for prasugrel or 
ticagrelor active metabolite generation in this setting. 
 
Heestermans et al, work from 2008, which focuses on clopidgrel 
pharmacokinetics, provides some insights into the altered drug handling that 
occurs secondary to a STEMI.  Generation of clopidogrel active metabolite 
was shown to be significantly reduced in STEMI patients when compared to 
healthy controls.  The consequent reduction in bioavailability and platelet 
inhibition is thought to be secondary to impaired GI absorption (Heestermans, 
van Werkum et al. 2008). 
 
Although not undertaken STEMI patients, the study by Hobl et al has been 
included in this systematic review, since it investigates the extent of the 
morphine-antiplatelet drug-drug interaction in healthy patients and 
demonstrates that the co-administration of morphine leads to a reduction in 
active metabolite generation, demonstrated by a delay in the time take to 
achieve maximum concentration (Tmax), decrease in maximum concentration 
(Cmax) and a 34% reduction in area under the curve (AUC).  Consequently, a 
decrease in antiplatelet effect is seen as demonstrated by a PRI >50% (Hobl, 
Stimpfl et al. 2014). 
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3.5.3 Limitations 
There are several limitations to the systematic review undertaken, mainly 
attributable to the heterogeneity of final studies included.  Patient 
characteristics and the type of platelet function assays utilised were variable 
between the studies reviewed.  In addition the timing of maximal IPA in 
relation to administration of the loading dose is not always clear and the use 
of background antithrombotic therapy between the different studies was 
markedly different.   
 
The reporting of clinical outcomes, pharmacodynamic and pharmacokinetic 
data is variable and the impact this may have on patient outcomes is not 
clear.  Lastly, the studies included are not adequately powered to make 
inferences with regards to clinical outcomes, but they do provide further 
insights into and support emerging evidence indicating that even the newer 
generation oral P2Y12 inhibitors are not effective in the setting of STEMI. 
 
3.6 Conclusion 
The pharmacokinetic and pharmacodynamic data collated and scrunitised 
during the review demonstrate inadequate levels of platelet inhibition in the 
first few hours after presentation in STEMI patients.  The results of this 
systematic review indicate that despite the administration of oral P2Y12 
inhibitors such as prasugrel and ticagrelor that should allow for greater and 
more consistent levels of platelet inhibition, the physiological state of STEMI 
and the co-administration of opioid based analgesia (e.g. morphine) are 
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associated with a reduction in the degree of platelet inhibition achieved 
following their administration.  
 
The results from chapter 2 and the findings of this systematic review, 
(although the latter was completed following the commencement of my 
research project), provide further justification and rationale for undertaking 
and completing the pharmacokinetic and pharmacodynamic assessment of 
oral P2Y12 inhibitor activity during the acute phase of a myocardial infarction 
(Chapter 4 onwards). 
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Chapter 4 – Materials and Methods describing the 
Pharmacokinetic and Pharmacodynamic assessment of Oral 
P2Y12 Inhibitors in Patients Undergoing Percutaneous 
Coronary Intervention (PCI) for Acute Myocardial Infarction 
 
4.1 Introduction 
PPCI is an emergency procedure, which should be performed within 60 
minutes of a patient’s arrival at hospital (or within 120 minutes of symptom 
onset).  The currently available oral agents within the armamentarium of 
antiplatelet therapies have all demonstrated clinical benefits in patients who 
present following a myocardial infarction.  Much of the available 
pharmacodynamic and pharmacokinetic data are largely derived from healthy 
volunteers (Brandt, Payne et al. 2007). In addition to the short time scales 
involved for PPCI, it is possible that the condition of STEMI itself, with the 
effects of concomitant treatments (e.g. opioid based analgesia) might limit the 
effectiveness of oral antiplatelet agents (Lincoff, Steinhubl et al. 2008) 
It is unlikely that gastro-intestinal absorption during a STEMI is equivalent to 
that of a healthy resting patient.  The physiological effects of severe pain and 
neurohormonal activation will redirect blood flow away from the gut, this 
coupled with the administration of opioid analgesia will lead to delayed 
absorption of oral antiplatelet agents from the gut (Parodi, Bellandi et al. 
2015).  The increase in intrinsic platelet reactivity seen during the acute phase 
of a MI will further impair the effectiveness of the antiplatelet agents (Kumana, 
Rambihar et al. 1982, Mathur, Robinson et al. 2001, Frelinger, Michelson et 
al. 2011). 
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As demonstrated by the findings of the systematic review undertaken and 
reported in chapter 3, there are little data concerning the comparative speed 
of onset in terms of IPA/clinical efficacy of the oral antiplatelet agents in the 
context of an acute STEMI when compared to other more stable 
presentations of ACS e.g. NSTEMI/UA.  Much of the data reported are 
derived from STEMI patients only or healthy patients or a comparison 
between the two. The findings of the current study demonstrate the extent to 
which clopidogrel, prasugrel or ticagrelor are having a significant clinical effect 
during the primary angioplasty (STEMI patients) and provide insights into the 
pharmacodynamic and pharmacokinetic properties of these agents in the 
setting of STEMI.  By also studying patients with UA/NSTEMI, we were able 
to determine whether the condition of STEMI per se affects the 
pharmacokinetics and pharmacodynamics of these orally administered P2Y12 
inhibitors. 
 
4.2 Study Objectives 
1. To determine the degree and time course of platelet inhibition by 
clopidogrel, prasugrel and ticagrelor administered acutely before 
emergency primary percutaneous coronary intervention (PPCI) for 
STEMI, during the procedure and in the following four hours. 
2. To determine whether the state of acute STEMI reduces the absorption 
and/or subsequent efficacy of the oral P2Y12 inhibitors when compared 
to patients with other acute coronary syndromes e.g. unstable 
angina/NSTEMI. 
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4.3 Study Design 
This was a single-centre, non-randomised, prospective observational study, in 
which the efficacy of oral antiplatelet agents, clopidogrel, prasugrel and 
ticagrelor were investigated during the acute phase of a myocardial infarction.  
A total of 87 patients were recruited to the study following a diagnosis of 
STEMI or UA/NSTEMI; since this was a pilot study, power calculations were 
not undertaken to determine sample size.  The study was non-randomised to 
allow for adherence to local prescribing protocols as well as compliance with 
national and international guideline recommendations regarding the use of 
antiplatelet therapies in the setting of ACS.  In terms of allocation to a 
treatment arm, the initial phase of patient recruitment involved the use of 
clopidogrel and prasugrel only, as per local treatment guidelines.  Following 
successful and complete recruitment to the prasugrel arm of the study, the 
use of prasugrel was discontinued in our centre and ticagrelor was introduced 
in its place.  Our local antiplatelet prescribing guidelines were updated to 
reflect the change in practice. 
4.4 Study Outcome Measures 
In order to determine the pharmacokinetic and pharmacodynamic profile of 
oral P2Y12 inhibitors, in addition to the degree and time course of platelet 
inhibition following the administration of clopidogrel, prasugrel and ticagrelor 
in patients presenting with a STEMI and UA/NSTEMI, the following 
parameters were recorded for all three oral agents: 
1. The degree of platelet inhibition (pharmacodynamic effect) as 
measured by VerifyNow. 
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2. The degree of platelet inhibition (pharmacodynamic effect) as 
measured with VASP flow cytometry. 
3. The concentration of active metabolite or parent compound) present in 
plasma (pharmacokinetic effect) as measured by liquid 
chromatography with tandem mass spectrometry. 
 
4.5 Materials and Methods 
4.5.1 Subject Selection 
The study recruited those patients who presented following an acute coronary 
syndrome; either a STEMI or UA/NSTEMI. 
 
STEMI patients were identified following activation of the STEMI/PPCI 
pathway and admission to the Heart and Lung Centre for PPCI.  UA/NSTEMI 
patients were identified with the assistance of the Cardiac Assessment Team 
nurses following their admission to either the Accident and Emergency 
department or the Emergency Admissions Unit at RWH. 
 
Patient groups were carefully selected such that all patients who were to 
undergo PCI received anti-platelet medications as per current national and 
local guidelines and manufacturers datasheet recommendations. 
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Table 11. Patient allocation to treatment groups. 
Group 1 
(n=15) 
Patients admitted with STEMI who were under the age of 75 years and 
greater than 60kg were administered prasugrel 60mg as a single loading 
dose followed by 10mg daily as a maintenance dose. 
Group 2 
(n=15) 
Patients admitted with NSTEMI who were under the age of 75 years and 
greater than 60kg were administered prasugrel 60mg as a single loading 
dose, however 
- After sample collection, diabetic patients who were stented 
received  maintenance treatment with prasugrel 10mg daily 
as per the licensing agreement and NICE recommendations. 
- After sample collection, non-diabetic patients and those who 
were not stented received maintenance treatment with 
clopidogrel 75mg daily. 
Group 3 
(n=13) 
Patients admitted with STEMI who were over the age of 75 years or 
under 60kg were administered clopidogrel 600mg as a single loading 
dose followed by 75mg daily as a maintenance dose. 
Group 4 
(n=14) 
Patients admitted with UA/NSTEMI who were over the age of 75 years 
and under 60kg were administered clopidogrel 600mg as a single 
loading doses followed by 75mg daily as a maintenance dose. 
Group 5 
(n=15) 
Patients admitted with STEMI were administered ticagrelor 180mg as a 
single loading dose, followed by 90mg twice daily as a maintenance 
dose. 
Group 6 
(n=15) 
Patients admitted with NSTEMI were administered ticagrelor 180mg as a 
single loading dose, followed by 90mg twice daily as a maintenance 
dose. 
NB – patient recruitment to the ticagrelor STEMI or NSTEMI groups did not commence until 
all prasugrel STEMI and NSTEMI patients were recruited.  
 
4.5.2 Inclusion Criteria 
1. STEMI patients who presented for PPCI (characterised by chest 
discomfort and prominent ST-segment elevation). 
2. NSTEMI patients as characterised by their clinical presentation; chest 
discomfort, raised levels of myocardial enzymes and/or ST-segment 
depression or prominent T-wave inversion. 
3. Provision of verbal assent (STEMI patients pre-procedure) and/or 
written consent (STEMI patients post-procedure and NSTEMI patients 
prior to enrolment). 
4. Age > 18 years. 
5. Able to take aspirin and either clopidogrel, prasugrel or ticagrelor. 
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6. Do not have a concurrent septic or inflammatory illness. 
7. Are P2Y12 inhibitor naïve (are not currently taking clopidogrel or 
prasugrel or ticagrelor). 
4.5.3 Exclusion Criteria 
1. Are unable to provide verbal assent and written consent. 
2. Have a documented allergy to aspirin or clopidogrel or prasugrel or 
ticagrelor. 
3. Are diagnosed with pre-existing cardiogenic shock. 
4. Have concurrent septic or inflammatory disease e.g. rheumatoid 
arthritis, lupus or pneumonia. 
5. Are already taking a P2Y12 inhibitor. 
6. Have known bleeding diathesis. 
7. Patients over the age of 75 years or under 60kg or those who have had 
a previous stroke/transient ischaemic attack would not receive 
treatment with prasugrel. 
8. Patients with a history of intracranial haemorrhage would not receive 
treatment with prasugrel or ticagrelor but would receive clopidogrel. 
9. Peri-procedural administration of glycoprotein IIb/IIIa inhibitor 
(abciximab or eptifibatide) due to their adverse effects on platelet 
reactivity and ability to generate meaningful results using VerifyNow. 
4.5.4 Withdrawal Criteria 
For those patients who chose to withdraw consent to participate in the study, 
all collected samples were to be discarded.  All patient specific information 
collected for the purpose of the study would be erased.  Patient withdrawal 
would be documented in the clinical notes and in the study patient 
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identification log.  The patients treatment would however, continue in 
accordance with clinical guidelines should the participant choose to withdraw 
or not. 
4.5.6 Assessment and Follow-up 
4.5.6.1 Subjects 
A total of 87 patients were recruited to the study of which 43 were recruited to 
the STEMI arm following activation of the PPCI pathway and 44 to the 
NSTEMI/UA arm following identification and assessment against the inclusion 
criteria. 
4.5.6.2 Sampling 
4.5.6.2.1 STEMI Patients 
Following verbal assent, an oral P2Y12 inhibitor was administered (as per 
current local and national guidelines).  The time at which the loading dose 
was administered was recorded on the case report form (CRF – refer to 
appendices 4 and 5) and documented within the medical notes; the patient 
was then transferred to the cardiac catherisation suite for PPCI. 
After insertion of the radial or femoral sheath, 15ml of whole blood was drawn 
from this sheath at 20 minutes post-loading (or as close to this time as 
practicable) and also at the time of first balloon inflation.  A further 15ml of 
blood was collected at 60 minutes post-loading.  A final 15ml sample was 
collected at 4 hours post-loading; at this point the patient will have returned to 
a ward environment and as such the 15ml blood sample was collected from 
an anticubital vein using a 21 gauge needle. 
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4.5.6.2.2. NSTEMI Patients: 
Following written consent, a P2Y12 inhibitor was administered (as per current 
local and national guidelines).  The time at which the loading dose was 
administered was recorded, and 15ml of whole blood was taken at 20 
minutes, 60 minutes and 4 hours post loading from an anticubital vein using a 
21 gauge needle. 
 
Aspirin was administered by the ambulance staff or medical staff in the 
Accident & Emergency/Emergency Admissions Unit and samples for 
assessment were collected at 20 minutes, the time of balloon inflation (for 
PPCI patients) and 60 minutes following the administration of the P2Y12 
inhibitor loading dose. The process of patient recruitment and sample 
collection are described in appendices 6 - 9.  The corresponding patient 
information sheet given to patients and consent forms can be viewed in 
appendices 10 - 13. 
 
Each sample was collected for: 
1. Estimation of P2Y12 inhibition using the near patient VerifyNow test. 
2. Estimation of P2Y12 inhibition by flow cytometry using a VASP-
phosphorylation test. 
3. Estimating the effect of aspirin on platelet inhibition using the near 
patient VerifyNow test 
4. Estimation of the active metabolites generated for clopidogrel and 
prasugrel in addition to the parent compound of ticagrelor and its active 
metabolite which is generated following enzymatic degradation of 
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ticagrelor using liquid chromatography in tandem with mass 
spectrometry. 
 
 
Table 12. Sample collection and sampling times. 
Time Pre-
dosing 
20 minutes 
post dosing 
Balloon time 
(STEMI only) 
60 minutes 
post dosing 
240 minutes 
post dosing 
Procedure Consent 15ml blood 15ml blood 15ml blood 15ml blood 
VN Aspirin  X  X X 
VN P2Y12  X X X X 
VASP 
Phosphorylation 
 X X X X 
Estimation of 
plasma 
concentration 
 X X X  
X 
 
4.6 Pharmacodynamic Analysis 
 
4.6.1 VerifyNow for aspirin and P2Y12 analysis 
VerifyNow TM (Accumetrics, San Diego, California, USA) is a near patient test 
comprising a turbidimetric based optical detection system that measures 
platelet aggregation as an increase in light transmittance (Bouman, Parlak et 
al. 2010).  
 
The VerifyNow point of care assay has an established role in facilitating the 
pharmacodynamic assessment of platelet reactivity following the 
administration of either aspirin a P2Y12 inhibitor or an GP IIb/IIIa inhibitor and 
is endorsed by the FDA in this capacity (Michelson, Frelinger et al. 2006).  
The utility of using VerifyNow to assess the effectiveness of clopidogrel, 
prasugrel and ticagrelor is also well established in clinical practice 
(Varenhorst, James et al. 2009, Jeong, Bliden et al. 2012). 
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While undertaking the VerifyNow assay, 2ml of whole blood was transferred 
into a Greiner Bio-one Vacuette containing 3.2% sodium citrate and inverted 
carefully, after which the tube was left at room temperature for a minimum of 
15 and 30 minutes for both the P2Y12 and aspirin assays respectively. 
After the appropriate rest period, the vacuette was loaded into the assay 
device and analysed as per the manufacturers instructions (Accumetrics). 
The VerifyNow device was calibrated on a daily basis and full quality control 
was carried out for each batch of new assays to ensure the integrity of the 
products being used.  For this component of the analysis, I assisted with 
sample collection and the preparation of samples for analysis using the 
VerifyNow point of care device. 
 
In terms of assessing platelet function, the VerifyNow assay employs the 
same principles as those used in the current gold standard for assessing 
platelet function; light transmission aggregometry (LTA) (Michelson, Frelinger 
et al. 2006).   
 
The aspirin specific assay utilises arachadonic acid as the principal agonist to 
stimulate platelet aggregation; aspirin 300mg is often administered at the 
point of presentation and initial assessment by the ambulance staff.  In terms 
of assessing the anti-platelet effects of aspirin, samples were collected at 20 
minutes, balloon inflation (for STEMIs only), 60 and 240 minutes after 
administration of the oral P2Y12 inhibitor. 
 
 97 
The P2Y12 assay contains 20micromol/L of adenosine diphosphate (ADP) as 
the principle agonist of platelet aggregation.  ADP however, can activate 
platelet aggregation via both the P2Y1 and P2Y12 cell surface receptors.  In 
order to reduce platelet activation via the P2Y1 receptor, a second agonist 
prostaglandin E1 (PGE1) was also added to the vacuette (Bouman, Parlak et 
al. 2010).   
 
The magnitude of arachadonic acid induced platelet activation is expressed 
as aspirin response units (ARU) and the magnitude of ADP-induced platelet 
activation is expressed as P2Y12 reaction units (PRU). 
4.6.1.1 Interpretation of VerifyNow pharmacodynamic data 
4.6.1.1.1 The P2Y12 reaction unit (PRU) 
The measure of P2Y12 reaction unit (PRU) provides an indication of the 
degree of ADP-mediated aggregation specific to the P2Y12 receptor: 
o PRU ≥ 230 is indicative of high on treatment platelet reactivity 
and patients who display such high values are termed 
“clopidogrel non-responders”. 
o PRU ≥ 208 indicates patients are at increased risk of 
experiencing an adverse cardiac event. 
o PRU ≤ 95 indicates an increased risk of experiencing bleeding 
complications. 
These values suggest that there is a “therapeutic PRU window” which 
provides insights into the degree optimal inhibition of platelet aggregation that 
can be achieved with an antiplatelet agent, whilst minimising bleeding 
complications, and can be found at PRU values between 95-208. 
 98 
4.6.2 VASP Flow Cytometry 
VASP is another assay commonly used to determine the degree of P2Y12 
inhibition; a flow cytometric analysis of the vasodilator-stimulated 
phosphoprotein phosphorylation provides an indication of the platelet 
reactivity index (% PRI).  A high PRI value (>50%) is indicative of poor levels 
of platelet inhibition (Sinhal and Aylward 2013). 
 
VASP, an intracellular actin regulatory protein, is a substrate of both cyclic 
adenosine monophosphate (cAMP) and cyclic guanosine monophosphate 
(cGMP) dependent protein kinases (Waldmann, Nieberding et al. 1987, Aleil, 
Ravanat et al. 2005).  The final platelet reactivity index (PRI) generated 
following a VASP analysis provides an indication of the degree of P2Y12 
inhibition/activation seen in the presence of a P2Y12 inhibitor.  P2Y12 
receptor stimulation leads to the dephosphorylation of VASP and inhibition of 
the P2Y12 receptor, for example, by clopidogrel and stimulation of the PGE1-
activated adenylcyclase induces phosphorylation of VASP by cAMP 
dependent protein kinase.  Consequently, the resulting levels of VASP 
phosphorylation/dephosphorylation provide an indication of P2Y12 receptor 
activation/inhibition (Aleil, Ravanat et al. 2005). 
 
Although VASP flow cytometry is commercially available as an assay 
(Biocytex, Asnieres, France), it is a labour intensive, complex and highly 
specialised procedure that requires significant technical expertise in order to 
conduct the test accurately.  As such it is not freely available in cardiac 
treatment centres and is primarily housed in research /higher education 
 99 
institutes.  For the purposes of my study, I assisted in the preparation of 
samples for analysis within the cardiac department at RWH.  Prepared 
samples were stored for no more than 48 hours within our Clinical Chemistry 
department, prior to transfer to The University of Wolverhampton. 
 
The method for carrying out VASP flow cytometry has been previously 
described by Bonello et al (Bonello, Camoin-Jau et al. 2008), but in summary, 
whole blood is transferred to tubes containing 3.2% sodium citrate and 
incubated for 10 minutes with PGE1 or with PGE1 and ADP and then fixed with 
paraformaldehyde.  The platelets are then permeablised with a non-ionic 
detergent prior to being “labeled with a primary monoclonal antibody against 
serine 239-phosphorylated VASP (16C2), followed by a secondary fluorescein 
isothiocyanate-conjugated polyclonal goat antimouse antibody”(Aleil, Ravanat 
et al. 2005) 
 
The VASP flow cytometry analysis was performed on a Becton Dickinson 
(Plymouth, UK) FACS Calibur flow cytometer, and 10,000 platelets were 
gated per assessment as per the manufacturers instructions.  VASP flow 
cytometry was performed within 48 hours of sampling and the subsequent 
results were expressed as the percentage platelet reactivity (%PRI) (Aleil, 
Ravanat et al. 2005, Cotton, Worrall et al. 2010). The VASP-phosphorylation 
analysis was undertaken within the School of Applied Science at the 
University of Wolverhampton. 
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4.6.2.1 Interpretation of VASP-P pharmacodynamic data 
VASP-PRI (%) provides an indication of platelet reactivity following the 
administration of a P2Y12 inhibitor: 
o A PRI (%) value =100% is indicative of a complete lack of 
antiplatelet effect 
o PRI (%) value >50% is indicative of poor levels of platelet inhibition 
(Sinhal and Aylward 2013). 
o A PRI (%) value < 50% is indicative of adequate levels of platelet 
inhibition 
o A PRI (%) value at or near 0% is indicative of excessive levels of 
platelet inhibition. 
 
4.7 Pharmacokinetic Analysis 
Liquid chromatography in tandem with mass spectrometry (LC-MS/MS) was 
used to determine the plasma concentrations of clopidogrel and prasugrel 
active metabolites, as well as the presence of ticagrelor parent compound and 
active metabolite, using already established and validated methods (Farid, 
McIntosh et al. 2007, Takahashi, Pang et al. 2008, Sillen, Cook et al. 2010, 
Peer, Spencer et al. 2012).   The active metabolites of clopidogrel and 
prasugrel are not stable in blood and therefore to ensure metabolite stability 
during sample handling and storage, 2-bromo-3’methoxy acetophenone 
(MPB) was added within 30 seconds of sample collection to the blood 
collected in the EDTA tubes.  MPB, an alkylating agent, was therefore, used 
to derivatise and stabilise the active metabolites (Payne, Li et al. 2007).  The 
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derivatised samples were centrifuged at 1500g for 10 minutes, the plasma 
was then extracted and frozen at -80C until analysis.   
 
Blood samples for ticagrelor parent compound and active metabolite 
quantification were collected in lithium tubes; the ticagrelor parent compound 
and active metabolite are stable in blood and therefore did not require the 
addition of a stabilising agent 
 
The derivatised clopidogrel and prasugrel samples and ticagrelor samples 
underwent solid phase extraction before being separated using liquid 
chromatography and quantified using mass spectrometry.  A Principal Clinical 
Scientist carried out this activity in the Clinical Chemistry department at RWH. 
 
The primary pharmacokinetic parameters (i.e. the active metabolites of 
clopidogrel, prasugrel and ticagrelor) are expressed as plasma concentration 
(ng/ml) (Farid, McIntosh et al. 2007). 
4.7.1 Interpretation of LC-MS/MS pharmacokinetic data 
 
Previously reported pharmacokinetic studies, indicate that maximal 
antiplatelet effects of clopidogrel, prasugrel and ticagrelor are observed when 
the following peak plasma concentrations are observed following LC-MS/MS: 
o In healthy patients a clopidogrel active metabiolite (C-AM) 
concentration of 43ng/ml is associated with a maximal antiplatelet 
effect (Taubert, Kastrati et al. 2004). 
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o Prasugrel active metabolite (P-AM) concentration between the range of 
87 ng/ml to 512 ng/ml have been documented in healthy patients 
(Brandt, Payne et al. 2007, Payne, Li et al. 2007, Cattaneo 2010). 
o Ticagrelor parent compound (T-PC) and ticagrelor active metabolite (T-
AM) concentrations of 549 ng/,ml and 135ng/ml, respectively, were 
associated peak antiplatelet effects in patients with stable coronary 
artery disease (SCAD) (Wallentin 2009). 
4.8 Statistics and Data Analysis 
All statistical analyses were undertaken using SPSS (IBM SPSS Statistics for 
Mac, Version 21.0. Armonk, NY: IBM Corp).  Continuous variables were 
expressed as mean ± SD and categorical variables as frequencies (%). 
Continuous variables were analysed individually using student’s independent 
sample t-tests.  Categorical variables were assessed using separate Fisher’s 
exact (Chi-square) test. A p value < 0.05 was considered to be statistically 
significant. 
Comparison of means between groups was assessed using analysis of 
variance (ANOVA) technique.  ANOVA allowed for a comparison of more than 
two means and enabled an assessment to be made of the relationship 
between, different drugs (clopidogrel vs prasugrel vs ticagrelor), different 
clinical states (STEMI vs NSTEMI/UA) and different time points. 
In order to determine the relationship between the different platelet function 
assays utilised and the plasma concentrations observed following LC-MS/MS, 
a Pearson Correlation Co-efficient test was used. 
4.8.1 Interim Analyses 
Due to the small study population, an interim analysis was not be performed. 
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4.8.2 Number of subjects to be enrolled 
Since this was a pilot study, power calculations were not undertaken to 
determine sample size; fifteen patients were recruited into each group.  This 
study was non-randomised such that current local and international guidelines 
could be fully adhered to.    
4.8.3 Definition of the end of the trial 
The trial aimed to recruit 15 patients to each arm; on collection of the four-
hour sample in patient 90, all data collection was discontinued. 
4.9 Ethical Considerations 
The study was carried out in line with the spirit and the letter of the 
Declaration of Helsinki and in accordance with the International Council for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human 
Use (ICH) Good Clinical Practice Guidelines. 
4.9.1 Consent 
All patients freely gave their informed assent and/or consent to participate in 
the study in accordance with the process outlined below.  Patients were able 
to withdraw from the study at any time without any compromise to their future 
care. 
 
STEMI patients were likely to be acutely unwell and therefore, it would be 
inappropriate to request written consent the time of admission.  In order to 
avoid unnecessary delays in treatment initiation, a two-staged consent 
process was implemented.  STEMI patients were read a shortened patient 
information sheet (appendix 10) enabling them to provide verbal assent.  
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Because the study medications were still to be administered as per local 
protocol, this approach would not delay urgent medical intervention and 
initiation of PPCI, while allowing collection of the first 3 blood samples.  This 
practice was in line with National Research Ethics Service (NRES) guidelines, 
which suggest that patients admitted with a diagnosis of STEMI are 
considered as unconscious patients initially.  If verbal consent was gained 
post-procedure, it was recorded in the patient’s clinical notes and the site file 
consent record.  
 
The second stage of consent was initiated once the patient was pain free and 
following a period of rest and stabilisation on return to the ward.  At this time, 
a full patient information leaflet was given to the patient and written consent 
sought and documented in the medical notes.  If the patient did not wish to 
participate in the study, their collected samples would be discarded and their 
data not used for analysis.  However, this did not occur with the patients we 
recruited since all gave their full consent for the collection and subsequent 
analysis of samples obtained throughout the study period. 
 
For UA/NSTEMI patients, full written consent was requested and recorded 
after the patient was able to read the full patient information sheet. 
 
The patient’s participation in the trial ceased with the collection of the four-
hour sample.  Patient data was fully anonymised and stored on RWH fully 
encrypted computers. 
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4.9.2 Ethics Approval 
An initial study protocol was seen, reviewed and approved by RWH R&D peer 
review and ethics committee.  The initial study protocol consisted of four 
groups only, as outlined in table 13. 
Table 13. Patient allocations to treatment groups (prior to substantial 
amendment and REC re-submission). 
Group 1 
(n=15) 
Patients admitted with STEMI who were under the age of 75 years and 
greater than 60kg were administered prasugrel 60mg as a single 
loading dose followed by 10mg daily as a maintenance dose. 
Group 2 
(n=15) 
Diabetic patients admitted with NSTEMI who were under the age of 75 
years and greater than 60kg were administered prasugrel 60mg as a 
single loading dose, followed by a 10mg maintenance dose 
Group 3 
(n=13) 
Patients admitted with STEMI who were over the age of 75 years or 
under 60kg were administered clopidogrel 600mg as a single loading 
dose followed by 75mg daily as a maintenance dose. 
Group 4 
(n=14) 
Patients admitted with UA/NSTEMI who were over the age of 75 years 
under 60kg were administered clopidogrel 600mg as a single loading 
doses followed by 75mg daily as a maintenance dose. 
 
Ethical approval for the above study protocol and patient groups was granted 
by the South Birmingham Research and Ethics Committee (REC reference 
number: 13/WM/0025 – appendix 13) in January 2013 and the pilot study was 
designated a non-CTIMP. 
At the time at which the initial protocol was presented to the South 
Birmingham REC, ticagrelor was a non-formulary medication at RWH. In 
January 2013 the South Birmingham REC were informed that once patient 
recruitment to the clopidogrel and prasugrel groups was near to completion, a 
formulary application would be submitted for the inclusion of ticagrelor to our 
hospital formulary.  In parallel to this process we would request a substantial 
amendment to allow for its inclusion in the study protocol. 
Due to difficulties in recruiting to the diabetic NSTEMI prasugrel group (group 
2), it was decided that as part of the substantial amendment, in addition to the 
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inclusion of ticagrelor, we would also request extension of the eligibility criteria 
for group 2, to include non-diabetic NSTEMI patients also. 
 
In June 2014, a substantial amendment was submitted to IRAS, in view of the 
amendment to group 2, the study was deemed to be a CTIMP and therefore 
required MHRA approval also.  All patient recruitment was subsequently 
halted until the necessary approvals were granted. 
The amended protocol was presented to the Coventry and Warwick REC in 
November 2014, following which a favourable opinion was granted (REC 
reference number 14/WM/1236 – appendix 14).  MHRA approval was granted 
on February 13th 2015 an active patient recruitment recommenced on 
February 16th 2015 and the final patient was recruited to the study on 
December 14th 2015. 
 
The final study protocol consisted of six groups that are outlined in Table 11.  
Recruitment to groups 5 and 6 (ticagrelor groups) commenced only after all 
patients were recruited to groups 1 and 2 (prasugrel groups).  The switch over 
from prasugrel to ticagrelor also coincided with the adoption of a new 
antiplatelet prescribing protocol within the Black Country (Wolverhampton, 
Walsall and Dudley) in which ticagrelor became our first line antiplatelet for 
STEMI patients.  
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Chapter 5 -  A Pharmacokinetic and Pharmacodynamic 
Assessment of Clopidogrel in Patients Undergoing 
Percutaneous Coronary Intervention (PCI) for Acute 
Myocardial Infarction 
 
5.1 Introduction 
A detailed overview of clopidogrel, its mechanism of action, clinical efficacy 
and place in therapy has been covered extensivley in chapter 1. 
5.2 Objectives 
 
This chapter aims to compare the degree and time course of platelet inhibition 
observed following the administration of a clopidogrel 600mg loading dose in 
STEMI and NSTEMI patients.  In addition, we will also determine whether the 
state of STEMI per se adversely affects the clinical efficacy of clopidogrel. 
5.3 Ethical Considerations and Consent 
 
All ethical considerations and procedures for patient consent and recruitment 
are described in Chapter 4. 
5.4 Materials and Methods 
 
All materials and methods are described in Chapter 4. 
5.5 Statistics and Data Analysis 
 
The methods for data collection and statistical analyses are outlined in 
chapter 4. 
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5.6 Results 
 
Table 14. Baseline patient characteristics  - clopidogrel treatment group 
Characteristic 
STEMI  
(n = 13) 
NSTEMI  
(n = 14) 
P-value 
Age (yrs) 78 ± 9.7 62.4 ± 15.4 0.005 
Sex        
     Female 6 (46) 2 (14) 0.103 
Risk Factors        
     Diabetes Mellitus 0 (0) 2 (14) 0.481 
     Hypertension 6 (46) 7(50) 1.000 
     Current Smoker 2 (15) 3 (21) 1.000 
     Ex Smoker 4 (31) 7(50) 0.440 
     Hyperlipidaemia 4 (31) 8 (57) 0.252 
     Familial History of CAD 6 (46) 6 (43) 1.000 
     Previous MI 2 (15) 6 (43) 0.209 
     Previous PCI 2 (15) 3 (21) 1.000 
     Previous CABG 0 (0) 0 (0) 1.000 
     Previous stroke/TIA 1 (8) 0 (0) 0.481 
Patient therapy on admission       
     Analgesia 10 (77) 7 (57) 0.236 
     Comprising of:- 
                                    Morphine 10 2 0.002 
GTN 0 5 0.041 
 
5.6.1 Pharmacodynamic analysis of the degree of platelet inhibition 
following clopidogrel loading (600mg) STEMI vs NSTEMI 
5.6.1.1 VerifyNow Results 
 
Table 15. Clopidogrel - VerifyNow (PRU)  
Verify Now result 
expressed as PRU 
post loading 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
STEMI 13 270.23 57.02 
[20.62,93.42] 
38.56 10.693 0.003 
NSTEMI 14 213.21 51.74 13.828 
60 minutes  
STEMI 13 293.46 66.10 
[27.01, 105.20] 
31.68 8.787 0.002 
NSTEMI 14 227.36 61.19 16.355 
240 minutes 
STEMI 12 226.42 12.42 
[-44.20,69.03] 
69.44 20.046 0.655 
NSTEMI 14 214.00 69.98 18.702 
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Figure 17.  VerifyNow mean PRUs (and standard error) after the 
administration of clopidogrel in STEMI vs NSTEMI patients. 
 
 
 
5.6.1.1.2 Summary 
Following administration of a 600mg loading dose of clopidogrel, this data 
indicates a statistically significant difference in mean PRU values between 
STEMI and NSTEMI samples taken at 20 minutes (270.2 ± 10.69 vs 213.12 ± 
13.83 p<0.003) and 60 minutes (293.5 ± 8.79 vs 227.4 ±16.36 p < 0.002).    
At 240 minutes following the administration of a 600mg loading dose of 
clopidogrel, there is no statistically significant difference in the mean PRU 
values observed between the STEMI and NSTEMI groups (226.4 ± 20.05 vs 
214 ±18.70 p = 0.655). 
The data in table 15 were analysed using a two-way analysis of variance test 
in which the effect of disease state (STEMI vs NSTEMI) on the degree of 
platelet inhibition (PRU) over time was examined.  There was no significant 
difference between the effect of disease state on the degree of platelet 
inhibition, F(2,23) = 3.094, p = 0.065.  However, there was a highly significant 
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increase in the degree of platelet inhibition observed over time (that is at 240 
minutes compared to 20 minutes), F(2,23) = 8.890, p = 0.001. 
5.6.1.2 VASP Results 
 
Table 16. Clopidogrel - VASP-PRI (%) 
 
VASP-PRI (%) 
result post 
loading 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
STEMI 7 76.29 1.12 
[-14.69,16.93] 
23.214 8.774 0.883 
NSTEMI 12 75.17 9.476 2.735 
60 minutes  
STEMI 7 71.57 5.18 
[-27.26,16.90] 
30.908 11.682 0.627 
NSTEMI 12 76.75 15.076 4.352 
240 minutes 
STEMI 7 63.14 1.31 
[-25.19, 27.81] 
35.08 13.26 0.918 
NSTEMI 12 61.83 20.16 5.82 
 
 
Figure 18 Mean VASP-PRI (%) (and standard error) after the 
administration of clopidogrel 600mg in STEMI vs NSTEMI patients. 
 
 
5.6.1.2.1 Summary 
Following administration of a 600mg loading dose of clopidogrel, this data 
does not indicate a statistically significant difference in mean VASP-PRI (%) 
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at 20 minutes (76.29 ± 8.77 vs 75.17 ± 2.74 p<0.883) at 60 minutes (71.57 ± 
11.68 vs 76.75 4. ± 35 p < 0.002) and at four hours (63.14 ±13.26  vs  61.83 
± 5.82 p = 0.510) following the administration of a 600mg loading dose of 
clopidogrel, there are no statistically significant difference in the mean VASP-
PRI (%) values observed between the STEMI and NSTEMI groups. 
The data in table 16 were analysed using a two-way analysis of variance test 
in which the effect of disease state (STEMI vs NSTEMI) on the degree of 
platelet inhibition (expressed as mean %PRI) over time was examined. No 
significant difference between the effect of disease state on the degree of 
platelet inhibition was observed, F(2, 16) = 0.702, p = 0.510.  However, a 
significant increase in the degree of platelet inhibition over time was observed 
in both groups, F(2,26) = 4.060, p = 0.037. 
5.6.2 Pharmacokinetic analysis of active metabolite generation following 
clopidogrel loading (600mg) STEMI vs NSTEMI 
 
Liquid Chromatography/Mass Spectrometry Results 
 
Table 17. Clopidogrel active metabolite plasma concentration (ng/ml) 
Active metabolite 
generation (ng/ml) 
result post loading 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
STEMI 12 39.12 -6.37 
[-72.01, 59.26] 
56.00 16.17 0.842 
NSTEMI 12 45.49 94.25 27.21 
60 minutes  
STEMI 12 71.02 -19.10 
[-134.42, 96.23] 
94.24 27.21 0.736 
NSTEMI 14 90.11 172.43 46.09 
240 minutes 
STEMI 12 32.41 9.70 
[-10.26, 29.65] 
23.23 6.71 0.325 
NSTEMI 12 22.71 23.90 6.90 
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Figure 19. Mean active metabolite generation (ng/ml) (and standard 
error) after administration of Clopidogrel in STEMI vs NSTEMI patients. 
 
5.6.2.1 Summary 
Following administration of a 600mg clopidogrel loading dose, the degree of 
clopidogrel active metabolite generation as assessed by liquid 
chromatography in tandem with mass spectrometry indicates that there is no 
difference in the generation of clopidogrel active metabolite at any of the time 
points following loading between the two groups (table 17). 
The data in table 17 were analysed using a two-way analysis of variance test 
in which the extent of clopidogrel active metabolite generation/plasma 
concentration over time in STEMI vs NSTEMI patients was examined.  There 
was no significant difference between the effect of disease state on the 
generation of clopidogrel active metabolite, F(2, 19) = 0.133, p = 0.876.  
There was no significant difference in the degree of active metabolite 
generation observed over time, F(2,19) = 2.104, p = 0.150. 
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5.6.3 Correlation between platelet function assays (VerifyNow and 
VASP-PRI) and active metabolite generation. 
 
A Pearson’s Correlation Co-efficient test was undertaken to determine the 
strength of the relationship between the two platelet function assays utilised 
during the study.  Since all VerifyNow samples were collected and assessed 
at the base hospital and the results generated are more reliable, this test has 
been used as the baseline against which to compare the VASP-PRI (%) and 
active metabolite plasma concentration (ng/ml) results.   
 
 
 
Table 18. Correlation the degree of platelet inhibition observed using 
VerifyNow compared with VASP-PRI following the administration of a 
clopidogrel 600mg loading dose 
 
 
 
VerifyNow 
VASP-PRI 
STEMI NSTEMI 
r p-value r p-value 
20 minutes 
post loading 
0.528 0.223 -0.178 0.581 
At Balloon 
Inflation 
0.657 0.109 x x 
60 minutes 
post loading 
-0.059 0.900 0.063 0.845 
240 minutes 
post loading 
0.636 0.125 0.523 0.081 
 
Both VerifyNow (expressed as PRU) and VASP-PRI (%) results provide an 
indication as to the degree of platelet inhibition achieved following the oral 
administration of a clopidogrel loading dose to both STEMI and NSTEMI 
patients.   
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Table 19.  Correlation between the degree of platelet inhibition observed 
using VerifyNow compared with clopidogrel active metabolite plasma 
concentration following the administration of a 600mg loading dose. 
 
 
VerifyNow 
Clopidogrel active metabolite plasma concentration 
STEMI NSTEMI 
r p-value r p-value 
20 minutes 
post loading 
-0.005 0.989 -0.273 0.390 
At Balloon 
Inflation 
-0.096 0.767 x x 
60 minutes 
post loading 
-0.124 0.700 -0.324 0.280 
240 minutes 
post loading 
0.412 0.183 0.481 0.113 
 
Based on the mechanism of action of clopidogrel and the nature of the platelet 
function assays, one would expect a negative correlation between the degree 
of platelet inhibition (PRU) and the amount of active metabolite generated in 
both the STEMI and NSTEMI groups.  
 
5.7 Discussion  
Baseline patient characteristics are described in table 14.  There are no 
significant differences with regards to risk factors/co-morbidites between the 
STEMI and NSTEMI treated clopidogrel groups. There are distinct and 
clinically significant differences between the two groups with regards to the 
administration of opioid-based analagesia. These differences are based on 
guideline recommendations that do not advocate the administration of opioids 
in NSTEMI patients in view of the increase in mortality associated with this 
practice (Meine, Roe et al. 2005).  As a result there is a statistically significant 
difference in the number of patients administered morphine between the 
STEMI and NSTEMI groups (p = 0.002). 
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In terms of the patient population recruited to the clopidogrel arm of the study, 
a statistically significant difference in the mean age of patients recruited to the 
STEMI group in comparison to the NSTEMI group (78 ± 9.7 vs 62.4 ± 15.4 p 
= 0.005) is apparent.  At the time at which the study was commenced, our 
hospital prescribed both prasugrel and clopidogrel for STEMI patients; the 
licensing of prasugrel is such that its use in older patients (i.e over the age of 
75 years) and lighter patients (under 60kg body weight) is not recommended 
due to an increased associated risk of bleeding complications in these groups.  
As a consequence, the default P2Y12 inhibitor in patients aged over 75 years 
was clopidogrel in this study. 
5.7.1 Pharmacodynamic analysis - VerifyNow 
This pharmacodynamic VerifyNow data reported indicates that at the time of 
PPCI and for at least four hours after the administration of a 600mg loading 
dose in STEMI patients, clopidogrel does not afford sufficient IPA, since all 
values are >208 PRU (figure 17).  Furthermore, there is no significant 
difference in the observed degree of platelet inhibition over time in the 
NSTEMI group.  This is in contrast to the pharmacodynamic data derived from 
healthy volunteers in whom the administration of a 600mg loading dose leads 
to 40 – 45% reduction in inhibition of platelet reactivity after 2-3 hours 
(Wallentin, Becker et al. 2009, Floyd, Passacquale et al. 2012). 
 
This VerifyNow data further indicates that in the context of NSTEMI, although 
a significant difference in terms of the PRU at 20 and 60 minutes is calculated 
when compared to the STEMI group (p = 0.003 and p = 0.002 respectively), 
the administration of a clopidogrel 600mg loading dose does not lead to 
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sufficient levels of platelet inhibition as demonstrated by PRU values > 208 at 
all data collection time points (figure 17).  Therefore, this VerifyNow 
pharmacodynamic data indicates a lack of platelet inhibition over time, in 
addition, to no difference between the STEMI and NSTEMI groups.  This is 
the first study to demonstrate reduced antiplatelet effectiveness of clopidogrel 
in STEMI and NSTEMI patients using VerifyNow, as such there are no 
baseline data against which we can compare our NSTEMI results. 
 
5.7.2 Pharmacodynamic analsysis – VASP-PRI(%) 
VASP phosphorylation provides an indication of ADP induced platelet 
reactivity and subsequent clopidogrel induced platelet inhibition, the final 
value is expressed a percentage of the platelet reactivity index (% PRI).  
VASP-PRI (%) values can also be used to indicate the pharmacodynamics 
effects of clopidogrel following the administration of a loading dose.   A VASP-
PRI (%) > 50% provides an indication of an inadequate response to ADP-
induced platelet aggregation and in the context of clopidogrel can be viewed 
as “non-response” (Cuisset, Grosdidier et al. 2013).  A PRI% >50% is 
associated with an increased risk of recurrent ischaemic and thrombotic 
events e.g. MACE and stent thrombosis.  A PRI% <50% is indicative of an 
adequate antiplatelet response with consequent inhibition of platelet activity.  
A PRI% value of 100% would indicate a complete absence of clopidogrel 
effect and a lack of any antiplatelet cover. 
 
This data demonstrates that in STEMI patients administered a 600mg 
clopidogrel loading dose, there is insufficient clopidogrel induced inhibition of 
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platelet of activity, since all % VASP-PRI values are > 50%.  Indicating 
inadequate levels of platelet inhibition over time, this trend is observed in our 
NSTEMI patient group also (figure 18).  When comparing the VASP-PRI (%) 
results between the STEMI and NSTEMI groups, there is no observed 
difference in platelet inhibition at all time points, indicating a lack of 
pharmacodynamics effect in both disease states. 
 
On examining the relationship the VerifyNow and VASP phosphorylation 
assays (table 18), there is a reasonable to high correlation between the 
results generated using both assay.  Both VerifyNow and VASP 
phosphorylations assays confirm that the pharmacodynamic effect of 
clopidogrel is suboptimal following the administration of a 600mg loading dose 
in both STEMI and NSTEMI patients, since neither assay demonstrates 
adequate levels of platelet inhibition. 
 
5.7.3 Pharmacokinetic analysis – LC-MS/MS 
The pharmacokinetic analysis of clopidogrel active metabolite generation was 
assessed as the maximum plasma concentration determined using liquid 
chromatography in tandem with mass spectrometry.  A number of analyses 
have been undertaken to determine the pharmacokinetic profile of clopidogrel 
and its active metabolites following the administration of a 600mg loading 
dose.  The works of Taubert et al have postulated that a peak plasma 
concentration of clopidogrel active metabolite of 43 ng/ml leads to a maximal 
antiplatelet effect (Taubert, Kastrati et al. 2004).  This is in contrast to the data 
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reported in this thesis, which shows widely variable plasma concentrations of 
active metabolite (figure 19). 
 
The observed LC-MS/MS data demonstrates a non-linear relationship 
between the time from administration and plasma concentration observed.  
The plasma concentration in both STEMI and NSTEMI groups at 20 minutes 
and 60 minutes indicates a positive trend; increasing plasma concentrations 
with time, however at 240 minutes, the plasma concentration in both groups is 
less than that seen at 20 minutes. 
Furthermore, these results indicate that the disease state of STEMI does not 
have any effect on active metabolite generation when compared with the 
NSTEMI patient group, as demonstrated by non-significant differences in 
mean plasma concentration values obtained at each time point (figure 19). 
 
On examination of the relationship between pharmacodynamic and 
pharmacokinetic profiles captured following the administration of a clopidogrel 
600mg loading dose (table 19), no significant correlation was observed 
between the results of the degree of platelet inhibition assessed using the 
VerifyNow platelet function assay and plasma concentration of the clopidogrel 
active metabolite in the STEMI and NSTEMI groups at 20 and 60 minutes.  
However, at 240 minutes, in both groups, a reasonable positive correlation 
between the degree of platelet inhibition and plasma concentration was 
calculated.  In practice, this final result seems somewhat spurious since the 
plasma concentration at 240 minutes is less than that observed at 20 minutes.  
There is no reasonable explanation for this trend. 
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5.7.4 General overview 
Platelet adherence, activation and subsequent aggregation is a core 
component in the initiation and propagation of atherothrombosis and 
consequent ischaemic and thrombotic complications in patients who present 
with ACS and are managed with PCI.  Despite the administration of aspirin 
and clopidogrel, up to 25% of patients who undergo PCI with subsequent 
coronary artery stent implantation are clopidogrel non-responders and are 
therefore at increased risk of recurrent ischaemic events and thrombotic 
complications such as stent thrombosis, further myocardial infarction or death 
(Matetzky, Shenkman et al. 2004, Wallentin 2009). 
 
Different clinical manifestations of ACS will have varying effects on platelet 
behaviours (Mathur, Robinson et al. 2001). As described by Alexopolous et al 
the condition of STEMI is a highly pro-thrombotic state in which platelet 
reactivity is greatly enhanced in comparison to patients with stable coronary 
artery disease (Alexopoulos 2013).  Platelet reactivity becomes heightened 
during the acute phase of a myocardial infarction, this in combination with a 
revascularization strategy of percutaneous coronary intervention, justifies the 
need for potent platelet inhibition, since PCI itself can cause further 
endovascular injury, inflammation and additional activation of platelets 
(Sibbing, Kastrati et al. 2016) 
 
Platelet response to endothelial dysfunction/injury in STEMI is markedly 
different to that seen in UA/NSTEMI; the former is associated with a high 
thrombotic burden with significantly enhanced levels of platelet activation 
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(intrinsic platelet reactivity) even prior to the administration of clopidogrel 
(Alexopoulos, Xanthopoulou et al. 2013).  Intrinsic platelet reactivity can 
contribute high levels of platelet reactivity even after the administration of 
high-dose clopidogrel (P2Y12 inhibition), this phenomenon is known as high 
residual platelet reactivity (HRPR) and is associated with poor clinical 
outcomes (Frelinger, Michelson et al. 2011, Garabedian and Alam 2013). 
 
The high pre-treatment platelet reactivity observed in STEMI has a 
significantly detrimental effect on the time dependent inhibition of platelets 
after clopidogrel loading. Hence the statistically significant increase in mean 
PRU at 20 minutes and 60 minutes in the STEMI group compared with the 
NSTEMI group (p = 0.003). 
 
Following oral administration, the need for clopidogrel to undergo 
gastrointestinal absorption and metabolic biotransformation into its active 
metabolite, creates a time lag between oral administration and clinical effect in 
terms of inhibition of platelet activity and hence the delayed antiplatelet effect 
seen in both STEMI and NSTEMI patients (Cattaneo 2008).  As a 
consequence, clopidogrel is subject to both increased intrinsic (elevated 
baseline) platelet reactivity and high residual platelet reactivity.  This may well 
account for the increased PRU (>230 and 208) and %PRI (>50%) values 
observed in the STEMI patients. 
 
Clopidogrel treatment failure or lack of clinical efficacy is attributable to 
unpredictable pharmacodynamics and variable pharmacokinetics observed 
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following the administration of either loading and/or maintenance doses 
(Floyd, Passacquale et al. 2012).  Clinical outcomes in terms of reduction in 
further MACCE and complications such as stent thrombosis will vary 
depending on whether the patient is a clopidogrel non-responder or not.  The 
variability in pharmacokinetic and pharmacodynamics profiles and subsequent 
response to clopidogrel therapy can occur secondary to a number of factors, 
as described below. 
 
The physiological changes that occur during a STEMI and in particular the 
heightened platelet reactivity that manifests secondary to endovascular 
dysfunction and/or stent implantation are known to reduce the effectiveness of 
clopidogrel (Aradi, Vorobcsuk et al. 2010, Alexopoulos, Xanthopoulou et al. 
2013). 
 
The diversion of blood flow away from the gut during a myocardial infarction 
leads to reduced/delayed gastrointestinal absorption (Heestermans, van 
Werkum et al. 2008).  In addition, variations in P-gp efflux co-transporter may 
affect clopidogrel absorption via the intestine (Floyd, Passacquale et al. 
2012).  
 
Genetic polymorphisms in the cytochrome P450 2C19 allele (and to a lesser 
extent the CYP450 3A4 allele), can lead to marked differences in the activity 
of these enzymes; these differences often correlate with the variability in the 
degree of inhibition of platelet activity observed in patients (Wallentin 2009).  
The mean prevalence of clopidogrel non-response is 21%, polymorphisms 
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within the 2C19 allele is known to account for only 12% of the variability 
observed in clopidogrel response (Perry and Shuldiner 2013).  Thereby 
indicating that the variability in response seen is multifactorial and is 
attributable to both genetic (C19 loss of function allele, P-gp which is encoded 
by ABCB1) and non-genetic (smoking, diabetes, BMI, concomitant drug 
therapy) factors.  
 
Although weight was not always documented in the case report forms, the 
data collated in chapter 2 indicates that patients treated with clopidogrel in our 
centre have an average BMI of 26.6 ± 4.8, and are therefore considered to be 
overweight.  Patient demographics from table 14 indicate that there were no 
statistically significant differences between the STEMI and NSTEMI groups 
with regards to smoking status, incidence of diabetes or concomitant drug 
therapies (with the exception of morphine).  Smoking is known to alter 
CYP450 levels and can adversely affect drug metabolism and 
biotransformation.  In comparison to those with a normal weight, patients who 
are overweight, demonstrate higher levels of platelet reactivity and may 
display a sub-optimal response to clopidogrel therapy (Wallentin 2009).  The 
presence of diabetes is associated with high levels of platelet reactivity and an 
impaired response to clopidogrel (Wallentin 2009). 
 
Advancing age, is also an important independent predictor of an individual’s 
response to clopidogrel; the ability of clopidogrel to lead to sufficient levels of 
platelet inhibition during the acute phase of a MI is dependent on the patients 
age. Advancing age not only leads to a reduction in gastric motility and 
 123 
absorption, but is also associated with a reduction in the activity of CYP450 
substrates in the liver which can compromise the ability of an older patient to 
convert the clopidogrel prodrug into its active metabolite (Gurbel, Bliden et al. 
2003, Maree and Fitzgerald 2007).  The observed data demonstrates that 
there is a significant difference in age between our STEMI and NSTEMI 
groups (p = 0.005).  This difference is largely driven by the licensing of 
prasugrel which does not recommend its use in those over the age of 75 
years.   
 
A number of drug-drug interactions relating to the P2Y12 inhibitors and 
medications such as opioids, statins and proton pump inhibitors have also 
been proposed.  However, with the exception of the opioids, co-administration 
of statins/proton pump inhibitors is not considered to be clinically significant 
and would not warrant any intervention.     
The COGENT study in which the co-administration of omeprazole with 
clopidogrel was thought to lead to an increase in CV events was actually 
underpowered to make such an inference.  In addition, the period of co-
administration was not long enough to draw any firm conclusions regarding 
the validity of the interaction (Bhatt, Cryer et al. 2010).  A number of clinical 
trials in both healthy patients and in those who present with ACS have 
quantified the adverse impact of opioid based administration on the clinical 
efficacy of clopidogrel and indeed all P2Y12 inhibitors (Heestermans, van 
Werkum et al. 2008, Hobl, Reiter et al. 2015, Parodi, Bellandi et al. 2015). 
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Clopidogrel biovailability has been shown to be significantly impaired in 
STEMI patients compared with healthy volunteers and this has been 
attributed to impaired intestinal absorption of clopidogrel during STEMI. 
(Heestermans, van Werkum et al. 2008).    This reduction in intestinal 
absorption occurs secondary to a number of physiological changes that occur 
during a STEMI; reduction in cardiac output, increased sympathetic drive, 
vasoconstriction of peripheral arteries, reduced gut perfusion, permeability 
and motility are the main contributors to impaired drug absorption.  In addition, 
the administration of opioid-based analgesia has also been shown to reduce 
clopidogrel absorption with a consequent reduction in active metabolite 
generation and possible treatment failure (Hobl, Stimpfl et al. 2014). 
 
Patients who present with high baseline/intrinsic platelet reactivity will as a 
consequence be predisposed to high residual platelet reactivity and have less 
antithrombotic protection (Gurbel, Bliden et al. 2003).  This in part can be 
mitigated by the co-administration of intravenous antithrombotic agents (e.g. 
UFH or GPIs), which have the potential to achieve adequate levels of platelet 
inhibition during the acute phase for those patients who are scheduled for 
PCI, however, may predispose patients to bleeding complications. 
 
5.8 Conclusion 
In terms of the degree and time course of platelet inhibition following the 
administration of a 600mg loading dose of clopidogrel, there is no significant 
reduction in IPA observed over time.  Clopidogrel is ineffective for the first four 
hours after administration in both STEMI and NSTEMI patients.   
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As a consequence of the physiological state of STEMI, platelet activation 
secondary to endothelial dysfunction/vascular injury has already occurred; the 
platelets are activated to such a degree that they have gone past the point at 
which the P2Y12 inhibitor can exert its antiplatelet effect.  The administration 
of clopidogrel will prevent further platelet aggregation, but won't be able to 
inhibit the already activated platelets.  The results of this study in which the 
pharmacokinetics and pharmacodynamics of clopidogrel in STEMI vs 
NSTEMI have been investigated support the already proven concept as to 
why clopidogrel does not provide maximum efficacy in terms of IPA during an 
acute STEMI.  High residual platelet reactivity secondary to both genetic and 
non-genetic factors can compromise the clinical efficacy of clopidogrel during 
the acute phase of an MI. 
 
The inherent limitations of clopidogrel in terms of its sub-optimal 
characteristics coupled with the physiological changes that occur in a STEMI 
in addition to opioid administration and age related dysfunction with regards to 
drug metabolism, may account for the lack of antiplatelet effectiveness 
observed in our STEMI group.  It is apparent that interindividual variability in 
the degree of intestinal absorption may be an important determinant of the 
response in variability seen with clopidogrel. 
 
In conclusion, the state of STEMI itself leads to platelet hyperreactivity. The 
heightened/elevated levels of PRU in the context of STEMI indicate an 
increase in the degree of intrinsic platelet reactivity even before the 
administration of the P2Y12 inhibitor.  Pre-treatment/high intrinsic platelet 
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reactivity can lead to high residual platelet reactivity, which in turn can lead to 
further MACCE and ischaemic complications, particularly in patients treated 
with clopidogrel. 
 
Subsequent prasugrel and ticagrelor data (chapters 6 and 7) will provide 
further insights into whether those drugs which provide faster, greater and 
more consistent levels of platelet inhibition can overcome this increase in 
intrinsic and high residual platelet reactivity seen during a STEMI.   
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Chapter 6 - A Pharmacokinetic and Pharmacodynamic 
Assessment of Prasugrel in Patients Undergoing 
Percutaneous Coronary Intervention (PCI) for Acute 
Myocardial Infarction 
 
6.1 Introduction 
A detailed overview of prasugrel, its mechanism of action, clinical efficacy and 
place in therapy has been covered extensivley in chapter 1. 
 
6.2 Objectives 
This chapter aims to compare the degree and time course of platelet inhibition 
observed following the administration of a prasugrel 60mg loading doses in 
STEMI versus NSTEMI patients.  In addition, we will also determine whether 
the state of STEMI per se adversely affects the clinical efficacy of prasugrel, 
during the first few hours after a myocardial infarction. 
6.3 Ethical Considerations and Consent 
All ethical considerations and procedures for obtaining patient consent and 
patient recruitment are described in Chapter 4. 
6.4 Materials and Methods 
All materials and methods are described in Chapter 4. 
6.5 Statistics and Data Analysis 
The methods for data collection and statistical analyses are outlined in 
Chapter 4. 
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6.6 Results 
 
Table 20. Baseline patient characteristics – prasugrel treatment group. 
Characteristic 
STEMI  
(n =15) 
NSTEMI  
(n =15) 
P-value 
Age (yrs) 56 ± 12.9 61 ± 7.6 0.214 
Sex        
     Female 3 (20) 2 (13) 1.000 
Risk Factors        
     Diabetes Mellitus 4 (27) 7 (47) 0.450 
     Hypertension 7 (47) 6 (40) 1.000 
     Current Smoker 3 (20) 1 (7) 0.598 
     Ex Smoker 8 (53) 7 (47) 1.000 
     Hyperlipidaemia 5 (33) 5 (33) 1.000 
     Familial History of CAD 9 (60) 8 (53) 1.000 
     Previous MI 2 (13) 3 (20) 1.000 
     Previous PCI 1 (7) 4 (27) 0.330 
     Previous CABG 1 (7) 0 (0) 1.000 
     Previous stroke/TIA 0 (0) 0 (0) -  
Patient therapy on admission       
     Analgesia 13 (87) 7 (47) 0.050 
     Comprising of:- 
                                    Morphine 13 12 < 0.001 
GTN 0 5 0.017 
 
 
6.6.1 Pharmacodynamic analysis of the degree of platelet inhibition 
following prasugrel loading (60mg) STEMI vs NSTEMI 
6.6.1.1 VerifyNow Results 
Table 21. Prasugrel - VerifyNow (PRU) 
Verify Now result 
expressed as PRU 
post loading 
Group N Mean Mean Difference 
[95% CI] 
Std. 
Deviation 
Std. 
Error 
Mean 
 
p-value 
20 minutes  
STEMI 15 247.73 121.93 
[68.10, 175.77] 
48.78 12.60 0.000 
NSTEMI 15 125.80 89.34 23.07 
60 minutes  
STEMI 15 262.87 185.93 
[128.64, 243.23] 
43.43 11.21 0.000 
NSTEMI 15 76.93 99.24 25.62 
240 minutes 
STEMI 14 128.64 96.78 
[43.49, 150.16] 
89.16 23.83 0.002 
NSTEMI 15 31.87 45.52 11.75 
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Figure 20. Mean VerifyNow PRUs (and standard error) following the 
administration of Prasugrel in STEMI vs NSTEMI patients  
 
 
6.6.1.1.1 Summary 
Following administration of a 60mg loading dose of prasugrel, this data 
indicates a statistically significant difference in mean PRU values between 
STEMI and NSTEMI samples taken at 20 minutes (247.73 ± 12.60 vs 125.80 
± 83.07 p = 0.000) and 60 minutes (262.87 ± 11.21 vs 79.93 ±25.62 p = 
0.000).   At four hours following the administration of a 60mg loading dose of 
prasugrel, there is a highly statistically significant difference in the mean PRU  
values observed between the STEMI and NSTEMI groups (128.64 ± 23.83 vs 
31.87 ± 11.75 p = 0.002). 
The data in table 21 were analysed using a two way analysis of variance test 
in which the effect of disease state (STEMI vs NSTEMI) on the degree of 
platelet inhibition (PRU) over time was examined.  There was a highly 
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significant increase in the degree of platelet inhibition observed over time, for 
both the STEMI and NSTEMI groups, F(2,26) = 17.897 p = 0.000 
There was highly significant difference between the effect of disease state on 
the degree of platelet inhibition over time, F(2,26) = 7.114, p = 0.003. 
6.6.1.2 VASP-PRI (%) Results 
 
Table 22. Prasugrel – VASP-PRI (%) 
VASP-PRI (%) 
result post 
loading 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
 
 
p-value 
20 minutes  
STEMI 8 46.25 12.98 
[-23.34, 49.30] 
33.34 13.91 0.461 
NSTEMI 11 33.27 35.36 10.66 
60 minutes  
STEMI 8 50.50 28.59 
[-3.57, 60.75] 
33.62 11.89 0.078 
NSTEMI 11 21.91 32.23 9.72 
240 minutes 
STEMI 8 57.00 41.82 
[18.27, 65.36] 
29.38 10.39 0.002 
NSTEMI 11 15.18 19.40 5.85 
 
Figure 21. Mean VASP-PRI% (and standard error) following the 
administration of Prasugrel in STEMI vs NSTEMI patients. 
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6.6.1.2.1 Summary 
Following administration of a 60mg loading dose of prasugrel, this data 
indicates a non-significant difference in mean %PRI values between STEMI 
and NSTEMI samples taken at 20 minutes (46.25 ± 13.91 vs 33.27 ± 10.66 p 
= 0.461). At 60 minutes there was a significant difference in mean %PRI  
(50.50 ± 11.86 vs 21.91 ± 9.72 p = 0.078).   At four hours following the 
administration of a 60mg loading dose of prasugrel, there is a highly 
statistically significant difference in the mean %PRI values observed between 
the STEMI and NSTEMI groups (57.00 ± 29.38 vs 15.18 ± 5.85 p = 0.002). 
The data in table 22 were analysed using a two way analysis of variance test 
in which the effect of disease state (STEMI vs NSTEMI) on the degree of 
platelet inhibition (PRU) over time was examined.  There was a significant 
difference between the effect of disease state on the degree of platelet 
inhibition F(2,16) = 1.004, p = 0.389.  The observed reduction in the degree of 
platelet inhibition over time for both disease states was not significant, F(2,16) 
= 0.098, p = 0.907. 
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6.6.2 Liquid Chromatography/Mass Spectrometry Results 
 
6.6.2.1 Pharmacokinetic analysis of active metabolite generation 
following prasugrel loading (60mg) STEMI vs NSTEMI 
 
Table 23. Prasugrel active metabolite plasma concentration (ng/ml) 
Plasma 
concentration of 
active metabolite  
(ng/ml) post 
loading 
Group N Mean Mean Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
STEMI 15 14.27 -501.32 
[-714.61, -288.44] 
34.10 8.80 0.003 
NSTEMI 10 515.80 401.10 126.84 
60 minutes  
STEMI 14 36.86 -157.73 
[-228.82, -86.65] 
49.66 13.27 0.000 
NSTEMI 10 194.59 94.79 29.97 
240 minutes 
STEMI 15 38.44 -1.63 
[-19.20, 22.47] 
29.40 7.59 0.872 
NSTEMI 10 36.80 14.53 4.60 
 
 
 
Figure 22: Mean prasugrel active metabolite plasma concentration 
(ng/ml) (and standard error) following the administration of a prasugrel 
60mg loading dose in STEMI vs NSTEMI patients. 
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6.6.2.1.2 Summary 
Following administration of a 60mg loading dose of prasugrel, this data 
indicates a highly significant difference in mean plasma concentration of P-AM 
(ng/ml), between STEMI and NSTEMI samples taken at 20 minutes (14.27 ± 
8.80 vs 515.80 ± 126.38 p = 0.003). At 60 minutes there was a highly 
significant difference in mean plasma concentration (ng/ml) (36.86 ± 13.27 vs 
194.59 ± 29.97 p = 0.000).   At four hours following the administration of a 
60mg loading dose of prasugrel, there no statistical difference in the mean 
plasma concentration (ng/ml) values observed between the STEMI and 
NSTEMI groups (38.44 ± 7.59 vs 36.80 ± 4.60 p = 0.872). 
The data in table 23 were analysed using a two-way analysis of variance test 
in which the effect of disease state (STEMI vs NSTEMI) on the degree of P-
AM generation expressed as the plasma concentration (ng/ml) over time was 
examined.  There was a highly significant difference between the effect of 
disease state on the degree of platelet inhibition, F(2,21) = 13.475, p = 0.000.  
The observed reduction in the degree of platelet inhibition over time for both 
disease states was highly significant, F(2,21) = 11.779 p = 0.000. 
 
6.6.3 Correlation between platelet function assays, VerifyNow and VASP-
PRI (%) and active metabolite generation/plasma concentration. 
 
As explained in chapter 5, since all VerifyNow samples were collected and 
assessed at the base hospital and I was able to undertake a majority of these 
tests myself, the results generated are more reliable.  Therefore, our 
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VerifyNow results have been used as a baseline against which to compare 
the VASP-PRI (%) and active metabolite plasma concentration (ng/ml) results. 
 
Table 24 Correlation the degree of platelet inhibition observed using 
VerifyNow compared with VASP-PRI following the administration of a 
prasugrel 60mg loading dose 
 
 
VerifyNow 
VASP-PRI 
STEMI NSTEMI 
r p-value r p-value 
20 minutes 
post loading 
0.202 0.631 0.912 0.002 
At Balloon 
Inflation 
-0.614 0.105 x x 
60 minutes 
post loading 
0.357 0.385 0.532 0.113 
240 minutes 
post loading 
0.667 0.071 0.158 0.663 
 
VerifyNow (expressed as PRU) and VASP-PRI (%) results provide an 
indication as to the degree of platelet inhibition achieved following the oral 
administration of a prasugrel loading dose to both STEMI and NSTEMI 
patients.   
 
Table 25.  Correlation between the degree of platelet inhibition observed 
using VerifyNow compared with prasugrel active metabolite plasma 
concentration following the administration of a 60mg loading dose. 
 
 
VerifyNow 
Prasugrel active metabolite plasma concentration 
STEMI NSTEMI 
r p-value r p-value 
20 minutes 
post loading 
0.055 0.846 0.284 0.426 
At Balloon 
Inflation 
0.096 0.733  x x 
60 minutes 
post loading 
-0.169 0.564 0.532 0.113 
240 minutes 
post loading 
-0.512 0.061 0.158 0.663 
 
Based on the mechanism of action of prasugrel and the nature of the platelet 
function assays, one would expect a negative correlation between the degree 
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of platelet inhibition (PRU) and the amount of active metabolite generated in 
both the STEMI and NSTEMI groups.  
6.7 Discussion 
In terms of the patient population recruited to the prasugrel arm of the study 
(table 20), there are no statistically significant differences between the STEMI 
and NSTEMI groups; both groups are well matched in terms of their baseline 
characteristics.  There is a numerical but not statistical difference in the 
number of diabetic patients in the NSTEMI group compared with the STEMI 
group.  This difference is attributable to national guideline recommendations 
stipulating that diabetic NSTEMI patients under the age of 75 years and over 
60kg in body weight would be assigned the prasugrel arm of the study (NICE 
TAG 317 2014).  This inclusion criterion was amended part way through the 
study to extend the eligibility to non-diabetic patients also (as per the 
manufacturers recommendations), to facilitate recruitment to the NSTEMI arm 
(eMC 2016a). 
 
There is a highly statistically significant difference in the administration of 
morphine (p < 0.001) and statistically significant difference in the 
administration of sub-lingual glyceryl trinitrate (p = 0.017) between the STEMI 
and NSTEMI groups.  Again, this difference is attributable to evidence base 
and guideline recommendations which advise against the administration of 
either drug to NSTEMI patients in view of the increased mortality associated 
with their use in this particular patient group (Meine, Roe et al. 2005). 
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6.7.1 Pharmacodynamic analysis - VerifyNow 
A detailed explanation of the interpretation of VerifyNow data is given in 
chapter 4. 
 
The observed VerifyNow pharmacodynamic data demonstrates a statistically 
significant difference in PRU values between our STEMI and NSTEMI groups 
at all data collection time points (figure 21).  Thereby indicating the disease 
state of STEMI significantly impairs the onset of platelet inhibition when 
compared to NSTEMI. 
 
The pharmacodynamic superiority of prasugrel over clopidogrel results from 
its complete and rapid absorption following oral administration; 100% of the 
loading dose is absorbed via the gastrointestinal tract.  However, in the 
condition of STEMI, delays in gastric motility adversely affect the amount of 
prasugrel that undergoes gastrointestinal absorption, leading to a decrease in 
the amount of active metabolite generated because less parent compound is 
absorbed and available for conversion by intestinal esterases to the 
intermediate metabolite, which is then converted to the active moiety. 
 
The time delay between oral administration and subsequent gastric 
absorption and metabolic activation is evident by the increased PRU values 
observed at 20 minutes and 60 minutes (242 and 262 respectively) and 
adequate PRU value (128) at 240 minutes.  So despite, an enhanced and 
more efficient pathway for P-AM generation, prasugrel is still subject to and 
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limited by HRPR and provides sub-optimal levels of platelet inhibition at the 
time of angioplasty, as demonstrated by the reported data. 
 
HRPR observed during the immediate period following prasugrel 
administration is most likely attributable to heightened platelet reactivity that 
occurs secondary to acute endovascular injury following vulnerable 
atherosclerotic plaque rupture and the acute inflammatory response that 
occurs subsequent coronary artery stent implantation (Angiolillo, Fernandez-
Ortiz et al. 2007).  These manifestations in addition to the reduction in 
gastrointestinal absorption and hepatic metabolism due to the diversion of 
blood flow away from the gut and liver plus the administration of opioid-based 
analgesia can also contribute to reduced prasugrel effectiveness and the 
occurrence of HRPR. 
 
In contrast, the NSTEMI patients demonstrate adequate levels of platelet 
inhibition at 20 minutes (PRU < 208), and excessive levels of platelet 
inhibition at 60 and 240 minutes (PRU < 95).  This data indicates, that in 
comparison to our STEMI patients, the NSTEMI cohort are at increased risk of 
experiencing bleeding complications due to excessive inhibition of platelet 
aggregation. 
6.7.2 Pharmacodynamic analysis -  VASP-PRI (%) 
The interpretation of VASP-PRI (%) results is explained extensively in chapter 
5.  In contrast to the VerifyNow results, the pharmacodynamic VASP data 
indicates that there is no statistically significant difference in the degree of 
platelet inhibition observed over time following the administration of a 
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prasugrel 60mg loading dose (p = 0.389).  In addition, the disease state of 
STEMI does not affect the degree of platelet inhibition achieved when 
compared to our NSTEMI patient group as shown in figure 22 and 
documented in table 22. 
 
On further analysis of the VASP-PRI% data, an explanation for the increasing 
%PRI trend observed in our STEMI group cannot be given; the data appears 
to indicate a reduction in antiplatelet efficacy over time (figure 22).   
 
An explanation for this may be due to the lag time between oral administration 
to onset of action allows for even more platelets to become activated thereby 
reducing the clinical efficacy of prasugrel, such that it is only active against 
new platelets.  However, were this the case, then we would see a similar 
trend in our VerifyNow data. 
 
The NSTEMI data in comparison, demonstrates increasing antiplatelet 
effectiveness of prasugrel over time; the %PRI at each time point is below 
50% indicating an adequate level of platelet inhibition.  At 240 minutes, the 
%PRI observed, indicates that degree of platelet inhibition could predispose 
patients to increased bleeding risks.  These results are in line with previously 
reported data in which pre-treatment with prasugrel in the context of NSTEMI 
increases the risk of bleeding complications (Montalescot, Collet et al. 2014).   
 
On examining the relationship between our VerifyNow and VASP 
phosphorylation assays (table 24), there is no significant correlation  
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between the two assays in neither the  STEMI or NSTEMI groups. The 
numerical trend in our NSTEMI group for both assays indicates increasing 
antiplatelet effectiveness over time as demonstrated by the decreasing PRU 
and %PRI values recorded.  However, the data for our STEMI group is 
inconsistent between the two assays. 
 
As a result of the inconsistencies observed in the VASP data, which is most 
likely to due to inexperience of conducting the analytical techniques required 
to run the analysis and operate the flow cytometer, the VASP results reported 
in this work will be used and applied with caution. 
 
6.7.3 Pharmacokinetic analysis – LC-MS/MS 
The pharmacokinetic analysis of prasugrel active metabolite generation was 
assessed as the maximum plasma concentration determined using LC-
MS/MS.  The pharmacokinetic profile of prasugrel and its active metabolite 
has been investigated extensively in healthy patients.  The maximum plasma 
concentration of P-AM reported in these studies ranged from 87 ng/ml to 512 
ng/ml and usually occurred within 30 minutes of administration of a 60mg 
loading dose (Brandt, Payne et al. 2007, Payne, Li et al. 2007, Cattaneo 
2010) . 
 
Following oral administration, hydrolysis by intestinal esterases leads to the 
generation of an intermediate metabolite  (R-95913), the speed of conversion 
of R-95913 to the P-AM (R-138727) via CYP3A4 and CYP2B6 is so rapid and 
efficient that the intermediate metabolite is not detectable (Floyd, 
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Passacquale et al. 2012).  For this reason, our pharmacokinetic analysis 
focused on detection of the final P-AM (R-138727) only.  
 
The observed pharmacokinetic data demonstrates a marked and statistically 
significant difference in the pharmacokinetic profile and P-AM generation 
between the STEMI and NSTEMI groups over time (p = 0.000) as shown in 
figure 23.  However, this should be interpreted with caution in view of the 
erroneous NSTEMI results recorded. 
 
P-AM in the STEMI patients’ increases over time, although, the P-AM plasma 
concentrations are numerically quite low compared to the values previously 
reported data from healthy subjects.  Since this data are derived from STEMI 
patients during the acute phase of their presentation, the reduction in gastric 
absorption is likely to result in less prasugrel being available for conversion by 
intestinal esterases to the intermediate and subsequent active metabolite.  
 
To date there are no studies, which provide pharmacokinetic insights into the 
plasma concentrations of P-AM during a STEMI, as such there are no data 
against which to benchmark the results of this current study.  However, when 
comparing the outcomes to the average reported values in healthy patients 
(87ng/ml), it can be concluded that the physiological state of STEMI does 
adversely affect the pharmacokinetic profile of prasugrel. 
 
Interestingly, P-AM generation in the NSTEMI group decreases over time, 
with the highest value observed at 20 minutes and lowest at 240 minutes 
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(figure 23).  This finding is unusual and does not correlate with the 
pharmacodynamic data collated during the VerifyNow and VASP-PRI assays; 
both of which demonstrate a reduction in PRU and %PRI indicating an 
increase in antiplatelet effectiveness through a reduction in platelet reactivity 
over time. 
 
It was initially thought that our erroneous NSTEMI P-AM results were due to a 
labelling error.  However, all blood samples for the three analytical tests were 
collected and transferred to the appropriate sampling tubes and labelled at the 
same time for each patient.  If these results were due to a labelling error, then 
the same trend/irregularities would be expected with the VerifyNow and 
VASP-PRI samples also.   
 
Following discussion with our Clinical Chemist, the established and validated 
methods for sample collection, preparation and subsequent LC-MS/MS 
analysis as previously described in chapter 4 were utilised without 
modification (Farid, McIntosh et al. 2007, Payne, Li et al. 2007).  In order to 
ensure that the results were not due to incorrect coding of the sampling tubes 
at the time of the LC/MS/MS analysis, all sampling tubes were cross-
referenced against the original case report form documentation and the LC-
MS/MS analyses was undertaken again using the same column and a new 
column. In addition, new internal standards for P-AM were also sourced and 
were again prepared using the validated method described by Farid et al 
(Farid, McIntosh et al. 2007).  Unfortunately, the results of the second and 
third attempts also resembled those initially recorded.  In view of this, we 
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decided to use the original results generated, since the clopidogrel and 
ticagrelor LC-MS/MS analyses were also undertaken using the original 
column on which the prasugrel anaylsis was carried out. 
 
On examining the relationship between the pharmacodynamic and 
pharmacokinetic profiles generated following the administration of a prasugrel 
60mg loading dose (table 25), there are no significant correlation between the 
two sets of data. 
The pharmacokinetic and pharmacodynamic profile of prasugrel demonstrates 
homogeneity in terms of its clinical efficacy, speed of onset and resulting 
consistent and high levels of platelet inhibition when reviewing existing clinical 
trial outcomes and data (Brandt, Payne et al. 2007, Wiviott, Braunwald et al. 
2007).  However, platelet function assays and assessment of plasma active 
metabolite concentrations were not determined during the immediate period 
following diagnosis or at the time of angioplasty in patients scheduled to 
undergo PCI. 
 
For the STEMI patients, the mean dose to balloon time was 26.8 ± 12.7 
minutes; within this time frame, our prasugrel STEMI pharmacodynamic data 
indicates a PRU value of 240 and a %PRI of 46.25, and our pharmacokinetic 
data indicates a P-AM plasma concentration of 14.27ng/ml.  As such the 
pharmacokinetic/pharmacodynamic data collated in our study very clearly 
demonstrates a lack of antiplatelet effect following the administration of 
prasugrel 60mg at the time of balloon inflation and subsequent coronary 
artery stent implantation and for at least 60 minutes following administration.   
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This data is supported by and is in line with the findings of other recently 
reported pharmacodynamic studies in which prasugrel administration in 
STEMI patients is associated with a delay in the onset of antiplatelet activity, 
this delay persists for at least two to four hours (Alexopoulos, Xanthopoulou et 
al. 2012, Parodi, Valenti et al. 2013).  This delay in onset of action is most 
likely also influenced by the co-administration of morphine, which is 
associated with a reduction in the degree of platelet inhibition following the 
administration of prasugrel in both STEMI patients and healthy subjects (Hobl, 
Reiter et al. 2015, Parodi, Bellandi et al. 2015).  Although the outcomes of 
these studies are informative they investigate only the pharmacodynamic 
effect of the newer antiplatelet agents in STEMI patients; the results from this 
study build on the works of Parodi at al (2015) since these results also provide 
insights into the effect of STEMI on plasma P-AM concentrations and make 
direct comparisons against NSTEMI patients to determine the effect of 
disease state on drug handling. 
 
Based on its pathway of activation, a major determinant of the clinical efficacy 
of prasugrel is the degree of gastrointestinal absorption that will take place 
following oral ingestion.  Emerging evidence suggests that gastric motility is 
reduced in the setting of STEMI, either as a consequence of the shunting of 
blood flow away from the gut and/or the co-administration of morphine.  The 
delay in the onset of action of prasugrel and the inadequate antiplatelet effect 
observed is likely to be secondary to delayed gastrointestinal absorption. 
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While pretreatment/upstream administration of loading doses is necessary to 
partially overcome the lag time between administration and subsequent 
absorption and metabolic activation of antiplatelet pro-drugs in STEMI 
patients.  Observed data from this study indicates that pre-treatment with 
prasugrel 60mg in the NSTEMI group leads to levels of platelet inhibition that 
can predispose patients to increased bleeding risk; PRU values of < 208 and 
%PRI < 50% were recorded at 20 minutes in comparison to the STEMI group.  
These values continued to decrease over time to less than PRU < 95 and 
%PRI < 25% at 60 and 240 minutes; indicating effective, if not possibly 
excessive levels of platelet inhibition in our NSTEMI prasugrel treated group.  
The NSTEMI prasugrel data is therefore in line with the outcomes of the 
recently reported ACCOAST-PCI study in which pre-treatment with prasugrel 
in the context of NSTEMI was not associated with a reduction in ischaemic 
events but rather a three fold increase in non-CABG related TIMI major 
bleeding (Montalescot, Collet et al. 2014).  These findings have subsequently 
resulted in a change in the manufacturers recommendations and UK guideline 
recommendations, which no longer mandate upstream treatment with 
prasugrel in NSTEMI patients, but rather advise withholding administration of 
the loading dose until the time of PCI, particularly if coronary angiography is to 
be performed within 48 hours of the initial diagnosis (NICE TAG 317 2014). 
The relationship between pre-treatment with more potent P2Y12 inhibitors 
and bleeding risk in NSTEMI patients will be discussed further in chapter 8.   
 
Increased levels of ADP-induced platelet reactivity have been observed in 
older patients, this in part has been used to explain apparent treatment failure 
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with clopidogrel in patients over the age of 75 years (Gremmel, Steiner et al. 
2010).  This concept is in contrast to prasugrel data, which indicates that older 
age predisposes patients to increased bleeding as a consequence of 
increased exposure to P-AM; in patients over the age of 75 years, exposure to 
P-AM was 19% greater when compared to those under the age of 75 years 
(Wiviott, Antman et al. 2010). 
 
As described in earlier chapters, ACS and in particular the acute phase of a 
STEMI is associated with heightened platelet reactivity, despite the 
administration of potent antiplatelet agents (HRPR).  This occurrence is 
further perpetuated by the process of angioplasty and coronary artery stent 
implantation which is necessary to allow for timely reperfusion and adequate 
restoration of myocardial blood flow.  However, these mechanical 
interventions cause further platelet activation and contribute to the highly 
prothrombotic milieu that manifests during a STEMI. 
 
Prasugrel still needs to undergo gastrointestinal absorption and subsequent 
metabolic biotransformation to an intermediate and then active metabolite.  
This process is not reliant on the CYP2C19 allele and is not subject to genetic 
polymorphisms which are known to affect the onset of action and 
effectiveness of clopidogrel.  In contrast to clopidogrel, CYP3A4 is the key 
isoenzyme responsible for the biotransformation of prasugrel.  Animal studies 
have shown that a significant amount of R-138727 is formed during first-pass 
metabolism in the intestine; thereby supporting the notion that the intestine is 
an important contributor to the formation of P-AM and is fundamental to the 
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pharmacodynamic activity of prasugrel and its subsequent clinical effect 
(Hagihara, Kazui et al. 2011). 
 
Work undertaken by Small et al (2010) provides further insights into the 
mechanisms that contribute to the clinical effects of prasugrel.  Moderate 
hepatic dysfunction was found to have a negligible effect on P-AM exposure 
or generation.  When compared to healthy controls, in those with hepatic 
dysfunction the degree of platelet aggregation achieved following prasugrel 
administration remains unchanged (Small, Farid et al. 2009).  This is of 
importance, since it further supports the concept that hepatic 
biotransformation is not the most important contributor to the in-vivo formation 
of P-AM (R-138727).  Impaired gastric absorption, leads to a delay in the 
onset of action of antiplatelet effect as demonstrated by our VerifyNow and 
VASP-PRI data. 
 
Increased or intrinsic platelet reactivity even prior to the administration of a 
P2Y12 inhibitor contributes to the phenomenon of HRPR, to such an extent 
that even the administration of a more potent agent such as prasugrel is 
unable to result in sufficient levels of platelet inhibition at the time of PPCI 
(Frelinger, Michelson et al. 2011). 
6.8 Conclusion 
The reported prasugrel pharmacodynamic data in this thesis is in line with 
previously reported data; we conclude that the delay in onset of action and 
impaired antiplatelet effect observed following the administration of prasugrel 
is attributable to the variable and impaired gastrointestinal absorption that 
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occurs in the STEMI group compared to the NSTEMI group.  There is now 
increasing awareness of the inherent characteristics associated with the 
condition of STEMI (heightened platelet reactivity, diversion of blood flow 
away from the gut/liver, reduced peristalsis of the gut), which limit the clinical 
utility, and effectiveness of orally administered prasugrel during the acute 
phase of a myocardial infarction. 
 
In summary, the prasugrel data demonstrates that the degree and time course 
of platelet inhibition observed reduces over time in both the STEMI and 
NSTEMI groups (based on VerifyNow pharmacodynamic results).  However, 
prasugrel does not provide adequate levels of platelet inhibition at the time of 
angioplasty and coronary artery stent implantation. When compared to 
NSTEMI, the disease state of STEMI does adversely affect the clinical 
efficacy of prasugrel. 
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Chapter 7 - A Pharmacokinetic and Pharmacodynamic 
Assessment of Ticagrelor in Patients Undergoing 
Percutaneous Coronary Intervention (PCI) for Acute 
Myocardial Infarction 
 
7.1 Introduction  
 
A detailed overview of ticagrelor, its mechanism of action, clinical efficacy and 
place in therapy has been covered extensivley in chapter 1. 
7.2 Objectives 
This chapter aims to compare the degree and time course of platelet inhibition 
observed following the administration of a ticagrelor 180mg loading doses in 
STEMI and NSTEMI patients.  In addition, we will also determine whether the 
state of STEMI per se adversely affects the clinical efficacy of ticagrelor. 
7.3 Ethical Considerations and Consent 
All ethical considerations and procedures for patient consent and recruitment 
are described in Chapter 4. 
7.4 Materials and Methods 
All materials and methods are described in Chapter 4. 
7.5 Statistics and Data Analysis 
The methods for data collection and statistical analyses are outlined in 
chapter 4. 
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7.6 Results 
 
Table 26. Baseline patient characteristics 
Characteristic 
STEMI  
(n =15) 
NSTEMI  
(n =15) 
P-value 
Age (yrs) 63.7 ± 11.6 62 ±13.9 0.714 
Sex        
     Female 4 (27) 2 (13) 0.651 
Risk Factors     
     Diabetes Mellitus 2 (13) 4 (27) 0.651 
     Hypertension 7 (47) 7 (47) 1.000 
     Current Smoker 4 (27) 3 (20) 1.000 
     Ex Smoker 4 (27) 6 (40) 0.700 
     Hyperlipidaemia 3 (20) 12 (80) 0.003 
     Familial History of CAD 8 (53) 8 (53) 1.000 
     Previous MI 0 (0) 1 (7) 1.000 
     Previous PCI 0 (0) 1 (7) 1.000 
     Previous CABG 0 (0) 0 (0) -  
     Previous stroke/TIA 1 (7) 0 (0) 1.000 
Patient therapy on admission    
     Analgesia 13 (87) 3 (20) 0.001 
     Comprising of:-    
                                 Morphine 13 0 <0.001 
GTN 0 3 0.224 
 
7.6.1 Pharmacodynamic analysis of the degree of platelet inhibition 
following ticagrelor loading (180mg) in STEMI vs NSTEMI patients. 
 
7.6.1.1 VerifyNow Results 
 
Table 27. Ticagrelor VerifyNow (PRU)  
Verify Now result 
expressed as PRU 
post loading 
Group N Mean Mean Difference 
[95% CI] 
Std. 
Deviation 
Std. Error  
Mean 
 
 
p-value 
20 minutes  
STEMI 15 256.73 83.93 
[29.00, 139.77] 
50.81 13.12 0.005 
NSTEMI 15 172.80 92.54 23.90 
60 minutes  
STEMI 15 225.20 111.00 
[32.95, 189.05] 
82.70 21.35 0.007 
NSTEMI 15 114.20 122.22 31.56 
240 minutes 
STEMI 15 176.27 153.27 
[107.25,199.28] 
84.92 21.93 0.000 
NSTEMI 15 23.00 18.94 4.89 
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Figure 23. Mean VerifyNow PRUs (and standard error) after 
administration of a 180mg ticagrelor loading dose in STEMI vs NSTEMI 
patients. 
 
 
 
7.6.1.1.1 Summary 
Following administration of a 180mg loading dose of ticagrelor, the observed 
data indicates a statistically significant difference in mean PRU values 
between STEMI and NSTEMI samples taken at 20 minutes (256.73 ± 13.12 
vs 172.80 ± 23.90 p = 0.005), 60 minutes (225.20 ± 21.35 vs 114.20 ± 31.56 
p = 0.007).   At four hours following the administration of a 180mg loading 
dose of ticagrelor, there is a highly statistically significant difference in the 
mean PRU values observed between the STEMI and NSTEMI groups (176.27 
± 21.93 vs 23.00 ± 4.89 p = 0.000).  The data in table 27 were analysed using 
a two way analysis of variance test in which the effect of disease state 
(STEMI vs NSTEMI) on the degree of platelet inhibition (PRU) over time was 
examined.   
There was a highly significant decrease in the degree of platelet inhibition 
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observed over time, for both the STEMI and NSTEMI groups, F(2,27) = 31.27 
p = 0.000.  There was no significant difference between the effect of disease 
state on the degree of platelet inhibition over time, F(2,27) = 2.834, p = 0.076. 
 
7.6.1.2 VASP-PRI Results 
 
Table 28. Ticagrelor - VASP-PRI(%) 
VASP-PRI (%) 
result post loading 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
STEMI 8 79.75 17.75 
[-9.98, 45.45] 
26.01 9.20 0.190 
NSTEMI 7 62.00 23.25 8.79 
60 minutes  
STEMI 8 76.25 43.08 
[-0.37, 86.53] 
31.46 11.12 0.052 
NSTEMI 6 33.17 43.44 17.73 
240 minutes 
STEMI 8 51.38 30.66 
[-8.19, 69.51] 
39.78 14.07 0.112 
NSTEMI 7 20.71 27.74 10.48 
 
Figure 24. Mean VASP-PRI (%) (and standard error) following the 
administration of a 180mg ticagrelor loading dose in STEMI vs NSTEMI 
patients. 
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7.6.1.2.1 Summary 
Following administration of a 180mg loading dose of ticagrelor, this data 
indicates a non-significant difference in mean %PRI values between STEMI 
and NSTEMI samples taken at 20 minutes (79.75 ± 9.20 vs 62.00 ± 8.79 p = 
0.190).  At 60 minutes following administration of a 180mg loading dose a 
significant difference is observed (76.25 ± 11.12 vs 33.17 ± 17.73 p = 0.052).   
At four hours following the administration of a 180mg loading dose of 
ticagrelor, a non-significant difference in the mean %PRI values observed 
between the STEMI and NSTEMI groups (51.38 ± 14.07 vs 20.71 ± 10.48 p = 
0.112). 
The data in table 28 were analysed using a two way analysis of variance test 
in which the effect of disease state (STEMI vs NSTEMI) on the degree of 
platelet inhibition (%PRI) over time was examined.   
Interaction over time: there was a highly significant increase in the degree of 
platelet inhibition observed over time, for both the STEMI and NSTEMI 
groups, F(2,11) = 9.135 p = 0.005. 
Interaction between disease state by time: there was not a significant 
difference between the effect of disease state on the degree of platelet 
inhibition over time, F(2,11) = 2.329, p = 0.143. 
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7.6.2 Pharmacokinetic analysis of ticagrelor and ticagrelor active 
metabolite (AR-C124910X) generation following ticagrelor loading 
(180mg) in STEMI vs NSTEMI patients. 
 
7.6.2.1 Liquid Chromatography/Mass Spectrometry Results – Ticagrelor 
Parent Compound (T-PC) 
 
Table 29. Ticagrelor parent compound plasma concentration (ng/ml) 
Parent compound 
plasma 
concentration 
(ng/ml) post loading 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
STEMI 15 9.04 17.75 
[-9.98, 45.45] 
15.95 4.12 0.225 
NSTEMI 15 22.78 39.78 10.27 
60 minutes  
STEMI 15 47.13 -37.00 
[-122.39, 48.40] 
93.28 24.09 0.382 
NSTEMI 15 84.14 131.78 34.03 
240 minutes 
STEMI 15 84.92 -55.75 
[-169.47, 57.97] 
162.66 42.00 0.324 
NSTEMI 15 140.67 140.61 36.31 
 
Figure 25 Mean plasma concentration of ticagrelor parent compound 
(ng/ml) (and standard error) following administration of a loading dose 
in STEMI vs NSTEMI patients. 
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7.6.2.1.1 Summary 
Following administration of a 180mg loading dose of ticagrelor, this data 
indicates a non-significant difference in mean plasma concentration values 
between STEMI and NSTEMI samples taken at 20 minutes (9.04 ± 4.12 vs 
22.78 ± 10.23 p = 0.225), at 60 minutes (47.13 ± 24.09 vs 84.13 ± 34.03 p = 
0.382) and at 240 minutes (84.92 ± 42.00 vs 140.67 ± 36.31 p = 0.324). 
The data in table 29 were analysed using a two way analysis of variance test 
in which the effect of disease state (STEMI vs NSTEMI) on the plasma 
concentration expressed as ng/ml over time were examined.   
Interaction over time: there was a highly significant increase in the presence 
of ticagrelor parent compound observed over time, for both the STEMI and 
NSTEMI groups, F(2,27) = 6.930 p = 0.004. 
Interaction between disease state by time: there was a non-significant 
difference between the effect of disease state on the mean plasma 
concentration over time, F(2,27) = 0.339, p = 0.715. 
7.6.2.2 Liquid Chromatography/Mass Spectrometry Results – Ticagrelor 
Active Metabolite (T-AM). 
 
Table 30. Ticagrelor active metabolite plasma concentration (ng/ml) 
Active metabolite 
plasma 
concentration 
(ng/ml) post loading 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
STEMI 15 0.16 -7.76 
[-18.00, 10.19] 
0.63 0.16 0.150 
NSTEMI 15 7.72 19.74 5.10 
60 minutes  
STEMI 15 14.43 -43.97 
[-98.12, 10.19] 
28.21 7.28 0.107 
NSTEMI 15 58.40 98.42 25.41 
240 minutes 
STEMI 15 53.38 -60.21 
[-125.12, 4.70] 
97.62 25.21 0.068 
NSTEMI 15 113.59 74.38 19.21 
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Figure 26. Mean plasma concentration of ticagrelor active metabolite 
(ng/ml) (and standard error) following administration of a loading dose 
in STEMI vs NSTEMI patients. 
 
 
7.6.2.2.1 Summary 
Following administration of a 180mg loading dose of ticagrelor, this data 
indicates a non-significant difference in mean active metabolite plasma 
concentration values between STEMI and NSTEMI samples taken at 20 
minutes (0.16 ± 0.16 vs 7.72 ± 5.10 p = 0.150), at 60 minutes (14.43 ± 7.28 
vs 58.40 ± 25.41 p = 0.107) and at 240 minutes (53.38 ± 25.21 vs 113.59 ± 
19.21 p = 0.068).  The data in table 30 were analysed using a two way 
analysis of variance test in which the effect of disease state (STEMI vs 
NSTEMI) on the mean plasma concentration expressed as ng/ml over time 
were examined.  Interaction over time: there was a highly significant increase 
in the presence of ticagrelor active metabolite generated over time, for both 
the STEMI and NSTEMI groups, F(2,27) = 16.219 p = 0.000.  Interaction 
between disease state by time: there was a non-significant difference 
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between the effect of disease state on the mean plasma concentration over 
time, F(2,27) = 2.655, p = 0.089. 
7.6.2.3 Relationship between the mean plasma concentration of 
ticagrelor parent compound and active metabolite in STEMI patients. 
 
Table 31.  Mean plasma concentration (ng/ml) ticagrelor parent 
compound vs active metabolite in STEMI patients 
Plasma 
concentration 
(ng/ml) post 
loading 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
T-PC 15 9.04 8.88 
[0.44, 17.32] 
15.95 4.12 0.049 
T-AM 15 0.16 0.63 0.16 
Balloon 
Inflation 
T-PC 9 47.60 39.39 
[-4.19, 82.97] 
56.01 18.67 0.071 
T-AM 3 8.22 7.85 4.53 
60 minutes  
T-PC 15 47.13 32.70 
[-18.85, 84.24] 
93.28 24.09 0.204 
T-AM 15 14.43 28.21 7.28 
240 minutes 
T-PC 15 84.92 31.54 
[-68.79, 131.88] 
162.66 42.00 0.525 
T-AM 15 53.38 97.62 25.21 
 
 
Figure 27. Mean plasma concentration (ng/ml) (and standard error) of T-
PC vs T-AM in STEMI patients following the administration of a 180mg 
loading dose. 
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7.6.2.3.1 Summary 
The data in table 31 were analysed using a two way analysis of variance test 
in which the degree of absorption and subsequent metabolism of ticagrelor 
and its active metabolite as measured by the plasma concentration expressed 
as ng/ml over time were examined in STEMI patients.   
Interaction over time: there was a non-significant increase in the presence of 
ticagrelor parent compound and its active metabolite over time, F(3,8) = 1.965 
p = 0.198. 
Interaction between disease state by time: there was a non-significant 
difference in mean plasma concentration (ng/ml) between the presence of the 
parent compound and active metabolite over time, F(3,8) = 2.544, p = 0.129. 
 
7.6.2.4 Relationship between the mean plasma concentration of 
ticagrelor parent compound and active metabolite in NSTEMI patients. 
 
Table 32. Mean plasma concentration (ng/ml) ticagrelor parent 
compound vs active metabolite in NSTEMI patients. 
 
Plasma 
concentration 
(ng/ml) post 
loading 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
T-PC 15 22.78 15.07 
[-8.43, 38.55] 
39.78 10.27 0.280 
T-AM 15 7.72 19.74 5.10 
60 minutes  
T-PC 15 84.13 25.73 
[-61.26, 112.72] 
131.78 34.03 0.550 
T-AM 15 58.40 98.42 25.41 
240 minutes 
T-PC 15 140.67 27.09 
[-57.05, 111.22] 
140.61 36.31 0.515 
T-AM 15 113.59 74.38 19.21 
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Figure 28  Mean plasma concentration (ng/ml) (and standard error) of 
ticagrelor parent compound vs active metabolite in NSTEMI patients 
following the administration of a 180mg loading dose. 
 
 
7.6.2.4.1. Summary  
The data in table 22 were analysed using a two way analysis of variance test 
in which the degree of absorption and subsequent metabolism of ticagrelor 
and its active metabolite as measured by the plasma concentration expressed 
as ng/ml over time were examined in NSTEMI pateints.   
Interaction over time: there was a highly significant increase in the presence 
of ticagrelor parent compound and its active metabolite over time, F(2,27) = 
19.254 p = 0.000. 
Interaction between disease state by time: there was a non-significant 
difference in mean plasma concentration (ng/ml) between the presence of the 
parent compound and active metabolite over time, F(2,27) = 0.085, p = 0.918. 
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Table 33. Correlation the mean plasma concentration (ng/ml) of T-PC 
compared with T-AM following the administration of a ticagrelor 180mg 
loading dose 
Plasma 
concentration 
T-PC (ng/ml) 
Plasma concentration T-AM (ng/ml) 
STEMI NSTEMI 
r p-value r p-value 
20 minutes post 
loading 
0.744* 0.022 0.002 0.996 
At Balloon 
Inflation 
0.901** 0.000 x x 
60 minutes post 
loading 
0.850** 0.001 0.891** 0.000 
240 minutes 
post loading 
0.909** 0.000 0.449 0.107 
* Correlation is significant at the 0.05 level (2-tailed) 
* * Correlation is significant at the 0.01 level (2-tailed) 
 
The results of the Pearson correlation support the independent t-tests and 
ANOVA tests which indicate that there is no significant difference in the mean 
plasma concentrations of T-PC when compared with T-AM.  This supports the 
strong positive correlation, which is highly statistically significant, between T-
PC and T-AM plasma concentrations at all time points in the STEMI group.  
The relationship between T-PC and T-AM in the NSTEMI group also 
demonstrates a positive correlation, although overall, this was found to be 
non-significant. 
 
Using these results as a baseline, rather than quote both T-PC and T-AM in 
the remainder of the thesis, I will refer only to T-PC plasma concentrations. 
Previous pharmacokinetic studies have demonstrated that the maximum 
plasma concentration (Cmax) of T-PC is approximately 594ng/ml with the time 
to maximum concentration (Tmax) being 3.1 hours.  The Cmax for T-AM is 
135ng/ml with a Tmax of 3.7 hours (Husted, Emanuelsson et al. 2006, 
Wallentin 2009).  Although these data are from patients with stable coronary 
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artery disease, it does provide some insights into the drug handling following 
oral ingestion and the ratios in which T-PC and T-AM appear. 
7.6.3 Correlation between platelet function assays (VerifyNow and 
VASP-PRI) and ticagrelor plasma concentration as assessed using LC-
MS/MS. 
 
A Pearson’s Correlation Co-efficient test was also undertaken to determine 
the strength of the relationship between the two platelet function assays 
utilised during the study; VerifyNow and VASP phosphorylation assay.  Since 
all VerifyNow samples were collected and assessed at the base hospital and 
the results generated are more reliable, this test has been used as the 
baseline against which to compare the VASP-PRI (%).  In order to determine 
the correlation between the degree of platelet inhibition and plasma 
concentrations of ticagrelor, a Pearson’s correlation co-efficient test was also 
undertaken between the VerifyNow and ticagrelor parent compound LC-
MS/MS results. 
Table 34. Correlation the degree of platelet inhibition observed using 
VerifyNow compared with VASP-PRI following the administration of a 
ticagrelor 180mg loading dose 
 
 
VerifyNow 
VASP-PRI 
STEMI NSTEMI 
r p-value r p-value 
20 minutes 
post loading 
0.264 0.527 0.089 0.850 
At Balloon 
Inflation 
0.192 0.650 x x 
60 minutes 
post loading 
0.546 0.160 0.946** 0.004 
240 minutes 
post loading 
0.853* 0.007 -0.044 0.925 
* Correlation is significant at the 0.05 level (2-tailed) 
* * Correlation is significant at the 0.01 level (2-tailed) 
 
Both VerifyNow (expressed as PRU) and VASP-PRI (%) results provide an 
indication as to the degree of platelet inhibition achieved following the oral 
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administration of a ticagrelor loading dose to both STEMI and NSTEMI 
patients.   
 
Table 35.  Correlation between the degree of platelet inhibition 
observeusing VerifyNow compared with ticagrelor parent compound 
plasma concentration following the administration of a 180mg loading 
dose. 
VerifyNow 
(PRU) 
Ticagrelor parent compound plasma concentration (ng/ml) 
STEMI NSTEMI 
r p-value r p-value 
20 minutes post 
loading 
-0.482 0.069 -0.646* 0.017 
At Balloon 
Inflation 
-0.424 0.115 x x 
60 minutes post 
loading 
-0.438 0.103 -0.455 0.188 
240 minutes 
post loading 
-0.606* 0.017 0.120 0.683 
* Correlation is significant at the 0.05 level (2-tailed) 
 
Based on the mechanism of action of ticagrelor and the nature of the platelet 
function assays, one would expect a negative correlation between the degree 
of platelet inhibition (PRU) and the amount of active metabolite generated in 
both the STEMI and NSTEMI groups.  
7.7 Discussion  
Table 25 describes the baseline characteristics of the ticagrelor group.  In 
terms of the patient population recruited to the ticagelor arm of our study, all 
are well matched in terms of their age at presentation, co-morbidities and risk 
factors.  The only exception being a statistically significant difference in the 
incidence of hyperlipidaemia between the NSTEMI and STEMI groups (p = 
0.003).  In addition, a statistically significant greater number of patients in the 
STEMI group received treatment with opioid based analgesia compared to the 
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NSTEMI group (p = 0.001).  This has been explained and justified in previous 
chapters (5 and 6). 
 
7.7.1 Pharmacodynamic Analysis - VerifyNow 
The observed VerifyNow data (table 27) indicates that at the time of PPCI and 
for at least 60 (and maybe 120) minutes after the administration of a 180mg 
loading dose in STEMI patients, ticagrelor does not provide sufficient levels of 
platelet inhibition.  The PRU value at 20 minutes is > 230, which is indicative 
of HRPR and is > 208 at 60 minutes, indicating reduced antiplatelet effect and 
an increased risk of thrombotic complications. 
When comparing the STEMI results against the NSTEMI results, a statistically 
significant difference in PRU values is seen at each data collection time point.  
NSTEMI patients display adequate levels of platelet inhibition at 20 minutes 
and 60 minutes, however, the PRU at 240 minutes is very low indicating 
almost complete inhibition of platelet activity and an increased risk of bleeding 
complications. 
When determining the degree of platelet inhibition over time, there was a 
significant increase in IPA as shown in figure 25 (p = 0.000).  In terms of the 
effect of disease state on IPA, our ANOVA results indicate that the condition 
of STEMI does not have a significant impact on IPA when compared to 
NSTEMI (p = 0.076), however, this is in contrast to our t-test data in which a 
significant difference at each time point is observed. 
 
The reported VerifyNow data indicates that in the context of STEMI, despite 
being directly acting and able to provide faster and greater levels of IPA, 
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ticagrelor is still subject to HRPR limiting its clinical efficacy.  A possible 
explanation for this may lie in the reduction in gastric motility and subsequent 
reduction in gastric absorption that occurs during a STEMI, which will limit the 
amount of ticagrelor absorbed and able to exert its therapeutic antiplatelet 
effect. 
7.7.2 Pharmacodynamic analysis – VASP-PRI (%) 
The VASP-P pharmacodynamic results expressed as %PRI, in the STEMI 
group indicate an inadequate antiplatelet effect at all time points post loading 
as evidenced by %PRI values > 50%.  As explained in chapter 5, a %PRI > 
50% is associated with increased risk of further MACCE and complications 
such as stent thrombosis.  In comparison the NSTEMI group display 
increased levels of platelet reactivity at 20 minutes only with adequate levels 
of platelet inhibition at 60 minutes and 240 minutes.  The closer the %PRI 
value is to 0%, the greater the bleeding risk. 
 
The VASP-P data (table 28) indicates inadequate levels of platelet inhibition in 
our STEMI group, in comparison our NSTEMI group display inadequate levels 
at 20 minutes only, adequate levels at 60 minutes and excessive levels of 
platelet inhibition at 240 minutes. 
In terms of the degree of platelet inhibition over time, the data indicates a 
statistically significant increase in IPA (decrease in %PRI) over time, p = 
0.005.  However, the effect of disease state on the degree of platelet inhibition 
according to our VASP-PRI results indicates that there is no difference 
between the two groups (p = 0.143), as shown in figure 26. 
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7.7.3 Pharmacokinetic Analysis – LC-MS/MS 
T-PC and T-AM are equipotent; since T-AM is present in plasma at a 
concentration that is a third of that of the parent compound, the majority of the 
antiplatelet effect seen is due to the activity of the T-PC (Husted, 
Emanuelsson et al. 2006).  For the remainder of the thesis, all LC-MS/MS 
information regarding ticagrelor will relate to T-PC.  The subsequent sections 
demonstrate that although the final plasma concentrations are lower than 
those quoted in the literature, the trend in terms of T-PC:T-AM production are 
also observed in our STEMI and NSTEMI groups.  In addition, our data 
supports the rationale to quote T-PC plasma concentrations only, as outlined 
below. 
 
Plasma concentrations of T-PC and T-AM, indicate that levels in the region of 
549 ng/ml after 3.1 hours and 135ng/ml after 3.7 hours respectively in patients 
with SCAD can be achieved following the administration of a 180mg loading 
dose (Wallentin 2009).  At the time at which the ticagrelor patient group was 
recruited to the current study, there were no data relating to plasma 
concentrations of T-PC or T-AM in the context of STEMI against which the 
observed LC-MS/MS data could be benchmarked.  However, since 
completion of this study, a paper has been published in which the plasma 
concentrations of ticagrelor are investigated in STEMI patients.  This study 
was designed to provide a pharmacokinetic and pharmacodynamic 
comparison of crushed vs integral tablets in STEMI patients (Alexopoulos, 
Barampoutis et al. 2015).  The T-PC and T-AM plasma concentrations 
reported by Alexopoulos et al (2015) at 1 hour were 70ng/ml and 4.3ng/ml 
respectively (Alexopoulos, Barampoutis et al. 2015). 
 165 
This is not too dissimilar to the T-PC and T-AM results from this study, which 
in comparison demonstrate plasma concentrations of 47ng/ml and 14.3 ng/ml 
at 1 hour. 
 
This study data therefore is in line with recently reported pharmacodynamic 
data, which indicates, reduced plasma concentrations of intact ticagrelor 
tablets in STEMI patients, which is most likely secondary to delayed gastric 
absorption and the co-administration of morphine (Alexopoulos, Barampoutis 
et al. 2015, Kubica, Adamski et al. 2015).  Although this study was not 
adequately powered to determine the significance of the effect of morphine on 
the efficacy of ticagrelor, there is a growing body of evidence with 
pharmacodynamic data derived from both healthy volunteers and those who 
present following a STEMI, which indicates that this a drug-drug interaction 
that is of potential clinical significance (Kubica, Adamski et al. 2015, Parodi, 
Bellandi et al. 2015).  
7.7.3.1 Ticagrelor-Parent Compound (T-PC) 
 
Since, ticagrelor undergoes rapid and complete gastrointestinal absorption 
following oral ingestion, we would expect the STEMI plasma concentrations to 
more closely resemble the NSTEMI.  
In the STEMI group, the plasma concentrations at 20, 60 and 240 minutes are 
all less than 100ng/ml, comparatively, in the NSTEMI group, the plasma 
concentrations are numerically greater, but there is no statistical difference 
observed at each time point when comparing the two groups. 
The amount of T-PC detected in plasma over time increased significantly; the 
plasma concentration at 240 minutes compared to 20 minutes was statistically 
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significantly greater in both groups (p = 0.004).  However, when assessing the 
effect of STEMI of plasma concentrations/gastrointestinal absorption, our data 
indicates no significant difference between the two groups (p = 0.715) 
7.7.3.2 Ticagrelor-Active Metabolite (T-AM) 
As for theT-PC results, a statistically significant difference was not seen in the 
plasma concentration of T-AM between the STEMI and NSTEMI groups at 
each sample collection time point. 
However, in terms of the plasma concentration over time, a highly statistically 
significant increase in T-AM was seen at 240 minutes compared to 20 
minutes (p = 0.000).  When comparing the effect of STEMI against NSTEMI 
on the degree of T-AM present over time, we did not see a statistically 
significant difference between the two groups (p = 0.089). 
7.7.3.3 Correlation between T-PC and T-AM 
A Pearson’s correlation was undertaken to determine the strength of the 
relationship between the plasma concentration of T-PC and T-AM. A positive 
correlation was observed between the plasma concentrations of T-PC and T-
AM in each disease state and at each time point that was of statistical 
significance (table 33). 
 
On examining the relationship between the pharmacokinetic and 
pharmadynamic profiles generated following the administration of a ticagrelor 
180mg loading dose, the data in table 35, indicates a very high negative 
correlation between the degree of platelet inhibition as assessed by 
VerifyNow and the plasma concentration of T-PC, that is of high statistical 
significance at each time point in each disease state.  Our data indicates that 
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as the plasma concentration of T-PC increases, the antiplaletet effect of 
ticagrelor increases and the degree of inhibition of platelet reactivity and 
aggregation increases as evidenced by the reduction in PRU over time. 
 
Table 36.  Pharmacokinetic/Pharmacodynamic trend of ticagrelor over 
time 
 STEMI NSTEMI 
VerifyNow PRU   
VASP-P %PRI   
LC-MS/MS plasma 
concentration (ng/ml) 
  
 
7.8 Conclusion 
The reported pharmacodynamic data from this study indicates that even 
ticagrelor is subject to HRPR; there is a sufficient enough delay between the 
oral ingestion of ticagrelor and the onset of its therapeutic antiplatelet effect 
that reduces its efficacy in patients who present with a STEMI.  Since 
ticagrelor is directly acting, it does not rely on metabolic activation in order to 
execute its antiplatelet effect, however, in STEMI gastrointestinal absorption is 
impaired sufficiently enough to reduce the amount ticagrelor available to act 
as a P2Y12 inhibitor. 
So, despite ticagrelor being directly acting, in the context of STEMI it does not 
achieve adequate or sufficient levels of platelet inhibition at the time when it is 
most desirable in STEMI patients; at the time of angioplasty and coronary 
artery stent implantation. 
 
STEMI is a condition that precipitates heightened platelet reactivity and 
increased platelet turnover (Alexopoulos, Xanthopoulou et al. 2013).  The lag 
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time between the oral ingestion of ticagrelor and its ability to undergo 
gastrointestinal absorption and the subsequent onset of action and its 
antiplatelet effect is sufficiently long enough to allow for the phenomenon of 
HRPR to take place, as is apparent from our pharmacodynamic VerifyNow 
and VASP-P data.  So despite claims of an improved pharmacodynamic 
profile with faster onset of action and greater levels of IPA, the observed 
STEMI data indicates a lack of adequate antiplatelet action for at least 2 hours 
following administration.  This data is supported by other pharmacodynamic 
studies whose results were published as this study was in progress; these 
data also indicate reduced antiplatelet efficacy in the immediate period post 
loading indicating that at least 2 to 4 hours is required to achieve adequate 
levels of platelet inhibition (Alexopoulos, Xanthopoulou et al. 2012, Parodi, 
Valenti et al. 2013). 
 
In summary, the observed ticagrelor data demonstrates that the degree and 
time course of platelet inhibition observed reduces over time in both our 
STEMI and NSTEMI groups (based on VerifyNow and VASP-P 
pharmacodynamic results).  Depsite being directly acting, ticagrelor does not 
provide adequate levels of platelet inhibition at the time of angioplasty and 
coronary artery stent implantation.  From which we can conclude that the 
delay in gastric emptying and subsequent reduction in GI absorption 
adversely impacts on the speed of onset and clinical efficacy of ticagrelor. 
When compared to NSTEMI, the disease state of STEMI does adversely 
affect the degree of platelet inhibition observed following the administration of 
a ticagrelor loading dose.  NSTEMI patients are not subject to the same 
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physiological changes or the co-adminstration of opioids as are STEMI 
patients, these differences most likely account for the improved 
gastrointestinal absorption and enhanced antiplatelet effect seen. 
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Chapter 8 -  A Pharmacodynamic Comparison of all Three 
Oral P2Y12 Inhibitors in the context of STEMI vs NSTEMI in  
Patients Undergoing Percutaneous Coronary Intervention 
(PCI)  
 
8.1 Introduction 
Chapter 1 and the results presented in chapters 5,6 and 7 provide some initial 
insights into the clinical efficacy and drug handling of the three oral P2Y12 
inhibitors administered to patients who present following an ACS. 
 
Clopidogrel, although supported by a robust evidence base is accompanied 
by a number of inherent sub-optimal characteristics that limit its use in clinical 
practice.  As shown in figure 5, and described in chapter 1, clopidogrel 
following oral administration is subject to two pathways which dictate its 
pharmacological profile; a major pathway which is driven by human 
carboxylesterases and leads to inactivation of 85% of the orally administered 
dose (Varenhorst, James et al. 2009, Floyd, Passacquale et al. 2012). A 
second minor pathway is also involved and is a two-step process that is 
reliant upon the cytochrome P450 isoenzymes; 3A4 and 2C19 in particular 
(Floyd, Passacquale et al. 2012).  As a consequence, clopidogrel is relatively 
slow in terms of its onset of action and is subject to significant interindividual 
variability in response, secondary to genetic polymorphisms in the 2C19 allele 
(Tapp, Shantsila et al. 2010). 
Prasugrel, on the other hand, following oral ingestion, undergoes rapid and 
complete gastroinstestinal absorption and is subject to only a single major 
pathway prior to conversion of the inactive prodrug to its active metabolite 
(figure 6, chapter 1).   
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Ticagrelor also undergoes rapid and complete gastrointestinal absorption, 
however, it differs to the thienopyridines in that it does not require metabolic 
bioactivation; the parent compound is directly acting and able to exert an 
antiplatelet effect (figure 7, chapter 1). 
Initial study findings indicate that clopidogrel (chapter 5), prasugrel (chapter 6) 
and ticagrelor (chapter 7) demonstrate reduced antiplatelet efficacy in STEMI 
patients and that the disease state of STEMI does impact on their 
pharmacokinetic and pharmacodynamic profiles when compared to NSTEMI 
patients.  With this in mind, I aimed to provide a direct head to head 
comparison of all three agents and compare their relative effectiveness in 
both STEMI and NSTEMI patients. 
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Figure 29. Comparative pathways describing the absorption and 
metabolic biotransformation of oral P2Y12 inhibitors, clopidogrel, 
prasugrel and ticagrelor (adapted from Floyd et al 2012). 
 
 
Step 1 - gastrointestinal absorption.  Step 2 - metabolic biotransformation. 
 
8.2 Objectives 
This chapter aims to compare the degree and time course of platelet inhibition 
observed following the administration of clopidogrel 600mg, prasugrel 60mg 
and ticagrelor 180mg loading doses in STEMI and NSTEMI patients.  In 
addition, we will also determine whether the state of STEMI per se adversely 
effects the clinical efficacy of clopidogrel, prasugrel and ticagrelor. 
8.3 Ethical Considerations and Consent 
All ethical considerations and procedures for patient consent and recruitment 
are described in Chapter 4. 
8.4 Materials and Methods 
All materials and methods are described in Chapter 4. 
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8.5 Statistics and Data Analysis 
The methods for data collection and statistical analyses are outlined in 
chapter 4. 
8.6 Results 
 
Table 37. Baseline characteristics of study population – STEMI vs 
NSTEMI 
Characteristic 
STEMI  
(n = 43) 
NSTEMI  
(n = 44) 
P-value 
Age (yrs) 65.4 ± 14.4 61.5 ± 11.0 0.223 
Sex        
     Female 13  6 0.073 
Risk Factors     
     Diabetes Mellitus 6 14 0.073 
     Hypertension 20 20 1.000 
     Current Smoker 9 8 0.792 
     Ex Smoker 16 20 0.517 
     Hyperlipidaemia 12 25 0.009 
     Familial History of CAD 23 21 0.831 
     Previous MI 4 10 0.143 
     Previous PCI 3 8 0.196 
     Previous CABG 1 0 0.494 
     Previous stroke/TIA 2 0 0.241 
 
Table 38. Baseline characteristics - STEMI cohort 
Characteristic 
Clopidogrel 
(n =13) 
Prasugrel 
(n = 15) 
Ticagrelor 
(n =15) 
P-value 
Age (years) 78.00 ±9.70 56.00±12.9 63.73 ±11.59 <0.001 
Sex         
     Female 6 (46) 3 (20) 4 (27) 0.302 
Risk Factors      
     Diabetes Mellitus 0 (0) 4 (27) 2 (13) 0.127 
     Hypertension 6 (46) 7 (47) 7 (47) 1 
     Current Smoker 2 (15) 3 (20) 4 (27) 0.761 
     Ex Smoker 4 (31) 8 (53) 4 (27) 0.271 
     Hyperlipidaemia 4 (31) 5 (33) 3 (20) 0.691 
     Familial History of CAD 6 (46) 9 (60) 8 (53) 0.765 
     Previous MI 2 (15) 2 (13) 0 (0) 0.302 
     Previous PCI 2 (15) 1 (7) 0 (0) 0.280 
     Previous CABG 0 (0) 1 (7) 0 (0) 0.310 
     Previous stroke/TIA 1 (8) 0 (0) 1 (7) 0.566 
     Analgesia (opioid) 10 (77) 13 (87) 13 (87) 0.729 
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Table 39. Baseline Characteristics -  NSTEMI cohort. 
 
Characteristic 
Clopidogrel 
(n =14) 
Prasugrel 
(n = 15) 
Ticagrelor 
(n =15) 
P-value 
Age (years) 62.41 ± 5.40 61.07 ± 7.63 62.0 ±13.9 0.957 
Sex         
     Female 2 (14) 2 (13) 2 (13) 0.996 
Risk Factors      
     Diabetes Mellitus 2 (14) 7 (47) 4 (27) 0.068 
     Hypertension 7 (50) 6 (40) 7 (47) 0.858 
     Current Smoker 3 (21) 1 (7) 3 (20) 0.303 
     Ex Smoker 7 (50) 7 (47) 6 (40) 0.858 
     Hyperlipidaemia 8 (57) 5 (33) 12 (80) 0.036 
     Familial History of CAD 6 (43) 8 (53) 8 (53) 0.811 
     Previous MI 6 (43) 3 (20) 1 (7) 0.064 
     Previous PCI 3 (21) 4 (27) 1 (7) 0.332 
     Previous CABG 0 (0) 0 (0) 0 (0) 1.000 
     Previous stroke/TIA 0 (0) 0 (0) 0 (0) 1.000 
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Table 40. Baseline characteristics of study population – Clopidogrel vs Prasugrel vs Ticagrelor 
  
 Clopidogrel Prasugrel Ticagrelor 
Characteristic STEMI 
(n = 13) 
NSTEMI 
(n = 14) 
P-value STEMI 
(n = 15) 
NSTEMI 
(n = 15) 
P-value STEMI 
(n = 15) 
NSTEMI 
(n = 15) 
P-value 
Age (Years) 78.00 ± 9.70 62.41 ± 5.40 0.005 56.00 ± 12.9 61 ± 7.63 0.214 63.73 ± 11.59 62.00 ± 13.91 0.714 
Sex          
Female 6 (46) 2 (14) 0.103 3 (20) 2 (13) 1.000 4 (27) 2 (13) 0.651 
Risk Factors          
Diabetes Mellitus 0 (0) 2 (14) 0.481 4 (27) 7 (47) 0.450 2 (13) 4 (27) 0.651 
Hypertension 6 (46) 7 (50) 1.000 7 (47) 6 (40) 1.000 7 (47) 7 (47) 1.000 
Current Smoker 2 (15) 3 (21) 1.000 3 (20) 1 (7) 0.598 4 (27) 3 (20) 1.000 
Ex-smoker 4 (31) 7 (50) 0.44 8 (53) 7 (47) 1.000 4 (27) 6 (40) 0.700 
Hyperlipidaemia 4 (31) 8 (57) 0.252 5 (33) 5 (33) 1.000 3 (20) 12 (80) 0.003 
Family History of CAD 6 (46) 6 (43) 1.000 9 (60) 8 (53) 1.000 8 (53) 8 (53) 1.000 
Previous MI 2 (15) 6 (43) 0.209 2 (13) 3 (20) 1.000 0 (0) 1 (7) 1.000 
Previous PCI 2 (15) 3 (21) 1.000 1 (7) 4 (27) 0.330 0 (0) 1 (7) 1.000 
Previous CABG 0 (0) 0 (0) 1.000 1 (7) 0 (0) 1.000 0 (0) 0 (0) - 
Previous Stroke/TIA 1 (8) 0 (0) 0.481 0 (0) 0 (0) - 1 (7) 0 (0) 1.000 
Patient therapy on 
admission 
         
Analgesia 
Comprising of: 
10 (77) 7 (57) 0.236 13 (87) 7 (47) 0.050 13 (87) 3 (20) 0.001 
Morphine 10  2 0.002 13  2 0.000 13 0 0.000 
GTN 0 5 0.041 0 5 0.017 0 3 0.224 
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8.6.1 Pharmacodynamic analysis of the degree of platelet inhibition 
following aspirin loading (300mg) STEMI vs NSTEMI 
Aspirin is administered at the point of first medical contact either by 
ambulance staff or medical staff in A&E/emergency admissions unit as soon 
as a diagnosis of myocardial infarction is confirmed.  As for the P2Y12 
inhibitors, the pharmacodynamic profile of aspirin can also be assessed using 
the VerifyNow point of care platelet function assay.  
The Aspirin Reaction Unit (ARU) is used as a measure of the degree to which 
thromboxane A2-mediated platelet activation and aggregation is inhibited 
following the administration of a 300mg loading dose of aspirin.  An ARU of 
550 units is assigned as the cut off to determine whether the administration of 
aspirin yields a sufficient antiplatelet effect.  An ARU ≥ 550 is indicative of a 
lack of antiplatelet effect following the administration of aspirin 300mg orally. 
An ARU < 550 indicates therapeutic benefit following the administration of oral 
aspirin.  An ARU < 350, is indicative of an excessive antiplatelet effect, which 
may predispose patients to an increased bleeding risk.  The therapeutic 
window for aspirin following oral ingestion as indicated by the ARU is 350 -  
550 (Nielsen, Kristensen et al. 2008, Accumetrics 2016). 
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8.6.1.1 VerifyNow Results – Aspirin  
Table 41. Aspirin - VerifyNow (ARU) STEMI vs NSTEMI 
Verify Now result 
expressed as ARU 
(post P2Y12 
inhibitor loading) 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
STEMI 28 504.89 42.82 
[9.77, 75.88] 
72.27 13.66 0.012 
NSTEMI 58 462.07 72.22 9.48 
60 minutes  
STEMI 28 489.00 35.19 
[0.221, 70.16] 
83.29 15.74 0.049 
NSTEMI 58 453.81 72.93 9.58 
240 minutes 
STEMI 26 447.42 4.20 
[-28.92, 
37.31] 
71.64 14.05 0.801 
NSTEMI 
58 443.22 70/04 9.20 
 
Figure 30. VerifyNow mean ARUs (and standard error) after 
administration of aspirin in STEMI vs NSTEMI patients. 
 
 
 
8.6.1.2. Summary 
Following the administration of a 300mg loading dose of aspirin this data 
indicates a statistically significant difference in mean ARU values between 
STEMI and NSTEMI samples taken at 20 minutes (504.89 ± 72.27 vs 462.07 
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± 72.24 p < 0.012) and a marginally significant difference at 60 minutes 
(489.00 ± 83.29  vs 453.81 ± 72.93 p < 0.049).   
At four hours following the administration of a 300mg loading dose of aspirin, 
there is no statistically significant difference in the mean ARU  
values observed between the STEMI and NSTEMI groups (447.42 ± 71.62 vs 
443.22 ± 70.04 p = 0.087). 
The data in table 41 were analysed using a two-way analysis of variance test 
in which the effect of disease state (STEMI vs NSTEMI) on the degree of 
platelet inhibition (PRU) over time was examined (figure 30).  There was no 
significant difference between the effect of disease state on the degree of 
platelet inhibition, F(2,81) = 2.516, p = 0.087.  However, the observed 
reduction in the degree of platelet inhibition over time (e.g at 240 minutes 
compared to 20 minutes) for both disease states was significant, F(2,81) = 
9.072, p = 0.000. 
 
The reported data indicates that the disease state of STEMI has a minor 
impact on the degree of platelet inhibition observed following the 
administration of aspirin 300mg at 20 minutes and 60 minutes.  The ARU 
values reported indicate that aspirin is exerting an antiplatelet effect and the 
response to treatment is somewhat diminished in STEMI patients.  However, 
irrespective of disease state, a significant reduction in ARU and increase in 
platelet inhibition is observed over time.  
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As for the P2Y12 inhibitors, this data indicates that the state of STEMI and the 
accompanying reduction in gastric motility, particularly during the acute phase 
of presentation are sufficient enough to impair the onset of action of aspirin. 
The degree of platelet inhibition following aspirin administration may be further 
reduced by the co-administration of opioid-based analgesia, which would be 
administered by the ambulance staff.   This is purely hypothetical and not 
proven, since much of the current data in which the opioid-antiplatelet drug 
interaction has been investigated involves morphine plus a P2Y12 inhibitor in 
either healthy subjects or in STEMI patients (Heestermans, van Werkum et al. 
2008, Hobl, Stimpfl et al. 2014, Hobl, Reiter et al. 2015, Parodi, Bellandi et al. 
2015).   
 
The NSTEMI data indicates more consistent levels of platelet inhibition over 
time; from which we can postulate that the extent of gastrointestinal 
absorption in NSTEMI patients remains unchanged over time.  In contrast, in 
STEMI patients, once they have undergone mechanical reperfusion and have 
rested, the physiological changes that accompany the condition are no longer 
manifest.  In addition, further doses of opioid-based analgesia will not have 
been administered, and previously administered doses may have been 
metabolised and excreted.  So, in our STEMI patients, gastrointestinal motility 
returns to normal once PPCI has taken place and adequate myocardial 
perfusion has been restored. 
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8.6.2 Analysis of the degree of platelet inhibition following clopidogrel 
loading (600mg) compared with prasugrel loading (60mg) in STEMI and 
NSTEMI patients.  
8.6.2.1 VerifyNow Results – Clopidogrel vs Prasugrel STEMI 
 
Table 42. VerifyNow (PRU) – Clopidogrel vs Prasugrel STEMI 
VerifyNow PRU 
post loading 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
Clopidogrel 13 270.23 22.50 
[-12.05, 57.05] 
38.56 10.69 0.192 
Prasugrel 15 247.73 48.78 12.60 
Balloon inflation 
Clopidogrel 13 286.46 32.73 
[-3.25, 68.70] 
33.12 9.19 0.073 
Prasugrel 15 253.73 57.18 14.76 
60 minutes  
Clopidogrel 13 293.46 30.60 
[1.27, 59.92] 
31.68 8.79 0.041 
Prasugrel 15 262.87 43.43 11.21 
240 minutes 
Clopidogrel 12 226.42 97.77 
[32.23, 163.32] 
69.44 20.05 0.005 
Prasugrel 14 128.64 89.16 23.83 
 
Figure 31. VerifyNow mean PRUs (and standard error) following the 
administration of clopidogrel vs prasugrel in STEMI patients. 
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8.6.2.1.1 Summary 
In STEMI patients, the observed pharmacodynamic data (table 42) indicates a 
non-significant difference in mean PRU values following the administration of 
a 600mg loading dose of clopidogrel and a 60mg loading dose of prasugrel for 
samples taken at 20 minutes (270.2 ± 10.69 vs 247.73 ± 12.60 p<0.192).  A 
significant difference in mean PRU values following the administration of a 
600mg loading dose of clopidogrel and a 60mg loading dose of prasugrel in 
STEMI patients at balloon inflation (286.46 ± 9.19 vs 253.73 ± 14.76p < 
0.073) and 60 minutes (293.46 ± 8.79 vs 262.87 ±11.21 p < 0.041) was 
observed (figure 31).  At four hours following the administration of a 600mg 
loading dose of clopidogrel vs a 60mg loading dose of prasugrel, a highly 
statistically significant difference in the mean PRU values was observed 
(226.4 ± 20.05 vs 128.62 ± 23.83 p = 0.005).  The time by group interaction 
as assessed by ANOVA (the difference in mean PRU reduction over time 
between clopidogrel vs prasugrel) indicates a non-significant relationship (p = 
0.140).  However, irrespective of the drug administered, the degree of platelet 
inhibition at 240 minutes is significantly less than that at 20 minutes (p = 
0.000). 
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8.6.2.2. VerifyNow Results – Clopidogrel vs Prasugrel NSTEMI 
 
Table 43. VerifyNow (PRU) – Clopidogrel vs Prasugrel NSTEMI 
VerifyNow PRU 
post loading 
Group N Mean Mean Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
Clopidogrel 14 213.21 87.41 
[87.04, 213.81] 
51.74 13.83 0.004 
Prasugrel 15 125.80 89.34 23.08 
60 minutes  
Clopidogrel 14 227.36 150.42 
[87.04, 213.81] 
61.19 16.36 0.000 
Prasugrel 15 76.93 99.24 25.62 
240 minutes 
Clopidogrel 14 214.00 182.13 
[136.34, 227.93] 
69.98 18.70 0.000 
Prasugrel 15 31.87 45.52 11.75 
 
 
Figure 32. VerifyNow mean PRUs (and standard error) following the 
administration of clopidogrel vs prasugrel in NSTEMI patients. 
 
8.6.2.2.1 Summary 
In NSTEMI patients, the reported data (table 43) indicates a highly significant 
difference in mean PRU values following the administration of a 600mg 
loading dose of clopidogrel and a 60mg loading dose of prasugrel for samples 
taken at 20 minutes (213.21 ± 13.83 vs 125.80 ± 23.07 p<0.004), at 60 
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minutes (227.36 ± 16.36 vs 76.93 ± 25.62 p<0.000) and at 240 minutes 
(214.00 ± 18.70 vs 31.87 ± 11.75 p < 0.000).  The data in table 43 were 
analysed using a two way analysis of variance test in which the degree of 
platelet inhibition (PRU) over time was examined following the administration 
of clopidogrel vs prasugrel in NSTEMI patients.  There was a statistically 
significant difference in the degree of platelet inhibition following the 
administration of clopidogrel vs prasugrel at each time point (time*group 
interaction), F(2,26) = 10.224, p = 0.001. The observed reduction and 
difference in the degree of platelet inhibition over time between both drugs 
was also highly significant, F(2,26) = 8.612, p = 0.001. 
 
8.6.2.3 VASP-PRI% Results – Clopidogrel vs Prasugrel STEMI 
 
Table 44. VASP-PRI% – Clopidogrel vs Prasugrel STEMI 
VASP %PRI post 
loading 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
Clopidogrel 7 76.29 35.27 
[-2.34, 72.91] 
23.21 8.77 0.064 
Prasugrel 7 41.00 39.35 14.87 
Balloon inflation 
Clopidogrel 7 74.86 27.86 
[-6.62, 62.34] 
23.81 9.00 0.104 
Prasugrel 7 47.00 34.44 13.02 
60 minutes  
Clopidogrel 7 71.57 22.14 
[-17.03, 61.32] 
30.91 11.68 0.242 
Prasugrel 7 49.43 36.16 13.67 
240 minutes 
Clopidogrel 7 63.14 0.429 
[-35.78, 36.64] 
35.08 13.26 0.980 
Prasugrel 7 62.71 26.51 10.02 
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Figure 33. Mean VASP-PRI(%) (and standard error) following the 
administration of clopidogrel vs prasugrel in STEMI patients. 
 
 
 
 
 
8.6.2.3.1 Summary 
In STEMI patients, the reported data indicates a non-significant difference in 
mean VASP-PRI% values following the administration of a 600mg loading 
dose of clopidogrel and a 60mg loading dose of prasugrel for samples taken 
at 20 minutes (76.29 ± 8.77 vs 41.00 ± 14.87 p = 0.064), at the time of 
balloon inflation (74.68 ± 9.00 vs 47.00 ± 13.02 p = 0.104), at 60 minutes 
(71.57 ± 11.68 vs 49.43 ± 13.67 p = 0.242) and at 240 minutes (63.14 ± 
13.26 vs 62.71 ± 10.02 p = 0.980). 
The data in table 44 were analysed using a two-way analysis of variance test 
in which the degree of P2Y12 receptor blockade (platelet inhibition) as 
measured by the platelet reactivity index (%PRI) was examined over time 
following the administration of clopidogrel vs prasugrel in STEMI patients.  
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There was no significant difference in the degree of platelet inhibition following 
the administration of clopidogrel vs prasugrel at each time point (time*group 
interaction), F(3,10) = 1.564, p = 0.259.  The observed reduction and 
difference in the degree of platelet inhibition over time between both drugs 
was also not significant, F(3,10) = 0.54, p = 0.983. 
8.6.2.4 VASP-PRI% Results – Clopidogrel vs Prasugrel NSTEMI 
 
Table 45. VASP-PRI% – Clopidogrel vs Prasugrel NSTEMI 
%PRI 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
Clopidogrel 12 75.17 41.89 
[17.75, 66.04] 
9.48 2.74 0.003 
Prasugrel 11 33.27 35.36 10.66 
60 minutes  
Clopidogrel 12 76.75 54.84 
[33.34, 76.35] 
15.08 4.35 0.000 
Prasugrel 11 21.91 32.23 9.72 
240 minutes 
Clopidogrel 12 61.83 46.65 
[29.46, 63.84] 
20.16 5.82 0.000 
Prasugrel 11 15.18 19.40 5.85 
 
Figure 34. Mean VASP-PRI(%) (and standard error) following the 
administration of clopidogrel vs prasugrel in NSTEMI patients. 
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8.6.2.4.1 Summary 
In NSTEMI patients, the reported data indicates a significant difference in 
mean VASP-PRI% values following the administration of a 600mg loading 
dose of clopidogrel and a 60mg loading dose of prasugrel for samples taken 
at 20 minutes (75.17 ± 2.74 vs 33.27 ± 10.66 p = 0.003) and a highly 
significant difference at 60 minutes (76.75 ± 4.35 vs 21.91 ± 9.72 p = 0.000) 
and 240 minutes (631.83 ± 5.82 vs 15.18 ± 5.85 p = 0.000).  
The data in table 45 were analysed using a two-way analysis of variance test 
in which the degree of P2Y12 receptor blockade (platelet inhibition) as 
measured by the platelet reactivity index (%PRI) was examined over time 
following the administration of clopidogrel vs prasugrel in NSTEMI patients.  
There was no significant difference in the degree of platelet inhibition following 
the administration of clopidogrel vs prasugrel at each time point (time*group 
interaction), F(2,20) = 1.519, p = 0.243.  However, the observed reduction and 
difference in the degree of platelet inhibition over time, at 20 minutes 
compared to 240 minutes, between both drugs was significant, F(2,20) = 
3.741, p = 0.042. 
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8.6.3 Analysis of the degree of platelet inhibition following clopidogrel 
loading (600mg) compared with ticagrelor loading (180mg) in STEMI and 
NSTEMI patients.  
8.6.3.1 VerifyNow Results – Clopidogrel vs Ticagrelor STEMI 
 
Table 46. VerifyNow (PRU) – Clopidogrel vs Ticagrelor STEMI 
VerifyNow PRU 
post loading 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
Clopidogrel 13 270.23 13.50 
[-21.32, 48.32] 
38.56 10.69 0.441 
Ticagrelor 15 256.73 50.81 13.12 
Balloon 
inflation 
Clopidogrel 13 286.46 28.53 
[-10.58, 67.61] 
33.12 9.19 0.146 
Ticagrelor 15 257.93 61.12 15.71 
60 minutes  
Clopidogrel 13 293.46 68.26 
[19.85, 116.67] 
31.68 8.79 0.017 
Ticagrelor 15 225.20 82.70 21.35 
240 minutes 
Clopidogrel 12 226.42 22.50 
[=12.05, 57.05] 
69.44 20.05 0.111 
Ticagrelor 15 176.27 84.92 21.93 
 
 
 
Figure 35. VerifyNow mean PRUs (and standard error) following the 
administration of clopidogrel vs ticagrelor in STEMI patients. 
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8.6.3.1.1.Summary 
In STEMI patients, the reported data indicates a non-significant difference in 
mean PRU values following the administration of a 600mg loading dose of 
clopidogrel and a 180mg loading dose of ticagrelor for samples taken at 20 
minutes (270.23 ± 10.69 vs 256.73 ± 13.12 p<0.441) and at balloon inflation 
(213.21 ± 13.83 vs 125.80 ± 23.07 p<0.004).  A significant difference in 
mean PRU values following the administration of a 600mg loading dose of 
clopidogrel and a 180mg loading dose of ticagrelor in STEMI patients at 60 
minutes (293.46 ± 8.79 vs 225.20 ± 21.30 p < 0.017) was observed.   At 240 
minutes a non-significant difference between clopidogrel and ticagrelor was 
noted (226.42 ± 20.05 vs 176.27 ± 21.93 p < 0.111).  
The data in table 46 were analysed using a two-way analysis of variance test 
in which the degree of platelet inhibition (PRU) over time was examined 
following the administration of clopidogrel vs ticagrelor in STEMI patients.  
There was a non-significant difference in the degree of platelet inhibition 
following the administration of clopidogrel vs prasugrel at each time point 
(time*group interaction), F(2,23) = 2.143, p = 0.122 (figure 35). The observed 
reduction and difference in the degree of platelet inhibition over time between 
both drugs was also highly significant, F(3,23) = 8.770, p = 0.000 (figure 35). 
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8.6.3.2 VerifyNow Results – Clopidogrel vs Ticagrelor NSTEMI 
 
Table 47. VerifyNow (PRU) – Clopidogrel vs Ticagrelor NSTEMI 
VerifyNow PRU 
post loading 
Group N Mean Mean Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
Clopidogrel 14 213.21 40.41 
[-17.30, 98.13] 
51.74 13.83 0.162 
Ticagrelor 15 172.80 92.54 23.90 
60 minutes  
Clopidogrel 14 227.36 113.16 
[39.22, 187.09] 
61.19 16.36 0.004 
Ticagrelor 15 114.20 122.22 31.56 
240 minutes 
Clopidogrel 14 214.00 191.00 
[149.64, 232.26] 
69.98 18.70 0.000 
Ticagrelor 15 23.00 18.94 4.89 
 
 
Figure 36. VerifyNow mean PRUs (and standard error) following the 
administration of clopidogrel vs ticagrelor loading doses in NSTEMI 
patients. 
 
8.6.3.2.1 Summary 
In NSTEMI patients, the reported data indicates a non-significant difference in 
mean PRU values following the administration of a 600mg loading dose of 
clopidogrel and a 180mg loading dose of ticagrelor for samples taken at 20 
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minutes (213.21 ± 13.83 vs 172.80 ± 23.90 p<0.162).  A statistically 
significant difference in mean PRU values was observed for sample taken at 
60 minutes (227.36 ± 16.36 vs 114.20 ± 16.36 p<0.004) and at 240 minutes 
(214.00 ± 18.70 vs 23.00 ± 4.89 p < 0.000).  The data in table 47 were 
analysed using a two-way analysis of variance test in which the degree of 
platelet inhibition (PRU) over time was examined following the administration 
of clopidogrel vs ticagrelor in NSTEMI patients.  There was a significant 
difference in the degree of platelet inhibition following the administration of 
clopidogrel vs ticagrelor at each time point (time*group interaction), F(2,26) = 
19.052, p = 0.000 (figure 36). The observed reduction and difference in the 
degree of platelet inhibition over time between both drugs was also highly 
significant, F(2,26) = 16.998, p = 0.000 (figure 36). 
8.6.3.3 VASP-PRI% Results – Clopidogrel vs Ticagrelor STEMI 
 
Table 48. VASP-PRI% – Clopidogrel vs Ticagrelor STEMI 
%PRI 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
 
p-value 
20 minutes  
Clopidogrel 7 76.29 -3.46 
[-31.15, 72.90] 
23.21 8.77 0.791 
Ticagrelor 8 79.75 26.01 9.20 
Balloon 
inflation 
Clopidogrel 7 74.86 0.23 
[-31.85,32.31] 
23.81 9.00 0.988 
Ticagrelor 8 74.63 32.30 11.42 
60 minutes  
Clopidogrel 7 71.57 -4.68 
[-39.57, 30.21] 
30.91 11.68 0.777 
Ticagrelor 8 76.25 31.46 11.12 
240 minutes 
Clopidogrel 7 63.14 11.77 
[-30.37, 53.90] 
35.08 13.26 0.557 
Ticagrelor 8 51.38 39.78 14.07 
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Figure 37. Mean VASP-PRI(%) (and standard error) following the 
administration of clopidogrel vs ticagrelor in STEMI patients. 
 
 
8.6.3.3.1 Summary 
In STEMI patients, this reported data indicates a non-significant difference in 
mean VASP-PRI% values following the administration of a 600mg loading 
dose of clopidogrel and a 180mg loading dose of ticagrelor for samples taken 
at 20 minutes (76.29 ± 8.77 vs 79.75 ± 9.20 p = 0.791), at the time of balloon 
inflation (74.68 ± 9.00 vs 74.63 ± 11.42 p = 0.998), at 60 minutes (71.57 ± 
11.68 vs 76.25 ± 11.12 p = 0.777) and at 240 minutes (63.14 ± 13.26 vs 
51.38 ± 14.07 p = 0.557). 
The data in table 48 were analysed using a two-way analysis of variance test 
in which the degree of P2Y12 receptor blockade (platelet inhibition) as 
measured by the platelet reactivity index (%PRI) was examined over time 
following the administration of clopidogrel vs ticagrelor in STEMI patients.  
There was no significant difference in the degree of platelet inhibition following 
the administration of clopidogrel vs ticagrelor at each time point (time*group 
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interaction), F(3,11) = 0.361, p = 0.782 (figure 37).  The observed reduction 
and difference in the degree of platelet inhibition over time, at 20 minutes 
compared to 240 minutes, between both drugs was not significant, F(3,11) = 
1.405, p = 0.293 (figure 37). 
 
 
8.6.3.4 VASP-PRI% Results – Clopidogrel vs Ticagrelor NSTEMI 
 
Table 49. VASP-PRI% – Clopidogrel vs Ticagrelor NSTEMI 
%PRI 
Group N Mean Mean 
Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
 
p-value 
20 minutes  
Clopidogrel 12 75.17 13.17 
[-2.66, 29.00] 
9.48 2.74 0.097 
Ticagrelor 7 62.00 23.25 8.79 
60 minutes  
Clopidogrel 12 76.75 43.58 
[14.63, 72.53] 
15.08 4.35 0.057 
Ticagrelor 6 33.17 43.44 17.74 
240 minutes 
Clopidogrel 12 61.83 41.12 
[17.92, 64.32] 
20.16 5.82 0.002 
Ticagrelor 7 20.71 27.74 10.48 
 
Figure 38. Mean VASP-PRI(%) (and standard error) following the 
administration of clopidogrel vs ticagrelor in NSTEMI patients. 
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8.6.3.4.1 Summary 
In NSTEMI patients, the observed data indicates a non-significant difference 
in mean VASP-PRI% values following the administration of a 600mg loading 
dose of clopidogrel and a 180mg loading dose of ticagrelor for samples taken 
at 20 minutes (75.17 ± 2.74 vs 62.00 ± 8.79 p = 0.097).  At 60 minutes a 
marginally significant difference in mean VASP-PRI% values was observed 
(76.75 ± 4.35 vs 33.17 ± 17.73 p = 0.057) and a highly significant difference 
was seen at 240 minutes (61.83 ± 5.82 vs 20.17 ± 10.40 p = 0.002).  
The data in table 49 were analysed using a two-way analysis of variance test 
in which the degree of P2Y12 receptor blockade (platelet inhibition) as 
measured by the platelet reactivity index (%PRI) was examined over time 
following the administration of clopidogrel vs ticagrelor in NSTEMI patients.  
There was a highly significant difference in the degree of platelet inhibition 
following the administration of clopidogrel vs ticagrelor at each time point 
(time*group interaction), F(2,15) = 9.982, p = 0.002 (figure 38).  The observed 
reduction and difference in the degree of platelet inhibition over time, at 20 
minutes compared to 240 minutes, between both drugs was also highly 
significant, F(2,15) = 19.199, p = 0.000 (figure 38). 
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8.6.4 Analysis of the degree of platelet inhibition following prasugrel 
loading (60mg) compared with ticagrelor loading (180mg) in STEMI and 
NSTEMI patients. 
8.6.4.1 VerifyNow Results – Prasugel vs Ticagrelor STEMI 
 
Table 50. VerifyNow (PRU) – Prasugrel vs Ticagrelor STEMI 
VerifyNow PRU 
post loading 
Group N Mean Mean Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
Prasugrel 15 247.73 -9.00 
[-46.26, 28.26] 
48.78 12.60 0.625 
Ticagrelor 15 256.73 50.81 13.12 
Balloon 
inflation 
Prasugrel 15 253.73 -4.20 
 [-48.47, 40.07] 
57.16 14.76 0.847 
Ticagrelor 15 257.93 61.12 15.78 
60 minutes  
Prasugrel 15 262.87 24.12 
[-11.74, 87.07] 
43.43 11.21 0.130 
Ticagrelor 15 225.20 82.70 21.35 
240 minutes 
Prasugrel 14 128.64 -47.62 
 [-113.95, 18.70] 
89.16 23.83 0.152 
Ticagrelor 15 176.27 84.92 21.93 
 
Figure 39. VerifyNow mean PRUs (and standard error) following the 
administration of prasugrel vs ticagrelor loading doses in STEMI 
patients. 
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8.6.4.1.1 Summary 
In STEMI patients, the observed data indicates a non-significant difference in 
mean PRU values following the administration of a 60mg loading dose of 
prasugrel and a 180mg loading dose of ticagrelor for samples taken at 20 
minutes (242.73 ± 12.60 vs 256.73 ± 13.12 p = 0.625), at balloon inflation 
(253.73 ± 14.72 vs 257.93 ± 15.78 p = 0.847), at 60 minutes  (262.87 ± 
11.21 vs 225.20 ± 82.70 p = 0.130), and at 240 minutes (128.64 ± 23.83 vs 
176.27 ± 21.93 p = 0.152).    The data in table 50 were analysed using a two-
way analysis of variance test in which the degree of platelet inhibition (PRU) 
over time was examined following the administration of prasugrel vs ticagrelor 
in STEMI patients.  There was a significant difference in the degree of platelet 
inhibition following the administration of prasugrel vs ticagrelor over time, 
F(3,25) = 10.692, p = 0.000 (figure 39). The observed reduction and 
difference in the degree of platelet inhibition at each time point between both 
drugs was not of significance, F(3,25) = 2.729, p = 0.065 (figure 39). 
 
 
8.6.4.2 VerifyNow Results – Prasugel vs Ticagrelor NSTEMI 
 
Table 51. VerifyNow (PRU) – Prasugrel vs Ticagrelor NSTEMI 
VerifyNow 
PRU post 
loading 
Group N Mean Mean Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
 
p-value 
20 minutes  
Prasugrel 15 125.80 -47.00 
[-115.03, 21.03] 
89.34 23.07 0.168 
Ticagrelor 15 172.80 92.54 23.90 
60 minutes  
Prasugrel 15 76.93 -37.27 
[-120.54, 46.00] 
99.24 25.62 0.367 
Ticagrelor 15 114.20 122.24 31.56 
240 minutes 
Prasugrel 15 31.87 -8.87 
[-17.21, 34.94] 
45.52 11.75 0.492 
Ticagrelor 15 23.00 18.94 4.89 
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Figure 40. VerifyNow mean PRUs (and standard error) following the 
administration of prasugrel vs ticagrelor loading doses in NSTEMI 
patients. 
 
8.6.4.2.1 Summary 
In NSTEMI patients, the observed data indicates a non-significant difference 
in mean PRU values following the administration of a 60mg loading dose of 
prasugrel and a 180mg loading dose of ticagrelor for samples taken at 20 
minutes (125.80 ± 23.07 vs 172.80 ± 23.90 p = 0.168), at 60 minutes  (76.93 
± 25.62 vs 114.20 ± 31.56 p = 0.367), and at 240 minutes (31.87 ± 11.75 vs 
23.00 ± 4.89 p = 0.492).  The data in table 51 were analysed using a two-way 
analysis of variance test in which the degree of platelet inhibition (PRU) over 
time was examined following the administration of prasugrel vs ticagrelor in 
NSTEMI patients.  There was a non-significant difference in the degree of 
platelet inhibition following the administration of prasugrel vs ticagrelor at each 
time point (time*group interaction), F(2,27) = 1.696, p = 0.202 (figure 40). The 
observed reduction and difference in the degree of platelet inhibition over time 
for both drugs was highly significant, F(2,27) = 34.162, p = 0.000 (figure 40). 
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8.6.4.3 VASP-PRI% Results – Prasugrel vs Ticagrelor STEMI 
 
Table 52. VASP-PRI% – Prasugrel vs Ticagrelor STEMI 
%PRI 
Group N Mean Mean Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
p-value 
20 minutes  
Prasugrel 7 41.00 -38.74 
[-75.47, -2.03] 
39.35 14.87 0.040 
Ticagrelor 8 79.75 26.01 9.20 
Balloon 
inflation 
Prasugrel 7 47.00 -27.63  
[-64.86, 9.61] 
34.44 13.02 0.133 
Ticagrelor 8 74.63 32.30 11.42 
60 minutes  
Prasugrel 7 49.43 -26.82 
[-64.51, 10.87] 
36.16 13.67 0.148 
Ticagrelor 8 76.25 31.46 11.12 
240 minutes 
Prasugrel 7 62.71 11.34 
[-27.01, 49.69] 
26.51 10.02 0.534 
Ticagrelor 8 51.38 39.78 14.07 
 
Figure 41. Mean VASP-PRI(%) (and standard error) following the 
administration of prasugrel vs ticagrelor in STEMI patients. 
 
 
8.6.4.3.1 Summary 
In STEMI patients, observed data indicates a significant difference in mean 
VASP-PRI% values following the administration of a 60mg loading dose of 
prasugrel and a 180mg loading dose of ticagrelor for samples taken at 20 
 198 
minutes (41.00 ± 14.87 vs 79.75 ± 9.20 p = 0.040).  A non-significant 
difference in mean VASP-PRI% values was observed at the time of balloon 
inflation (47.00 ± 13.02 vs 74.63 ± 11.42 p = 0.131), at 60 minutes (49.43 ± 
13.67 vs 76.25 ± 11.12 p = 0.148) and at 240 minutes (62.71 ± 10.02 vs 
51.38 ± 14.07 p = 0.543). The data in table 52 were analysed using a two-
way analysis of variance test in which the degree of P2Y12 receptor blockade 
(platelet inhibition) as measured by the platelet reactivity index (%PRI) was 
examined over time following the administration of clopidogrel vs ticagrelor in 
STEMI patients.  There was no significant difference in the degree of platelet 
inhibition following the administration of clopidogrel vs ticagrelor at each time 
point (time*group interaction), F(3,11) = 1.522, p = 0.256 (figure 41).  The 
observed reduction and difference in the degree of platelet inhibition over 
time, at 20 minutes compared to 240 minutes, between both drugs was not 
significant, F(3,11) = 0.083, p = 0.968 (figure 41). 
 
 
8.6.4.4 VASP-PRI% Results – Prasugrel vs Ticagrelor NSTEMI 
 
Table 53. VASP-PRI% – Prasugrel vs Ticagrelor NSTEMI 
%PRI 
Group N Mean Mean Difference 
[95% CI] 
Std. 
Deviation 
Std. Error 
Mean 
p-value 
20 minutes  
Prasugrel 11 33.27 -28.73 
[-60.88, 3.43] 
35.36 10.66 0.076 
Ticagrelor 7 62.00 23.25 8.79 
60 minutes  
Prasugrel 11 21.91 -11.23 
[-50.58, 28.07] 
32.23 9.72 0.551 
Ticagrelor 6 33.17 43.44 17.73 
240 minutes 
Prasugrel 11 15.18 -5.53 
[-28.99, 17.92] 
19.40 5.85 0.624 
Ticagrelor 7 20.71 27.74 10.48 
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Figure 42. Mean VASP-PRI(%) (and standard error) following the 
administration of prasugrel vs ticagrelor in NSTEMI patients. 
 
 
8.6.4.4.1 Summary 
In NSTEMI patients, the oberserved data indicates a marginally significant 
difference in mean VASP-PRI% values following the administration of a 60mg 
loading dose of prasugrel and a 180mg loading dose of ticagrelor for samples 
taken at 20 minutes (33.27 ± 10.66 vs 62.00 ± 8.79 p = 0.076).  A non-
significant difference in mean VASP-PRI% values was observed at 60 
minutes (21.91 ± 9.72 vs 33.17 ± 17.73 p = 0.551) and at 240 minutes (15.18 
± 5.85 vs 20.71 ± 10.40 p = 0.624).   
The data in table 53 were analysed using a two-way analysis of variance test 
in which the degree of P2Y12 receptor blockade (platelet inhibition) as 
measured by the platelet reactivity index (%PRI) was examined over time 
following the administration of clopidogrel vs ticagrelor in NSTEMI patients.  
There was non-significant difference in the degree of platelet inhibition 
following the administration of clopidogrel vs ticagrelor at each time point 
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(time*group interaction), F(2,14) = 2.214, p = 0.146 (figure 42).  However, the 
observed reduction and difference in the degree of platelet inhibition over 
time, at 240 minutes compared to 20 minutes, between prasugrel and 
ticagrelor was significant, F(2,14) = 9.211, p = 0.003 (figure 42). 
8.6.4.7 VerifyNow Results – Clopidogrel vs Prasugel vs Ticagrelor STEMI 
 
Table 54. ANOVA descriptive statistics - Comparison of mean PRU over 
time following the administration of clopidogrel 600mg vs prasugrel 
60mg vs ticagrelor 180mg in STEMI patients. 
VerifyNow 
PRU post 
loading 
N Clopidogrel 
(Mean ± SD) 
Prasugrel 
(Mean ± SD) 
Ticagrelor 
(Mean ± SD) 
 
p-value 
20 minutes 41 269.42 ± 40.15 240.93 ± 42.60 256.73 ± 50.81 0.451 
Balloon 
inflation 
41 286.75 ± 34.58 248.29 ± 55.15 257.93 ± 61.12 0.224 
60 minutes 41 296.50 ± 31.05 257.36 ± 39.25 225.20 ± 82.70 0.013 
240 minutes 41 226.42 ± 69.44 128.64 ± 89.16 176.27 ± 84.92 0.017 
Figure 43. VerifyNow mean PRUs (and standard error) following the 
administration of clopidogrel vs prasugrel vs ticagrelor loading doses in 
STEMI patients. 
 
 
8.6.4.7.1 Summary 
The data in table 54 were analysed using a two-way analysis of variance test 
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in which the degree of platelet inhibition (PRU) over time was examined 
following the administration of clopidogrel vs prasugrel vs ticagrelor loading 
doses in STEMI patients.  There was a significant difference in the degree of 
platelet inhibition following the administration of clopidogrel vs prasugrel vs 
ticagrelor at each time point (time*group interaction), F(6,72) = 2.625, p = 
0.023 (figure 43).  This significance is driven by clopidogrel and the respective 
PRU observed in the prasugrel and ticagrelor groups). The observed 
reduction and difference in the degree of platelet inhibition over time between 
all three drugs was highly significant, F(3,36) = 12.282, p = 0.000 (figure 43). 
 
8.6.4.8 VerifyNow Results – Clopidogrel vs Prasugel vs Ticagrelor 
NSTEMI 
 
Table 55. ANOVA descriptive statistics - Comparison of mean PRU over 
time following the administration of clopidogrel 600mg vs prasugrel 
60mg vs ticagrelor 180mg in NSTEMI patients. 
VerifyNow 
PRU post 
loading 
N Clopidogrel 
(Mean ± SD) 
Prasugrel 
(Mean ± SD) 
Ticagrelor 
(Mean ± SD) 
 
p-value 
20 minutes 44  213.21 ± 51.74   125.80 ± 89.34   172.80 ± 92.54  0.021 
60 minutes 44  227.36 ± 61.19   76.93 ± 99.24  114.20 ± 122.22  0.001 
240 minutes 44  214.00 ± 69.98 31.87 ± 45.52 23.00 ± 18.94  0.000 
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Figure 44. VerifyNow mean PRUs (and standard error) following the 
administration of clopidogrel vs prasugrel vs ticagrelor loading doses in 
NSTEMI patients. 
 
 
8.6.4.8.1 Summary 
The data in table 55 were analysed using a two-way analysis of variance test 
in which the degree of platelet inhibition (PRU) over time was examined 
following the administration of clopidogrel vs prasugrel vs ticagrelor loading 
doses in NSTEMI patients.  There was a highly significant difference in the 
degree of platelet inhibition following the administration of clopidogrel vs 
prasugrel vs ticagrelor at each time point (time*group interaction), F(4,80) = 
7.759, p = 0.000 (figure 44). The observed reduction and difference in the 
degree of platelet inhibition over time between all three drugs was highly 
significant, F(2,40) = 29.097, p = 0.000 (figure 44). 
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8.6.4.9 VASP-PRI% Results – Clopidogrel vs Prasugrel vs Ticagrelor 
STEMI 
 
Table 56. ANOVA descriptive statistics - Comparison of change in mean 
VASP-PRI% over time following the administration of clopidogrel 600mg 
vs prasugrel 60mg vs ticagrelor 180mg in STEMI patients. 
 
%PRI post 
loading 
N Clopidogrel 
(Mean ± SD) 
Prasugrel 
(Mean ± SD) 
Ticagrelor 
(Mean ± SD) 
 
p-value 
20 minutes 22 76.29 ± 23.21 41.00 ± 39.35 79.75 ± 26.01 0.046 
Balloon 
inflation 
22 74.86 ± 23.81 47.00 ± 34.44 74.63 ± 32.30 0.169 
60 minutes 22 71.57 ± 30.91 49.43 ± 36.16 76.25 ± 31.46 0.276 
240 minutes 22 63.14 ± 35.08 62.71 ± 26.51 51.38 ± 39.78 0.755 
 
Figure 45. Mean VASP-PRI% (and standard error) following the 
administration of clopidogrel vs prasugrel vs ticagrelor loading doses in 
STEMI patients. 
 
 
8.6.4.9.1 Summary 
The data in table 56 were analysed using a two-way analysis of variance test 
in which the degree of  P2Y12 receptor blockade (platelet inhibition) as 
measured by the platelet reactivity index (%PRI) over time was examined 
following the administration of clopidogrel vs prasugrel vs ticagrelor loading 
doses in STEMI patients.  There was a non-significant difference in the 
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degree of platelet inhibition following the administration of clopidogrel vs 
prasugrel vs ticagrelor at each time point (time*group interaction), F(6,34) = 
20.994, p = 0.445 (figure 45). The observed reduction and difference in the 
degree of platelet inhibition over time between all three drugs was also non-
significant, F(3,17) = 0.321, p = 0.810 (figure 45). 
 
8.6.4.10 VASP-PRI% Results – Clopidogrel vs Prasugrel vs Ticagrelor 
NSTEMI 
 
Table 57. ANOVA descriptive statistics - Comparison of change in mean 
VASP-PRI% over time following the administration of clopidogrel 600mg 
vs prasugrel 60mg vs ticagrelor 180mg in NSTEMI patients. 
%PRI post 
loading 
N Clopidogrel 
(Mean ± SD) 
Prasugrel 
(Mean ± SD) 
Ticagrelor 
(Mean ± SD) 
 
p-value 
20 minutes 29 75.17 ± 9.48 33.27 ± 35.36 69.33 ± 14.04 0.002 
60 minutes 29 76.75 ± 15.08 21.91 ± 32.23 33.17 ± 43.44 0.000 
240 minutes 29 61.83 ± 20.16 15.18 ± 19.40 19.33 ± 30.12 0.000 
 
Figure 46. Mean VASP-PRI% (and standard error) following the 
administration of clopidogrel vs prasugrel vs ticagrelor loading doses in 
NSTEMI patients. 
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8.6.4.10.1 Summary  
The data in table 57 were analysed using a two-way analysis of variance test 
in which the degree of P2Y12 receptor blockade (platelet inhibition) as 
measured by the platelet reactivity index (%PRI) over time was examined 
following the administration of clopidogrel vs prasugrel vs ticagrelor loading 
doses in NSTEMI patients.  There was a significant difference in the degree of 
platelet inhibition following the administration of clopidogrel vs prasugrel vs 
ticagrelor at each time point (time*group interaction), F(4,50) = 3.077, p = 
0.024 (figure 46). The observed reduction and difference in the degree of 
platelet inhibition over time (at 240 minutes compared to 20minutes) between 
all three drugs was highly significant, F(2,25) = 14.103, p = 0.000 (figure 46). 
 
 
8.7 Discussion 
In terms of the patient population recruited to our study, there are no 
statistically significant differences between our STEMI and NSTEMI groups 
(tables 37-40); both groups are well matched in terms of their baseline 
characteristics, risk factors and co-morbidities.  The only exception being that 
there is a statistically significantly greater incidence of hyperlipidaemia in our 
NSTEMI group compared with our STEMI group (p = 0.003) and the use of 
opioid based analgesia is significantly greater in our STEMI cohort (p < 
0.000).  The rational behind the difference in opioid use has been explained in 
chapters 5-7.  A possible explanation for the difference in lipid profiles may 
relate to the time at which blood samples were taken to assess the patient’s 
cholesterol levels.  Following a cardiac event lipid levels are known to 
significantly decline secondary to down regulation of cholesterol biosynthesis 
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and take approximately 12 weeks to recover (Barth, Jackson et al. 2010).  In 
STEMI patients, a diagnosis is often made on the basis of signs and 
symptoms at presentation and ECG changes, and not necessarily the 
presence of cardiac biomarkers.  As a result blood samples are not usually 
requested or taken until the patient has returned to the ward after receiving 
treatment in the catheter lab.  At this time there will be a reduction in 
cholesterol synthesis, such that the lipid levels recorded may not be a true 
reflection of the patient’s actual baseline prior to presentation.  NICE 
recommendations regarding secondary prevention following a MI advocate 
aggressive lipid lowering therapy with high intensity statin (atorvastatin 80mg 
daily), irrespective of the patient’s cholesterol levels on presentation (NICE 
CG 167 2013). 
 
When comparing our STEMI cohort, they are again well matched in terms of 
co-morbidities and risk factors, however, a statistically significant difference in 
terms of age is apparent between the three groups (p <0.001) as shown in 
table 38.  In this study, younger patients were recruited to the prasugrel arm 
and older patients to the clopidogrel arm  (56.00±12.9 vs 78.00 ± 9.70, p 
<0.001).  These differences are primarily attributable to the licensing 
recommendations for prasugrel, which restricts its use to patients under the 
age of 75 years.  As explained in chapter 6, older patients are exposed to 
greater levels of P-AM compared to younger patients and are therefore at 
increased risk of experiencing bleeding complications. 
Although clopidogrel was the default antiplatelet of choice in patients over the 
age of 75 years, it’s clinical efficacy may be further compromised by age 
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related physiological changes which may occur in older patients, particularly 
with regards to reduced gastric emptying, motility and subsequent absorption.  
Age related physiological changes are known to adversely impact on drug 
absorption (Mangoni and Jackson 2003). 
 
8.7.1  Clopidogrel vs Prasugrel 
Our VerifyNow STEMI data indicates that there are no statistically significant 
differences in the degree of platelet inhibition achieved between prasugrel and 
clopidogrel at 20 minutes and balloon inflation and only a moderate difference 
at 60 minutes.  All PRU values > 230, indicating a significantly reduced 
antiplatelet effect and HRPR, at 240 minutes, however, prasugrel has a 
therapeutic PRU at 128, whilst the PRU for clopidogrel remains > 208 (table 
42).  In our NSTEMI group, a statistically significant difference in PRU values 
between clopidogrel and prasugrel is observed at all time points (table 43).  
Prasugrel demonstrates a superior pharmacodynamic profile in NSTEMI 
patients when compared to clopidogrel. 
 
As reported in chapters 5 and 7, our VASP-P data does follow the same trend 
as our VerifyNow pharmacodynamic data; however, the correlation between 
the results reported by the two platelet function assays is poor.  Although, 
VASP-P is the gold standard in terms of accurately assessing platelet 
reactivity, it is a highly specialist technique which requires a considerable 
degree of expertise to carry out correctly.  The inconsistencies in our reported 
VASP-P results render it inadequate as a reliable indicator of the 
pharamcocdynamic antiplatelet effect of orally administered P2Y12 inhibitors. 
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Our VerifyNow STEMI data indicate that neither clopidogrel nor prasugrel 
provide adequate levels of platelet inhibition at the time of angioplasty and 
stent implantation; furthermore, both agents are subject to HRPR.  Our data is 
therefore in line with previously reported work in which a reduced antiplatelet 
effect of clopidogrel and prasugrel in STEMI has been noted (Heestermans, 
van Werkum et al. 2008, Alexopoulos, Galati et al. 2012, Parodi, Valenti et al. 
2013).  However, our study is the first to provide a direct head to head 
comparison of clopidogrel and prasugrel in this context, and demonstrates 
that there is no difference between the two agents in terms of IPA achieved 
during the acute phase of a MI. 
 
The differences in IPA observed following the administration of a clopidogrel 
600mg loading dose compared with prasugrel 60mg loading dose are driven 
by the degree to which the parent compound is available for conversion 
following absorption via the gastrointestinal tract. As described in chapters 5 
and 6, 85% of orally administered clopidogrel is converted to an inactive 
compound following ingestion, in comparison, prasugrel undergoes complete 
and rapid gastrointestinal absorption facilitating greater generation of its active 
metabolite (as described in chapter 1, figure 4).   
 
In this study, sample collection was capped at 4 hours, however, in other 
reported studies, extending beyond this time, a plateau in IPA is observed 
with prasugrel; this is a pharmacodynamic limitation secondary to P2Y12 
receptor saturation as opposed to a pharmacokinetic limitation of active 
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metabolite generation, as is the case with clopidogrel (Floyd, Passacquale et 
al. 2012). 
 
The superior pharmacokinetic/pharmacodynamic profile of prasugrel over 
clopidogrel presents a number of advantages; there is a reduced period of 
time period from administration of a 60mg loading dose to conversion to P-AM 
and subsequent ability to achieve maximal IPA, thereby reducing the 
incidence and likelihood of HRPR. However, in contrast the PK and PD data 
reported in chapter 6, indicates that prasugrel is still subject to HRPR, which 
can limit its immediate effectiveness in the context of STEMI and pre-dispose 
patients to increased risk of further MACCE or complications such as stent 
thrombosis. 
 
Clopidogrel is known to demonstrate significant variations in IPA ranging from 
0% to 100% (Aleil, Ravanat et al. 2005).  However, our data indicate that 
irrespective of disease state, clopidogrel does not achieve adequate levels of 
platelet inhibition for at least 4 hours if not longer following the administration 
of a 600mg loading dose.  The pharmacodynamic profile of prasugrel, on the 
other hand is supposed to be more predictable, with a minimum IPA of 50% at 
any one time when compared to clopidogrel (Brandt, Payne et al. 2007).  Our 
data very clearly shows that in STEMI patients, the time course of platelet 
inhibition between the two drugs is similar.   
 
The endovascular injury that occurs during a STEMI and subsequent damage 
that may arise due to mechanical intervention leads to an increase in platelet 
turnover and consequently higher levels of circulating immature (juvenille) 
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platelets (Nylander and Schulz 2016).  This increase in platelet turnover 
contributes to the high prothrombotic environment encountered during a 
STEMI which increases the thrombotic burden associated with the condition 
and can subsequently lead to poorer cardiovascular outcomes (Alexopoulos, 
Xanthopoulou et al. 2013). 
 
The increase in platelet turnover and presence of immature/juvenille platelets 
may account for the reduced antiplatelet efficacy of clopidogrel and prasugrel 
seen in STEMI patients despite the administration of adequate loading doses 
and circulating levels of C-AM that are comparable in potency to P-AM 
(Ibrahim, Nadipalli et al. 2012). 
 
8.7.2 Clopidogrel vs Ticagrelor 
The pharmacodynamic VerifyNow data indicates that when comparing the 
degree of platelet inhibition between clopidogrel and ticagrelor in our STEMI 
patients there is no significant difference in the PRU values recorded (table 
48). Our data indicates that ticagrelor demonstrates inadequate levels of 
platelet inhibition early on in treatment and is also subject to HRPR (as shown 
in chapter 7).  As such our data is in line with previously reported 
pharmacodynamic studies which also demonstrate a delay in the onset of 
action and a lack of antiplatelet efficacy for at least two hours following the 
administration of a ticagrelor loading dose (Alexopoulos, Galati et al. 2012, 
Parodi, Valenti et al. 2013).  However, this study is the first to report on a 
direct head to head comparison of clopidogrel and ticagrelor during the acute 
phase of an MI; furthermore, our study demonstrates that although ticagrelor 
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is directly acting and should have a faster onset of action and a more 
enhanced antiplatelet effect, in the context of STEMI, the degree of IPA 
achieved is comparable to that seen with clopidogrel and neither agent is 
particularly effective at the time of angioplasty, with PRU values being > 230 
indicating HRPR (table 48). 
 
When comparing the efficacy of clopidogrel against ticagrelor in our NSTEMI 
patients, our data indicates that ticagrelor provides a level of IPA that is 
numerically greater at 20 minutes and statistically significantly greater than 
that seen with clopidogrel at 60 minutes and 240 minutes (table 49). 
 
The reported VASP-P data, very much like the VerifyNow data indicates that 
there are no differences in the degree of platelet inhibition observed, as 
expressed by the %PRI between our clopidogrel and ticagrelor STEMI 
groups.  However, all reported %PRI values are > 50% which is indicative of 
an inadequate antiplatelet effect and HRPR for both drugs over our study 
period. 
 
As reported in chapters 5 and 7, there is a poor correlation between the 
results of our two platelet function assays, however, the VASP-P trend 
observed is very similar to that seen with the VerifyNow results reported in our 
ticagrelor patients. 
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As for the VerifyNow NSTEMI data, our VASP-P results indicate a statistically 
significant difference between the %PRI observed at 60 and 240 minutes for 
clopidogrel vs ticagrelor and a numerically lower %PRI at 20 minutes. 
 
There are no published pharmacodynamic data comparing the onset of action 
of clopidogrel against ticagrelor in NSTEMI patients against which we can 
benchmark our data.  But based on what we have already established during 
our study and our understanding of the mechanisms of action and pathways 
of activation, ticagrelor is able to provide faster and more consistent levels of 
IPA in NSTEMI patients secondary to improved gastrointestinal absorption. 
 
8.7.3 Prasugrel vs Ticagrelor 
The VerifyNow pharmacodynamic data indicates that there are no statistically 
significant differences in the degree of platelet inhibition observed following 
the administration of prasugrel or ticagrelor loading doses in our STEMI 
patients, and that neither agent demonstrates an adequate or effective level of 
platelet inhibition for at least the first hour post-loading.  As shown in table 54, 
the PRU values at 20 minutes and at balloon inflation are > 230 for both 
agents indicating HRPR and an insufficient antiplatelet effect at the time of 
angioplasty and coronary artery stent implantation.  Our study findings are in 
line with those previously reported by Parodi et al and Alexopoulos et al 
(Alexopoulos, Xanthopoulou et al. 2012, Parodi, Valenti et al. 2013). 
Our VerifyNow NSTEMI data indicates that there is no significant difference in 
the degree of IPA observed following the administration of either prasugrel or 
ticagrelor (table 55); both agents achieve adequate levels of platelet inhibition 
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early after loading with possibly excessive levels IPA at 240 minutes.  Such 
low residual platelet reactivity (LRP) is known to be associated with increased 
bleeding risk (Montalescot, Collet et al. 2014). 
 
In contrast to the VerifyNow data, the STEMI VASP-P results indicate 
increasing levels of platelet reactivity (%PRI) over time despite the 
administration of prasugrel 60mg and decreasing levels of %PRI following the 
administration of ticagrelor 180mg.  Our NSTEMI VASP-P data demonstrates 
a reduction in %PRI over time, although the values noted are < 50% at all 
time points, indicating adequate if not slightly excessive levels of platelet 
inhibition.  Our NSTEMI VASP-P results are in line with our VerifyNow results; 
both agents demonstrate LRPR in the context of NSTEMI.   
 
Of note, both our VerifyNow and VASP-P results indicate that in the NSTEMI 
patients, prasugrel when compared to ticagrelor results in numerically lower 
PRU and %PRI values.  Since ticagrelor is directly acting, we would expect 
greater levels of IPA following its administration compared to prasugrel since 
the latter requires metabolic activation following GI absorption.  
 
As already discussed in our clopidogrel and prasugrel comparisons, the 
validity of our VASP-P dataset cannot be confirmed, as such these results are 
not the most reliable upon which to base any conclusions regarding the 
pharmacodynamic activity of the oral P2Y12 inhibitors used in our study. 
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The reported VerifyNow results are more reliable, consistent and reproducible 
and are in line with previously reported findings; they indicate a delay in the 
onset of action of both prasugrel and ticagrelor in STEMI patients 
(Alexopoulos, Galati et al. 2012, Parodi, Valenti et al. 2013).  Furthermore, our 
results indicate that despite displaying a superior pharmacodynamic profile to 
clopidogrel, prasugrel and ticagrelor are still subject to HRPR which limit their 
effectiveness in STEMI patients (Lemesle, Schurtz et al. 2015). 
 
 
8.7.4 Clopidogrel vs Prasugrel vs Ticagrelor 
When comparing the onset of action and degree of IPA in STEMI patients, our 
pharmacodynamic data indicates that neither clopidogrel, prasugrel or 
ticagrelor provide adequate levels of platelet inhibition at all data collection 
time points as evidenced by PRU values > 230.  Both prasugrel and ticagrelor 
are superior to clopidogrel resulting in a significant reduction in the degree of 
platelet reactivity over time, however, this significance only becomes apparent 
after 60 minutes.  Although prasugrel and ticagrelor are comparable in terms 
of inhibition of platelet activity at 20 minutes, time of balloon inflation, 60 
minutes and 240 minutes, they still do not achieve the desired levels of 
platelet inhibition necessary during PPCI (angioplasty and coronary artery 
stent implantation) as evidenced by PRU > 230. 
 
The reported VerifyNow results indicate that there was a significant difference 
over time in the degree of platelet inhibition observed between clopidogrel and 
prasugrel (p < 0.001), clopidogrel and ticagrelor (p = 0.04) and no statistically 
significant difference was found when comparing prasugrel with ticagrelor (p = 
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0.065).   In the NSTEMI group however, there is a marked and rapid reduction 
in platelet reactivity for prasugrel and ticagrelor at all time points.  Over time 
there was a significant difference between the effect of both prasugrel (p < 
0.001) and ticagrelor (p < 0.001) in STEMI vs NSTEMI patients.  When 
comparing the effect of clopidogrel on the degree of platelet inhibition over 
time in STEMI vs NSTEMI patients, there was no significant difference 
apparent (p = 0.065). 
 
The VASP-P data reported does not demonstrate the same degree of 
reliability or reproducibility as our VerifyNow results.  However, some 
inferences can be drawn from the data; both clopidogrel and ticagrelor show a 
reduction in %PRI over time, indicating an increase in the level of IPA.  In 
addition, the VASP-P data also indicates reduced antiplatelet efficacy during 
the acute phase of a STEMI as evidenced by %PRI values > 50%.  The 
VASP-P data indicates that there is a marginal significant difference between 
the three drugs over time (p = 0.445), however, this difference is driven by an 
increasing %PRI in the prasugrel group.  The VASP-P NSTEMI data indicates 
that as with our VerifyNow, clopidogrel displays higher levels of platelet 
activity at all data collection time point (%PRI > 50%) and that prasugrel is 
numerically superior to ticagrelor in terms of platelet inhibition. 
 
This study is the first to report a direct head to head comparison of all three 
orally administered P2Y12 inhibitors in both STEMI and NSTEMI patients.  
Our findings demonstrate variability in response, reduced antiplatelet 
effectiveness and slower onset of action following the administration of 
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clopidogrel, prasugrel and ticagrelor in STEMI patients when compared with 
NSTEMI/UA patients. 
 
The results of this thesis demonstrate that, the pathophysiological condition of 
STEMI has an adverse impact on the clinical effectiveness of all oral P2Y12 
inhibitors.  The reduction in cardiac output, increase in sympathetic tone, 
which in turn can lead to mesenteric vasoconstriction, can affect the ability of 
the gut to facilitate adequate absorption (Agrawal and Bhatt 2013).  
 
Gastrointestinal absorption is of paramount importance to the onset of action 
and ability of clopidogrel, prasugrel and ticagrelor to exert their antiplatelet 
effects.  Even ticagrelor which is directly acting and doesn't require metabolic 
activation via first pass metabolism was found to be just as ineffective as 
prasugrel and clopidogrel in terms of platelet inhibition, particularly at the time 
of PPCI and for at least 2 hours post administration of the loading dose. 
 
The reported data show that prasugrel and ticagrelor are also subject to 
HRPR with inadequate levels of early IPA such that neither are effective at the 
time of  PPCI (Lemesle, Schurtz et al. 2015). 
 
Platelets contribute to the inflammatory response exhibited following 
endovascular injury; upon activation, platelets release pro-inflammatory 
cytokines in addition to microRNA.  MicroRNA can trigger further inflammatory 
processes as well as contributing to further atherosclerosis and angiogenesis.  
Platelet inhibition, therefore not only prevents further aggregation but also 
restricts the pro-inflammatory capability of activated platelets (Nylander and 
Schulz 2016)  Despite administration of clopidogrel, prasugrel or ticagrelor, an 
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increase in the emerging population of uninhibited (juvenille) platelets occurs; 
juvenille platelets formed after the administration of an oral P2Y12 inhibitor 
contribute to thrombus formation and may well account for recurrent 
ischaemic and thrombotic complications observed in some patients even 
whilst on antiplatelet therapy (Nylander and Schulz 2016). 
 
There is a growing and compelling body of evidence that support the findings 
of our work; in that the pharmacodynamic effect of clopidogrel, prasugrel and 
ticagrelor are impaired and the subsequent onset of action and antiplatelet 
effect is delayed in STEMI patients (Heestermans, van Werkum et al. 2008, 
Alexopoulos 2013, Parodi, Valenti et al. 2013).  The pharmacodynamic effect 
of the P2Y12 receptor inhibitors is directly related to and proportional to the 
presence of the active moiety whether that is the directly acting parent 
compound or active metabolite. 
 
Unlike ticagrelor, the thienopyridines have very little effect when in the 
systemic circulation following GI absorption (figure 31 step 1), their antiplatelet 
effect occurs following metabolic activation in the hepatic circulation, where 
biotransformation to the active metabolite takes place. 
 
Despite shorter duration of exposure to their active metabolites, the 
thienopyridines have an overall prolonged duration of action, since recovery of 
platelet function takes at least 7-10 days following the cessation of prasugrel 
and 5-7 days with clopidogrel due to the irreversible binding of the AM to the 
P2Y12 receptor (Price, Walder et al. 2012).  Recovery of platelet function 
returns to almost normal levels after 3-5 days following the discontinuation of 
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ticagrelor.  Due to the reversibility of ticagrelor; the offset or reduction in IPA is 
more rapid when compared to clopidogrel, such that within 24 hours of 
discontinuation, a 50% reduction in IPA is seen, hence the need for twice 
daily dosing (Gurbel, Bliden et al. 2009). 
 
It has been proposed that the presence of ticagrelor within the systemic 
circulation in its directly acting form should allow for inhibition of these 
juvenille platelets also; such systemic exposure is not apparent with 
clopidogrel and prasugrel.  In view of this ticagrelor should not be limited by 
HRPR, since it should be able to inhibit older “established” activated platelets 
as well as newly formed platelets that appear in increased volumes in 
response to endovascular injury (Mathur, Robinson et al. 2001, Nylander and 
Schulz 2016).   
 
However, our pharmacodynamic data demonstrates that despite the 
pharmacokinetic and pharmacodynamic advantages of ticagrelor over 
clopidogrel and prasugrel, HRPR is still a limitation to its use in practice, 
particularly in the immediate period following administration in STEMI 
patients.  A possible reason for this may be attributable to the delay in 
gastrointestinal absorption that occurs in the setting of a STEMI, so even 
though ticagrelor is directly acting, the fact that its systemic exposure is reliant 
on GI absorption which is impaired in STEMI leads to a reduced antiplatelet 
effect.  Such that in the setting of a STEMI, ticagrelor’s onset of action is 
comparable to that of prasugrel and both are delayed by at least two to fours 
hours. 
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8.8 Conclusion 
Despite providing faster, greater and more consistent levels of platelet 
inhibition, in the setting of STEMI, prasugrel and ticagrelor are just as 
ineffective as clopidogrel and are still subject to HRPR within the first hour 
following administration of a loading dose.  The reported pharmacodynamic 
data indicates that prasugrel and ticagrelor take at least 4 hours to achieve 
effective levels of platelet inhibition.  As such, all oral P2Y12 inhibitors display 
a delayed and attenuated effect in the setting of STEMI.   
 
The narrow time frames from symptom onset and mechanical reperfusion 
coupled with the physiological changes that occur during a STEMI; reduced 
gastric motility and absorption, increase in intrinsic platelet reactivity in 
addition to the co-administration of opioid based analgesia, impose immediate 
barriers that significantly limit the clinical utility of orally administered P2Y12 
inhibitors in patients who present following a STEMI.  
 
In contrast, our NSTEMI patients display adequate if not excessive levels of 
platelet inhibition following the administration of prasugrel and ticagrelor.  
Clopidogrel despite the administration of a loading dose does not provide 
adequate levels of platelet inhibition during the study period. 
 
The results of this chapter demonstrate that the degree and time course of 
platelet inhibition is such that none of the orally administered P2Y12 inhibitors 
display an inadequate antiplatelet effect at the time of angioplasty and stent 
implantation in STEMI patients treated with PPCI.  When comparing STEMI to 
NSTEMI patients, both prasugrel and ticagrelor demonstrate an attenuated 
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antiplatelet effect in STEMI patients and clopidogrel displays a delayed onset 
of action in both groups.  Indicating that the disease state of STEMI does 
adversely impact on the onset of action and subsequent therapeutic effect of 
orally administered P2Y12 inhibitors. 
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Chapter 9 – Overall Summary and Conclusions 
 
 
The principle aim of this thesis was to provide insights into the 
pharmacokinetics and pharmacodynamics of orally administered P2Y12 
inhibitors during the acute phase of a myocardial infarction and to determine 
the degree to which the physiological state of a STEMI impacts on drug 
handling. 
 
In this chapter, the principal findings of my thesis will be discussed, with a 
particular focus on how they can be applied to influence and/or modify 
existing clinical practice, in addition to how they may act as a platform for 
future research projects. 
9.1 Summary of key findings 
The main findings of this thesis can be summarised as follows: 
1. Analysis of the STEMI antiplatelet registry indicates the use of 
prasugrel and ticagrelor is associated with a mortality benefit when 
compared with clopidogrel (p <0.001).  When comparing survival 
between prasugrel and ticagrelor, there is no statistically significant 
difference in outcome (p = 0.785).  However, when adjusted for 
confounders, no difference in survival outcomes between the three 
drugs was seen, indicating that irrespective of improved 
pharmacological profiles, in the context of AMI, the agent administered 
has no impact on mortality in the short-term in the study population. 
2. STEMI patients undergoing PPCI display sub-optimal levels of platelet 
inhibition following the administration of clopidogrel 600mg, prasugrel 
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60mg and ticagrelor 180mg loading doses at 20 minutes, at the time of 
angioplasty/balloon inflation and at 60 minutes as demonstrated by 
PRU > 230 and %PRI > 50%. 
3. The administration of prasugrel 60mg and ticagrelor 180mg loading 
doses in NSTEMI patients results in adequate if not optimal levels of 
platelet inhibition at all times. 
4. When comparing STEMI against NSTEMI, the state of STEMI 
adversely impacts on the pharmacodynamic profile of the oral P2Y12 
inhibitor antiplatelet agents administered as demonstrated by the 
significant differences in PRU values recorded.  The degree of platelet 
inhibition is far less in the STEMI cohort as evidenced by PRU and 
%PRI values in excess of 230 and 50% respectively, indicating that 
these patients remain at increased risk of experiencing thrombotic 
complications or further adverse cardiac events. 
5. When comparing the antiplatelet efficacy of prasugrel against 
ticagrelor, it is apparent that irrespective of disease state, there is no 
significant difference in the degree of platelet inhibition observed 
between the two agents following the administration of a loading dose.  
However, both prasugrel and ticagrelor are superior to clopidogrel. 
6. Gastrointestinal absorption appears to be a main contributor to and 
important determinant of the onset of action and clinically efficacy of 
the orally administered P2Y12 inhibitors.  Delays in gastric emptying 
and reduced absorption either secondary to the diversion of blood flow 
away from the gut or as a consequence of opioid administration, 
introduces significant delays and inter-individual variability in response 
 223 
to the effects of clopidogrel, prasugrel and ticagrelor in the context of 
STEMI. 
9.2 General Discussion 
 
The STEMI/PPCI pathway has been refined and standardised through audit 
and national benchmarking to such an extent that the timescales from 
symptom onset and diagnosis to reperfusion are now very short.  Whilst this 
leads to improved outcomes for the patient, it presents a number of 
challenges in ensuring the pharmacological management options utilised are 
effective; the reduced period of time from presentation to reperfusion reduces 
the time over which orally administered drugs can exert an optimal therapeutic 
effect. 
 
The improved pharmacokinetic and pharmacodynamic profiles supporting the 
large phase III studies behind prasugrel and ticagrelor apply data that were 
taken from healthy patients or those with SCAD. The work presented in this 
thesis has shown that these findings cannot be extrapolated and applied to 
STEMI patients; not only do the physiological changes that occur during a 
major heart attack impose inherent and immediate barriers to onset of action 
and clinical efficacy of oral P2Y12 inhibitors, the short time scales between 
presentation, administration of loading doses and mechanical reperfusion are 
too narrow to allow for a clinically meaningful antiplatelet effect to take place.   
The pharmacodynamic data reported in this thesis indicates a lack of 
antiplatelet effect for at least the first hour following administration of an oral 
loading dose of either clopidogrel, prasugrel or ticagrelor; the mean DTB in 
our centre for STEMI patients is 26.8 ±12.7 minutes.  As such the data 
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presented in this thesis clearly demonstrates inadequate levels of platelet 
inhibition at the time of angioplasty and coronary artery stent implantation.  
As well as being the first study to report a direct head to head comparison of 
all three oral P2Y12 inhibitors, this study is also unique in that it is the first to 
report a direct comparison of the degree and time course of platelet inhibition 
between STEMI and NSTEMI patients allowing us to quantify the extent by 
which the efficacy of orally administered antiplatelet agents is impaired by the 
physiological state of STEMI.  The results generated for the STEMI cohort 
directly correlate with those previously reported in which the majority of 
STEMI patients require at least 2 to 4 hours to achieve a sufficient degree of 
platelet inhibition following the administration or prasugrel and ticagrelor 
loading doses (Alexopoulos, Galati et al. 2012, Parodi, Valenti et al. 2013).  
The clopidogrel STEMI data indicates a delay in onset of action and reduced 
degree of platelet inhibition is also in line with previously reported works 
(Heestermans, van Werkum et al. 2008). 
The elevated baseline PRU and %PRI values seen in our STEMI group are 
indicative of high intrinsic platelet reactivity implying higher activation of 
platelets in STEMI patients even prior to the administration of an oral 
antiplatelet loading dose.  A direct pharmacodynamic comparison of baseline 
PRU values between the STEMI and NSTEMI groups demonstrates that a 
greater period of time is required for clopidogrel, prasugrel and ticagrelor to 
achieve sufficient levels of platelet inhibition in the context of STEMI.   This 
delay in the onset of action/lag time between administration to absorption 
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and/or metabolic activation contributes to the development of HRPR and lack 
of antiplatelet effect. 
The results of this thesis suggest that the majority of PPCI procedures were 
performed without functional levels of platelet inhibition.  In contrast to 
NSTEMI patients, there is a distinct and marked reduction in the PRU values 
observed for patients treated with prasugrel and ticagrelor.  From this we can 
surmise that the high prothrombotic milieu and physiological changes that 
occur during a STEMI are not present in NSTEMI patients.   
This is supported by the PRU values observed in our NSTEMI cohort; all 
patients demonstrate low levels of platelet reactivity as evidenced by PRU < 
208, indicating adequate and sufficient antiplatelet effects immediately 
following the administration of prasugrel/ticagrelor loading doses.    
This work has highlighted that the safety and efficacy of prasugrel and 
ticagrelor in NSTEMI patients is largely an underexplored area.  The study 
results demonstrate that when compared with STEMI patients, the NSTEMI 
cohort achieve adequate if not excessive levels of platelet inhibition, 
particularly if treated with the more potent prasugrel and ticagrelor.  Although 
this was not an outcome driven study, the recently published meta-analysis by 
Bavishi et al indicates an increased incidence of TIMI minor and major 
bleeding in patients who receive pre-treatment with prasugrel or ticagrelor 
(Bavishi, Panwar et al. 2015). 
Bleeding complications in ACS patients are associated with poor clinical 
outcomes and prognosis in both the short and long term (Becker and Gurbel 
2010).  The low PRU values observed following the administration of 
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prasugrel and ticagrelor loading doses at all time points in the our NSTEMI 
group can be seen as having a strong positive predictive value for bleeding 
complications in patients pretreated with oral P2Y12 inhibitors (Cuisset, 
Grosdidier et al. 2013).  Based on our results, it would therefore seem 
reasonable to suggest withholding the administration of oral antiplatelet 
loading doses in NSTEMI patients until coronary angiography is scheduled or 
until coronary anatomy is known post angiography.  This latter strategy was 
heavily criticised following the publication of TRITON-TIMI 38 since it was 
thought to disadvantage clopidogrel in view of its slower onset of action in 
comparison to prasugrel (Wiviott, Braunwald et al. 2007).  Furthermore, such 
an approach at that time was not reflective of UK practice in which all patients 
received antiplatelet loading doses upstream of any planned/emergency PCI.   
The timing of antiplatelet loading with an oral P2Y12 inhibitor is still under 
debate; pre-treatment with prasugrel in NSTEMI patients does not lead to a 
reduction in ischaemic complications, but is associated with a significant 
increase in bleeding risk (Montalescot, Collet et al. 2014).  The findings of 
ACCOAST-PCI prompted a change in national recommendations regarding 
the use of prasugrel in NSTEMI patients such that a loading dose should only 
be administered at the time of PCI if angiography is performed within 48 hours 
of admission. (NICE TAG 317 2014).  
Although, pre-hospital treatment with ticagrelor is associated with a reduction 
in stent thrombosis without any increase in bleeding complications, this 
benefit was observed in STEMI patients only (Montalescot and van 't Hof 
2014).  Study data from this work regarding the degree of platelet inhibition 
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achieved after the administration of ticagrelor loading doses in NSTEMI 
patients implies that the low PRU values observed will predispose patients to 
an increased risk of bleeding complications and as such would support the 
case to withhold administration in line with the recommendations for 
prasugrel. 
In summary, the pharmacodynamic data presented in this thesis indicates that 
despite treatment with prasugrel and ticagrelor STEMI patients demonstrate 
HRPR at the time of PPCI.  Increased platelet reactivity is known to adversely 
impact on angiographic success following PPCI.  The co-administration of 
intravenous antithrombotic therapies must therefore contribute to mitigating 
against peri-procedural thrombotic complications during this period of 
inadequate antiplatelet cover.   
In contrast, the effectiveness of oral antiplatelet loading in NSTEMI patients is 
not adversely affected by the limitations observed in STEMI patients. NSTEMI 
itself is not a highly prothrombotic state and does not stimulate an increase in 
platelet reactivity, nor is it associated with haemodynamic instability, the 
administration of catecholamines, significant adrenergic activation or the 
diversion of blood flow away from the gut/liver, all of which are attributable to 
the impaired effectiveness of orally administered antiplatelet agents observed 
in STEMI patients (Alexopoulos, Galati et al. 2012, Parodi, Valenti et al. 2013, 
Orban, Mayer et al. 2014). 
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9.2.1 Opioid based analgesia and antiplatelet drug interaction 
 
Opioid-based analgesia, in particular morphine/diamorphine is recommended 
for pain relief in STEMI patients (Parodi, Bellandi et al. 2015). Additional 
benefits include an anxiolytic effect, reduction the patient’s respiration rate 
and subsequent myocardial oxygen consumption in addition to vasodilatory 
effects leading to a reduction in afterload. 
Since the use of morphine is associated with increased mortality and poor 
outcomes in NSTEMI patients, it should be noted that NSTEMI patients are 
not pre-disposed to the potential drug-drug interaction between antiplatelet 
agents and opioid-based analgesia (Meine, Roe et al. 2005).  This interaction 
has recently been reported to be of clinical significance when assessed in 
both healthy subjects and STEMI patients (Hobl, Reiter et al. 2015, Parodi, 
Bellandi et al. 2015). Morphine as well as being highly emetogenic, is known 
to cause inhibition of the normal muscular activity of stomach and intestines, 
causing a reduction in peristalsis of the gut which delays gastric emptying and 
in turn delays antiplatelet drug absorption as shown by a reduction in IPA 
(PRU >230 and %PRI >50%) as demonstrated by the studies scrutinised as 
part of the systematic review in chapter 3 (Parodi, Valenti et al. 2013, Kubica, 
Adamski et al. 2015, Parodi, Bellandi et al. 2015). 
The deleterious effects of opioid administration on gastric absorption on the 
background of the physiological changes that occur during a STEMI have 
been discussed from as early as the 1980’s.  Kumana et al (1982), very 
eloquently summarise that the absorption and subsequent pharmacological 
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handling of orally administered drugs is altered and impaired during an acute 
MI. Pharmacokinetic and pharmacodynamic profiles are altered secondary 
gastrointestinal hypoperfusion, the presence of nausea and vomiting and the 
administration of opioid based analgesia such as morphine that can 
predispose to gastric stasis (Kumana, Rambihar et al. 1982)  This concept is 
further supported by Heestermans who demonstrated that physiological state 
of STEMI adversely influences intestinal absorption of orally administered 
clopidogrel (Heestermans, van Werkum et al. 2008). 
 
The importance of gastric emptying as a predictor of pharmacological efficacy 
and subsequent clinical outcomes is demonstrated by the reduction in IPA, 
presence of HRPR and increased PRU as seen in the pharmacodynamic data 
reported in chapters 5-8.  The systematic review in chapter 3 also highlights 
that morphine administration is an important contributing factor to the delays 
seen in achieving maximal levels of IPA.  For example, the adverse impact of 
morphine on ticagrelor pharmacodynamics was also highlighted during the 
ATLANTIC-PCI study.  Although a directly acting agent that does not require 
metabolic activation, the co-administration morphine in the ambulance leads 
to a delay in the onset of action of ticagrelor (Montalescot and van 't Hof 
2014). Thereby indicating that ticagrelor is still reliant on gastric absorption in 
order to exert its therapeutic effect.   
 
As such, the systematic review questions the administration of opioid based 
analgesia in the context of ACS, since its use has previously been associated 
with increased mortality in NSTEMI patients (Meine, Roe et al. 2005) and 
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more recently a delay in the onset of action for clopidogrel, prasugrel and 
ticagrelor when administered to patients in the setting of STEMI 
(Heestermans, van Werkum et al. 2008, Parodi, Bellandi et al. 2015) 
 
  
9.2.2 Alternative Treatment Options – antiplatelet therapy 
In summary, this work shows that, despite administration of clopidogrel, 
prasugrel and ticagrelor loading doses, a significant proportion of patients 
undergoing PPCI do not achieve optimal levels of platelet inhibition during the 
acute phase of presentation.  Gastrointestinal and hepatic hypoperfusion lead 
to impaired gastrointestinal absorption and subsequent delays in the 
metabolic conversion of clopidogrel and prasugrel.  Ticagrelor, a directly 
acting agent that does not require metabolic conversion to its active form, is 
dependent on gastrointesinal absorption and as such is also be subject to a 
delayed onset of action in STEMI patients.   Consequently, all three agents 
display sup-optimal levels of IPA in the context of STEMI patients who 
undergo PPCI. 
 
In the highly prothrombotic state encountered in the setting of STEMI, more 
rapid and profound platelet inhibition, as achieved by intravenous agents such 
as cangrelor, may be advantageous in patients undergoing PPCI.  
Intravenous cangrelor offers the ability to achieve optimal levels of IPA during 
the narrow door to balloon time window, while the ability to transition to oral 
prasugrel/ticagrelor will allow for the longer-term benefits that are derived from 
DAPT (Bhatt, Stone et al. 2013).  Cangrelor also has a rapid offset of action, 
which may be of value in certain patient subsets, for example those 
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undergoing surgery or with bleeding complications (Angiolillo, Firstenberg et 
al. 2012).   
 
While there are no head to head trials comparing the effectiveness of 
intravenous cangrelor with intravenous GPIs (abciximab, eptifibatide, 
tirofiban), both have proven efficacy in achieving rapid, high levels of platelet 
inhibition.   Previous guideline recommendations for the use of GPIs are 
based on data derived from clinical trials that precede recent pharmacological 
advances in oral antiplatelet therapies.  A number of studies have questioned 
the co-administration of GPIs in combination with the more potent oral 
antiplatelet agents, prasugrel and ticagrelor, particularly in view of the 
additional bleeding complications that can arise following such a combination 
(De Luca, Suryapranata et al. 2005, Mehilli, Kastrati et al. 2009).   A number 
of large-scale clinical trials have failed to demonstrate a significant clinical 
benefit following the administration to GPI +/- UFH in STEMI patients, such 
that even international guideline recommendations are unable to provide 
definitive endorsements regarding the utility of GPI in the era of potent oral 
P2Y12 inhibitors (Stone, Witzenbichler et al. 2008, Mehilli, Kastrati et al. 2009, 
Steg, James et al. 2012).  
 
 
 
Recent trial data has demonstrated that modifying the formulation of prasugrel 
and ticagrelor administered to STEMI patients provides earlier and more 
pronounced levels of platelet inhibition (Alexopoulos, Barampoutis et al. 2015, 
Parodi, Xanthopoulou et al. 2015, Rollini, Franchi et al. 2016).  The 
administration of crushed tablets dispersed in water (unlicensed use) rather 
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than intact film coated tablets allows for faster and enhanced drug absorption, 
particularly in the first hour following administration and results in higher 
plasma levels of prasugrel active metabolite in addition to ticagrelor and its 
active metabolite and consequently greater reduction in platelet reactivity 
(Alexopoulos, Barampoutis et al. 2015, Parodi, Xanthopoulou et al. 2015, 
Rollini, Franchi et al. 2016).   While modification of the dosage form 
represents an unlicensed, off-label use of prasugrel and ticagrelor, 
administration in such a manner often occurs as part of our routine clinical 
practice, for example in patients who are unconscious and/or intubated. The 
works of Rollini, Alexopoulos and Parodi provide some reassurance and 
demonstrate that crushing oral antiplatelets does not compromise their 
efficacy or lead to an increase in adverse effects e.g. stent thrombosis 
(Alexopoulos, Barampoutis et al. 2015, Parodi, Xanthopoulou et al. 2015, 
Rollini, Franchi et al. 2016).  
 
9.2.3 Alternative Treatment Options – analgesia 
 
The systematic review in this thesis and previous studies undertaken by 
Parodi, Hobl and Alexopoulos, show that the co-administration of opioid 
based analgesia with oral antiplatelet medications introduces a clinically 
significant drug-drug interaction which should not be overlooked (Alexopoulos 
2013, Parodi, Valenti et al. 2013, Hobl, Stimpfl et al. 2014, Hobl, Reiter et al. 
2015, Parodi, Bellandi et al. 2015).  While this study was not adequately 
powered to determine whether the administration of morphine has a 
significant impact on the rate at which orally administered P2Y12 inhibitors 
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undergo gastrointestinal absorption, there is a signal indicating a potential 
interaction is present. 
 
Although there is little evidence base to support the use of intravenous 
paracetamol in ACS patients, it does have a place in other cardiac settings 
e.g. post cardiac surgery, post-transcatheter aortic valve implantation and 
during renal denervation procedures.   Paracetamol is known to be opioid 
sparing, and evidence from other clinical settings has shown that intravenous 
paracetamol is comparable in terms of clinical efficacy and effectiveness to 
intravenous morphine (Remy, Marret et al. 2005, Cattabriga, Pacini et al. 
2007, Fassl, Walther et al. 2009).  As such, the administration of intravenous 
paracetamol in STEMI patients due to undergo PPCI may well be a possible 
avenue of investigation in future studies; providing comparable degrees of 
pain relief without contributing to further delays in gastric emptying and 
compromising the onset of action of orally administered medications. 
9.3 Limitations 
9.3.1 Antiplatelet registry  
The data included in the antiplatelet registry relates to STEMI patients only 
and as such a real world analysis of the use antiplatelet agents in all ACS 
patients cannot be made.  In addition, there are further statistical analyses, 
which will be undertaken to determine the true effect of antithrombotic 
therapies, both oral and intravenous on clinical outcomes.  Due to the 
timescales involved, much of this more complex work and analysis will be 
undertaken after submission of this thesis. 
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9.3.2 Pharmacokinetic and Pharmacodynamic comparisons of oral 
P2Y12 inhibitors; STEMI vs NSTEMI 
This was a pilot and not outcome/event driven study and is therefore not 
adequately powered to detect clinical outcomes.  Due to the small sample 
size, the clinical effect of morphine in STEMI patients cannot be determined.  
However, data and outcomes from recently published studies can be applied 
to our patient population to indicate that the co-administration of morphine has 
a deleterious effect on the pharmacodynamic profile of both prasugrel and 
ticagrelor impairing antiplatelet effectiveness in practice. 
The cohorts and patients recruited to each treatment arm are not equally 
matched in terms of their age and co-morbidities; licensing restrictions 
resulted in younger and heavier patients being recruited to the prasugrel arm, 
such patients will have a lower propensity for bleeding. 
A significant limitation to the reliability of the results produced in my thesis 
relate to the platelet function assays utilised and the LC-MS/MS analysis 
undertaken.  I have confidence in the VerifyNow results, since these were 
obtained using a point of care device within 15-30 minutes of sample 
collection.  However, third parties undertook the VASP-P and LC-MS/MS 
analyses, the former at the University of Wolverhampton and the latter in the 
clinical chemistry department at The Royal Wolverhampton Hospital. Since I 
am not skilled or trained in either technique, there was a necessity to rely on 
others to complete this work.  While the correct method was used to collect 
and prepare samples for analysis, the results obtained were very inconsistent 
and not in line with published literature.  The methodology utilised for VASP-P 
and LC-MS/MS is questionable, therefore this limits the reliability of the results 
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obtained and inferences that can be drawn from them.  In future studies, we 
will move to using VASP-FIX kits, which allow for the samples to be stored at -
80c for up to 6 months, rather than 48 hours, thereby facilitating batch 
analysis rather than the ad hoc analysis undertaken for our current study. 
In terms of the LC-MS/MS analysis, it is unlikely we will be able to undertake 
such an approach again in our own organisation. 
 
During the study baseline platelet reactivity was not determined for patients 
administered an oral P2Y12 inhibitor.  While a baseline sample would have 
been useful, the absence of one is neither detrimental nor critical to my data 
interpretation, since the principle aim of my work was to determine antiplatelet 
efficacy at the time of angioplasty and coronary artery stent implantation.  
However, if I were to conduct similar work in future, this is certainly a 
parameter that I would incorporate into my data collection. 
 
9.4 Future Research and Projects 
9.4.1 Antiplatelet registry  
9.4.1.1 Propensity Score Analysis 
 
The propensity score analysis as developed by Rosenbuam and Ruben in 
1983, can be used as a method by which we are able to minimise any bias 
that may be inadvertently introduced in the dataset, which is collated from 
non-randomised, retrospective observational data (Becker 2002, 
Spreeuwenberg, Bartak et al. 2010).  Since allocation of study participants to 
the treatment and control groups is not randomised, the presence of 
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confounding factors may influence the estimation of treatment effect (Becker 
2002).  To provide an unbiased review of observational “real-world” data 
collected regarding pre-defined outcomes following the administration of an 
oral P2Y12 inhibitor prior to PPCI a propensity score analysis will need to be 
undertaken.  The propensity score will allow for patient characteristics and 
other pre-specified confounder to be balanced between treatment groups, 
thereby allowing a direct comparison between equally weighted groups.  
 
9.4.2 Pharmacokinetic/Pharmacodynamic Study 
 
The pharmacokinetic/pharmacodynamic study undertaken has created a 
platform for further antiplatelet work in which a comparison of the efficacy of 
intravenous cangrelor against oral ticagrelor can be made.  Both agents are 
directly acting P2Y12 inhibitors that do not require metabolic 
biotransformation.  A direct pharmacodynamic comparison of IV vs PO 
administration will allow for us to determine degree of platelet inhibition prior 
to, during and up to 36 hours after PPCI between the two agents.  I am a co-
investigator in this study. 
There is also scope to undertake a prospective study comparing the efficacy 
of intravenous paracetamol against intravenous morphine/diamorphine. 
The antiplatelet registry provides an opportunity to undertake a number of 
retrospective observational analyses using the information contained within 
the database; management of out of hospital cardiac arrest patients, the effect 
of switching between antiplatelets on bleeding and outcomes, the effects of 
ethnicity, age and gender on call to balloon time and subsequent clinical 
outcomes.   
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9.5 Changes in clinical practice 
Since we are a tertiary referral cardiac centre for the Black Country, I am in 
the process of updating our antiplatelet prescribing protocols to reflect not 
only the findings of this study but also recently reported outcomes which 
advice against pre-treatment with the newer more potent P2Y12 inhibitors, 
prasugrel and ticagrelor in NSTEMI patients. 
The results of the IV Cangrelor vs PO Ticagrelor study will help to determine 
whether pre-treatment with prasugrel/ticagrelor in the context of STEMI is still 
necessary and will help to determine future prescribing protocols.  Since pre-
treatment with oral P2Y12 inhibitors is a contra-indication to the use of IV 
cangrelor; withholding pre-procedural loading doses will be a significant 
change in practice which goes against current national and international 
guideline recommendations. 
 
9.6 Conclusions 
Despite the administration of more potent P2Y12 inhibitors, in-hospital and 30 
day mortality in our STEMI group is not affected by the choice of agent 
administered.  Indicating that other factors affect the ability of oral antiplatelet 
agents to influence clinical outcomes. 
 
This study is the first to characterise and define the pharmacokinetic and 
pharmacodynamic profile of all three orally available P2Y12 inhibitors in a 
head to head manner in STEMI patients.   This study contributes to the 
mounting “real world data” that HRPR in the context of STEMI impairs the 
onset of action and clinical efficacy of even the newer more potent agents, 
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prasugrel and ticagrelor, such that even they are not effective at the time of 
PPCI. 
This study is the first to quantify the extent to which the disease state can 
affect the clinical efficacy and onset of action of prasugrel and ticagrelor in 
ACS patients.  The findings of the systematic review, in addition to the 
pharmacokinetic and pharmacodynamic data collated during during study 
highlight that interindividual variability in antiplatelet response is not a 
limitation that is restricted to just clopidogrel, but is manifest with all three 
orally administered P2Y12 inhibitors; the reasons being predominantly 
variability in the degree and extent of gastrointestinal absorption, since even 
directly acting agents (ticagrelor) that do not require metabolic activation, 
demonstrate a delay in onset of action in the context of STEMI. 
This research indicates that the degree and time course of platelet inhibition 
following the oral administration of clopidogrel, prasugrel and ticagrelor is 
highly variable and does not provide adequate levels of platelet inhibition that 
are required at the time of PPCI in STEMI patients 
 
9.7 Key messages 
- Despite providing faster, greater and more consistent degrees of 
inhibition of platelet activity (IPA), prasugrel and ticagrelor in the setting 
of STEMI are still subject to HRPR and take at least 2 to 4 hours to 
achieve effective levels of platelet inhibition. 
- The disease state of STEMI does contribute to an attenuated 
antiplatelet effect when comparing the efficacy of orally administered 
P2Y12 inhibitors between STEMI and NSTEMI patients. 
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- The administration of morphine impairs the gastrointestinal absorption 
of all three orally administered P2Y12 inhibitors with a consequent 
delay in their activity as demonstrated by a reduction in active 
metabolite generation and increased PRU and %PRI values following 
their co-administration in STEMI patients. 
- Modifying the formulation of the P2Y12 agent administered, either to a 
crushed tablet/liquid or as an intravenous agent allows for greater 
levels of platelet inhibition even in the context of STEMI and provides 
an opportunity to overcome the delay in onset of action seen following 
the administration of orally administered tablets. 
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10. Appendices 
 
Appendix 1.  Case report form – antiplatelet registry data collection 
 
Year  LVEF category  
Hospital ID  LVEF %  
NHS Number  DES (name)  
Patient surname  BMS (name)  
Patient first name  POBA  
Date and time of operation  Flow IRA (pre)  
DOB  Flow IRA (post)  
Age at presentation  PCI hospital outcome  
Sex  Status at discharge  
Ethnicity  LOS  
Diagnosis  In hospital mortality  
Clinical syndrome  30 day mortality  
Indication for intervention  1 year mortality  
Procedure urgency  DTB  
Cardiogenic shock (pre-
procedure) 
 CTB  
Admission route  PCI for ST  
Cardiac enzymes raised  Pre aspirin/dose  
Previous MI  Pre clopidogrel/dose  
Previous CABG  Pre prasugrel/dose  
Previous PCI  Pre ticagrelor/dose  
Height/Weight/BMI  Peri UFH  
Diabetes  Peri bivalirudin  
PVD  Peri abciximab  
CHD  Post clopidogrel  
Afib  Post prasugrel  
COPD/Asthma  Post ticagrelor  
VHD  Post BB/RLCCB  
Smoking status  Post ACEI/ARB  
FHx  Post statin  
Medical Hx  EF on discharge  
Hypercholesterolaemia  Epler/Spiro  
Tc on admission  Bleeding comp  
Hypertension  Transfusion  
SBP on admission  MACCE Death  
HR on admission  MACCE Stroke  
Hb on admission  MACCE MI  
Glucose on admission  OHCA  
Cr > 200microM    
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Appendix 2. Systematic review - Inclusion and Exclusion Criteria 
 
 Inclusion Criteria  Exclusion Criteria  
Populations PD/PK human studies (Phase 
II, III or dose finding studies) 
 PD/PK animal studies  
Adults > 18 years  Children < 18 years  
Adults < 70 years  Adults > 70 years 
(co-morbidities make DAPT 
difficult) 
 
Patients diagnosed 
with/recruited following an MI 
- STEMI 
- NSTEMI 
 Primary prevention or other non-
cardiac disease states 
 
Patients with unstable angina  Patients with chronic stable 
angina (stable coronary artery 
disease) 
 
Those who undergo elective PCI  
Those who are medically 
managed 
 
Doesn’t relate to inclusion criteria  
Interventions Primary PCI  Thrombolysis  
Antiplatelets -  Oral P2Y12 
inhibitors: Clopidogrel, 
Prasugrel, Ticagrelor 
Pre-procedural loading 
 
Intravenous antiplatelet 
agents:Cangrelor, 
eptifibatide, abciximab 
 
 Oral antiplatelets: 
Cilostazol, dipyridamole, 
ticlodipine 
 
Oral P2Y12 inhibitor 
(clopidogrel/prasugrel/ticagrelor) 
loading post-PCI 
 
 
 
 
Other medications 
administered at the time of 
PCI – morphine/diamorphine 
 
Comparators STEMI vs NSTEMI  Doesn’t relate to inclusion criteria 
 
Papers on HTPR with clopidogrel 
and clopidogrel 
pharmacogenomics. 
 
Drug handling - ADME  
Degree of IPA STEMI vs 
NSTEMI vs healthy volunteer 
 
Clopidogrel, prasugrel, 
ticagrelor, cangrelor 
 
In extremis vs healthy  
Outcomes %IPA    
 PRI    
 PRU    
 Adverse events (relate back 
to question) 
   
 Mortality (relate back to 
question) 
   
 Bleeding complications 
(relate back to question) 
   
Study Design RCTs  Abstracts  
 Comparative studies  Case reports  
 Placebo controlled studies    
 English only papers    
 
 242 
Appendix 3. Screening questions to assess the quality and 
appropriateness of the final articles selected for scrutiny prior to 
inclusion in the systematic review. 
 
 Yes Can’t tell No 
1. Does the study/paper relate back to the research question? 
(Is there a clear statement of the aims of the research/paper?) 
   
Population/problem?    
Intervention?    
Comparator/control?    
Outcomes? (is primary outcome identified?)    
RCT    
2. Was the population randomised? If yes, were the methods 
appropriate? 
   
Was allocation to a comparator/group concealed?    
Were the participants/investigators blinded to group 
allocation? 
   
Were interventions/comparators well described and 
appropriate? 
   
Were the groups similar at the start of the trial?    
Was the sample size sufficient?    
Were participants appropriately accounted for?    
Data analysis – appropriate?    
Results – were outcomes measures reliable and complete?    
Qualitative    
3. Was the qualitative methodology appropriate?    
4. Was the research strategy appropriate to the aims of the 
research? 
   
5. Was the recruitment strategy appropriate to the aims of the 
research? 
   
6. Was the data collected in a way that addressed the 
research issue? 
   
7. Have ethical issues been taken into consideration?    
8. Was the data analysis sufficiently rigorous?    
9. Is there a clear statement of findings?    
10. Are there any major limitations?    
11. How well does the paper/research relate back to your 
research question? 
 
 
 Yes/No Explanation 
Include   
 
 
 
 
Exclude   
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Appendix 4. Case Report Form STEMI 
 
 
 
 
CASE REPORT FORM 
 
Pharmacokinetics and Pharmacodynamics of Platelet P2Y12 Inhibitors in Patients 
Undergoing Percutaneous Coronary Intervention (PCI) for Acute Myocardial Infarction 
(P3-AMI): A Pilot Study 
 
 
 
 
 
 
2. ANALGESIA GIVEN 
Pain relieving agent given: 
 
Total (mg): 
 
Time of dose: 
 
 
3. P2Y12 AGENT DATA 
P2Y12 inhibitory agent given:  
Time of loading dose: 
Sampling time:  1  2  3  4  
 
 
 
 
 
 
1. DEMOGRAPHIC DATA 
Age (yrs):   Sex: Female  Male   
Height (m):          
Weight (Kg):          
Body Mass Index (BMI = Wt (kg)/H
2
 (M):          
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4. RISK FACTORS 
Treatment/Condition *Yes No Ex 
Diabetes    
Family history    
Hypertension    
Hyperlipidaemia    
Smoker    
Other    
 
 
5. PREVIOUS MEDICAL HISTORY 
Treatment/Condition *Yes No 
Myocardial infarction   
CABG   
PCI   
CVA/TIA   
 
 
 
 
 
6. CURRENT MEDICATION 
Medication 
Daily Dose  
Medication Daily Dose 
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7. ANGIOGRAPHIC/PPCI DATA 
Number of vessels diseased:   
Number of stents used:   
Drug eluting stents used:  Yes    No   
Total stent length (mm)     
 
 
 
8. POST PPCI RESULTS  9. POST PPCI ADVERSE EVENTS  
Result *Yes No Figure  Event *Yes No 
TIMI flow     ITU admission   
Slow flow/no reflow     Stroke   
ST-segment resolution     Revascularisation   
Balloon pump     Death   
     TIMI minor bleed   
     TIMI major bleed   
 
 
 
Completed by  
 
 
Name…………………………………. 
 
 
Signature……………………………... 
 
 
Date………………………………….. 
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Appendix 5. Case Report Form NSTEMI 
 
 
 
CASE REPORT FORM 
 
Pharmacokinetics and Pharmacodynamics of Platelet P2Y12 Inhibitors in Patients 
Undergoing Percutaneous Coronary Intervention (PCI) for Acute Myocardial Infarction 
(P3-AMI): A Pilot Study 
 
 
 
 
 
 
2. ANALGESIA GIVEN 
 
Pain relieving agent given: 
 
Total (mg): 
 
Time of dose: 
 
 
3. P2Y12 AGENT DATA 
P2Y12 inhibitory agent given:  
Time of loading dose: 
Sampling time:  1  2  3  4  
 
 
 
 
 
 
1. DEMOGRAPHIC DATA 
Age (yrs):    Sex: Female  Male   
Height (m):          
Weight (Kg):          
Body Mass Index (BMI = Wt (kg)/H
2
 (M):          
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4. RISK FACTORS 
Treatment/Condition *Yes No Ex 
Diabetes    
Family history    
Hypertension    
Hyperlipidaemia    
Smoker    
Other    
 
 
5. PREVIOUS MEDICAL HISTORY 
Treatment/Condition *Yes No 
Myocardial infarction   
CABG   
PCI   
CVA/TIA   
 
 
 
  
6. CURRENT MEDICATION 
Medication 
Daily Dose  
Medication Daily Dose 
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Completed by 
 
 
Name……………………………….. 
 
 
Signature…………………………… 
 
 
Date………………………………… 
  
7. ADVERSE EVENTS 
Event *Yes No N/A 
Angiography/PCI    
Stroke    
Death    
    
TIMI minor bleed    
TIMI major bleed    
 
 
 
 
249 
 
   VERIFYNOW P2Y12 RESULTS 
 
 
SAMPLE 1.       SAMPLE 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLE 3.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   VERIFYNOW ASPIRIN RESULTS 
 
 
SAMPLE 1.       SAMPLE 2. 
 
 
 
 
 
 
 
 
 
 
250 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLE 3.       
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   VERIFYNOW P2Y12 RESULTS 
 
 
SAMPLE 1.       SAMPLE 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLE 3.      SAMPLE 4. 
 
 
 
 
 
 
 
 
 
 
 
   VERIFYNOW ASPIRIN RESULTS 
 
 
SAMPLE 1.       SAMPLE 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLE 3.      SAMPLE 4. 
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Appendix 6. Process for sample collection from patients admitted following STEMI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient admitted with STEMI 
1
st
 blood sample (15ml) 
Verbal consent obtained  
from patient 
Treatment will continue 
in accordance with local 
and national guidelines 
Transfer patient to catheter suite for PPCI 
Group 1 Group 3 
Prasugrel 
60mg (po) 
Clopidogrel 
600mg (po) 
Sample 
collection 
20 minutes post 
loading 
2
nd
 blood sample (15ml) 
3
rd
 blood sample (15ml) 
Transfer patient to cardiology 
ward 
Written consent obtained from 
patient 
60 minutes post 
loading dose 
Yes 
No 
No 
At first balloon 
inflation 
Each blood sample will be analysed using VerifyNow, 
Flow Cytometry using VASP phosphorylation and 
Liquid Chromotography with Mass Spectometry 
1
st
, 2
nd
 and 3
rd
 samples will be discarded and the  
data will not be used for analysis.  Treatment will 
continue unchanged. 
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Appendix 7. Process for sample collection from patients admitted following NSTEMI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
st
 blood sample (15ml) 
Written consent obtained  
from patient 
Treatment will  
continue in 
accordance with 
local and  
national guidelines 
Group 2 Group 4 
Prasugrel 
60mg (po) 
Clopidogrel 
600mg (po) 
Sample 
collection 
20 minutes post 
loading 
2
Nd
 blood sample (15ml) 
3
rd
 blood sample (15ml) 
60 minutes post 
loading dose 
4 hours post 
loading dose 
Each blood sample will be analysed using VerifyNow, 
Flow Cytometry using VASP phosphorylation and 
Liquid Chromotography with Mass Spectometry 
Yes 
No 
Patient admitted with NSTEMI 
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Appendix 8. Following approval of substantial amendment – process for sample 
collection from patients admitted following a STEMI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient admitted with STEMI 
1
st
 blood sample (15ml) 
Verbal consent obtained  
from patient 
Treatment will continue 
in accordance with local 
and national guidelines 
Transfer patient to catheter suite for PPCI 
Group 5 
Ticagrelor 
180mg (po) 
Sample 
collection 
20 minutes post 
loading 
2
nd
 blood sample (15ml) 
3
rd
 blood sample (15ml) 
Transfer patient to cardiology 
ward 
Written consent obtained from 
patient 
4
th
 blood sample (15ml) 
60 minutes post 
loading dose 
4 hours post 
loading dose 
1
st
, 2
nd
 and 3
rd
 samples will  
be  discarded and the data will not 
be used for analysis.  Treatment will 
continue  unchanged. 
Each blood sample will be analysed using VerifyNow, 
Flow Cytometry using VASP phosphorylation and 
Liquid Chromotography with Mass Spectometry 
Yes 
Yes 
No 
No 
At first balloon 
inflation 
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Appendix 9. Following approval of substantial amendment - process for sample 
collection from patients admitted following a NSTEM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient admitted with NSTEMI 
1
st
 blood sample (15ml) 
Written consent obtained  
from patient 
Treatment will continue 
in accordance with local 
and national guidelines 
Group 2 Group 6 
Prasugrel 
60mg (po) 
Ticagrelor 
180mg (po) 
Sample 
collection 
20 minutes post 
loading 
2
nd
 blood sample (15ml) 
3
rd
 blood sample (15ml) 
60 minutes post 
loading dose 
4 hours post 
loading dose 
Each blood sample will be analysed using VerifyNow, 
Flow Cytometry using VASP phosphorylation and 
Liquid Chromotography with Mass Spectometry 
Yes 
No 
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Appendix 10 – Shortened Patient Information Sheet to obtain verbal assent STEMI 
 
   Patient information sheet 
 
Pharmacokinetics and Pharmacodynamics of Platelet P2Y12 Inhibitors in 
Patients Undergoing Percutaneous Coronary Intervention (PCI) for Acute 
Myocardial Infarction:  
A Pilot Study 
To be read to the patient to gain verbal consent prior to primary angioplasty 
You doctor will have explained that you are having a heart attack and require an emergency 
angioplasty procedure. As part of this procedure you will receive tablets to prevent your blood 
from clotting as per current guidelines. 
 We are inviting you to be part of a research study looking at how well these tablets work 
during and shortly after your angioplasty procedure. The study does not require a change in 
your medical treatment, but we will take extra blood samples after 20 minutes, during the 
angioplasty procedure, after 60 minutes, and again 4 hours after taking your tablets. Each 
sample will be approximately 3 teaspoons of blood which will not harm your health. If you are 
happy to take part in this study we will give written information after your procedure when you 
are feeling better, and will ask for your written consent. Your treatment will not be affected 
should you choose to take part in the study or not.   
Thank you for considering this trial. 
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Appendix 11. Patient Information Sheet STEMI 
 
 
Patient information sheet (STEMI) 
 
Pharmacokinetics and Pharmacodynamics of Platelet P2Y12 Inhibitors in 
Patients Undergoing Percutaneous Coronary Intervention (PCI) for Acute 
Myocardial Infarction:  
A Pilot Study 
You have been previously invited to take part in this research study. Before you decide whether you would like to 
continue your participation it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it with others if you wish. Please 
do not hesitate to ask if there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part.    
 
Thank you for reading this. 
 
 
Background 
 
Major heart attacks are caused by a number of factors. The two main causes are furring up of a coronary artery 
and sudden clot formation in this area leading to a blockage and subsequent interruption of blood flow. The clots 
that lead to heart attacks are largely made of clotting blood cells (platelets) which, in health are involved in 
stopping bleeding and the repair damaged blood vessels. When a patient is admitted with a major heart attack, 
they are first treated medically with aspirin and one of three anti-platelet agents called clopidogrel, prasugrel, and 
ticagrelor which are taken in tablet form. The combination of aspirin and one of the three anti-platelet agents 
named above will help to make the platelets less “sticky”. Patients are then transferred to a catheter suite where 
they undergo emergency primary percutaneous coronary intervention (PPCI), a technique where a wire and 
balloon are used to reopen the blocked coronary artery and then usually a slotted metal tube or stent is placed to 
keep the artery open. You have already undergone this procedure. 
 
In a healthy stable patient, it can take up to 2 hours for an anti-platelet agent to develop its full effect. Often the 
angioplasty procedure is performed urgently, well within this timescale. Furthermore patients who are having a 
heart attack may not have normal drug absorption with blood being diverted away from the stomach and gut 
activity being suppressed by other drugs such as morphine.  
This research proposes to look at whether having a major heart attack affects the absorption and activity of these 
three anti-platelet agents and to determine which agent takes effect and works most quickly.  
 
Why me? 
 
You have been chosen because you have been admitted to the hospital after suffering a major heart attack and 
have been treated with aspirin and the anti-platelet agent ticagrelor. 
 
 
Do I have to take part? 
 
You have previously given verbal consent to inclusion in the trial; we will also require written consent from you. It 
is entirely up to you to decide whether or not to take part. If you decide to take part you are still free to withdraw at 
any time and without giving a reason. If you now decline to be in the study we will destroy your blood samples that 
have been taken and not use any of your data in the trial. 
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What is involved in the study? 
 
At this stage of the study we will require one further blood sample 4 hours following your first dose. The quantity of 
blood taken from each sample time is 15 ml (approx. 3 teaspoons in volume). A variety of tests will be used to 
check the activity of the anti-platelet agent including measuring the concentration of the active component in the 
blood. Thus this study will allow us to determine if the anti-platelet agent you have been administered is working 
adequately during the procedure, given the very short timescales involved. You will exit the study after the 4 hour 
blood test and will have no on-going commitment to the trial 
 
 
What are the benefits of taking part? 
 
Although you will not directly benefit from taking part in this study, the information gained from the study should 
help us to understand if the anti-platelet agent you have been administered is the best treatment for future 
patients and indeed whether these agents are working at the time of emergency angioplasty. As part of the study 
your care will be closely scrutinised.  
 
 
What are known risks of the study or the side effects? 
 
It is unlikely you will suffer any detrimental effects if you continue with your participation in the study at this stage. 
The one extra blood sample to be taken may require 1 extra needle prick; therefore there is a possibility of 
bruising. We will however endeavour to keep the bruising to a minimum. There are no significant risks associated 
with participation in the trial. Ticagrelor is licenced to be used as part of the routine treatment for people with your 
condition. Ticagrelor can be associated with bleeding complications when compared to the standard anti-platelet 
clopidogrel. Conversely there is evidence of better clinical outcomes with ticagrelor when compared to clopidogrel. 
 
 
 
 
Confidentiality 
 
All information about you that is collected during the course of this research will be kept strictly confidential. Your 
medical notes will need to be seen by members of the research team so they can collect information about you 
needed for this research study. The confidentiality of your medical notes will be respected at all times. 
 
Each participant will be allocated a study code, which will be known only to the researcher. All personal and 
medical details will be stored in accordance with the Data Protection Act (1998). All data will be kept on an 
encrypted, and password protected computerised storage system.  
 
 
What will happen to the results of the research study? 
 
This study is being carried out as part of an on-going program of research working towards better outcomes for 
patients. The results of this study will be submitted to medical journals for peer review and publication or 
presented at meetings. Again your identity will not be disclosed. Each patient should they wish will receive a 
feedback sheet which will summarise the results of the study; however individualised results will not be available.  
 
 
What if there is a problem?   
 
If you have any concerns about any aspect of the study you should speak to the investigator who will do his/her 
best to answer your questions. If you remain unhappy and wish to make a formal complaint please contact the 
Patient Advisory and Liaison Service on 01902 696362. 
 
Who reviewed and approved this study? 
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This study was reviewed by the Coventry and Warwickshire Research Ethics Committee who gave 
approval for the research team to conduct this study. 
 
 
Contact for further information 
 
Research Team: 
Principal Investigator: Dr James M. Cotton, Consultant Cardiologist. 
Tel:    
 
Co-Investigators: Ms Nazish Khan, Principal Pharmacist Cardiac Services 
Tel:  Bleep    
Dr Vincent Amoah, Cardiology Research Fellow 
Tel:  ext  
 
Thank you again for reading this leaflet and considering taking part in this study 
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Appendix 12. Patient Information Sheet NSTEMI                           
 
Patient information sheet (NSTEMI) 
 
Pharmacokinetics and Pharmacodynamics of Platelet P2Y12 Inhibitors in 
Patients Undergoing Percutaneous Coronary Intervention (PCI) for Acute 
Myocardial Infarction:  
A Pilot Study 
You are being invited to take part in a research study. Before you decide it is important for you to understand why 
the research is being done and what it will involve. Please take time to read the following information carefully and 
discuss it with others if you wish. Please do not hesitate to ask me if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you wish to take part.    
 
Thank you for reading this. 
 
 
Background 
 
Heart attacks are caused by a number of factors, the main two of which are furring up of a coronary artery and 
sudden clot formation on this area leading to a blockage and interruption of blood flow to the heart muscle. The 
clots that lead to heart attacks are largely made of clotting blood cells (platelets) which, in health, are involved in 
stopping bleeding and the repair damaged blood vessels. When a patient is admitted with a major heart attack, 
they are first treated medically with aspirin and one of three anti-platelet agents called clopidogrel, prasugrel, and 
ticagrelor which are taken in tablet form. The combination of aspirin and one of the three anti-platelet agents 
named above will help to make the platelets less “sticky”. Patients are then transferred to a catheter suite where 
they undergo a coronary angiogram and where possible an angioplasty technique, during which a wire and 
balloon are used to reopen the blocked coronary artery and then usually a slotted metal tube or stent, is placed to 
keep the artery open.  
 
In a healthy stable patient, it takes up to 2 hours for an anti-platelet agent to develop its full effect. In heart attack 
patients, often the angioplasty procedure is performed urgently well within this timescale. Furthermore patients 
who are having a heart attack may not have normal drug absorption with blood being diverted away from the 
stomach and gut activity being suppressed by other drugs such as morphine.  
 
 
Why me? 
 
You have been chosen because you have been admitted to the hospital after suffering an episode of severe 
angina or heart attack and are going to be treated with aspirin and one of two anti-platelet agents (prasugrel, or 
ticagrelor). You do not need emergency angiography and angioplasty but you do need aspirin plus an anti-platelet 
agent. We would like to study how the anti-platelet agent you have been administered affects your platelets 
compared to patients having a severe heart attack that requires more urgent treatment.  We anticipate that you 
will have your coronary angiogram investigation on the same day as taking part in the trial ( ie today). 
  
 
Do I have to take part? 
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It is entirely up to you to decide whether or not to take part. If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. If you decide to take part you are still free to 
withdraw at any time and without giving a reason. .  
 
 
 
What is involved in the study? 
 
If you decide to take part in this study you will be asked to provide consent. Following this we will gather some 
clinical information about you and take some of your blood at 20 and 60 minutes after dosing, and again at 4 
hours post dosing. The quantity of blood taken from each sampling time will be 15 ml (approx. 3 teaspoons in 
volume). A variety of tests will be used to check the activity of the anti-platelet agents including measuring the 
concentration of the active component in the blood. Thus this study will allow us to determine if the anti-platelet 
agent you have been administered is working adequately given the very short timescale required when treating 
heart attack patients. On the day of admission you may receive treatment with prasugrel or ticagrelor. If you are 
treated with prasugrel we may decide to switch to clopidogrel. This switch will be made for clinical reasons only 
and will not affect the care that you receive nor should it affect your recovery. You will exit the study after the 4 
hour blood test and will have no on-going commitment to the trial. 
 
 
What are the benefits of taking part? 
 
Although you will not directly benefit from taking part in this study, the information gained from the study should 
help us to understand which agent is the best treatment for future patients. As part of the study your care will be 
closely scrutinised.  
 
 
What are known risks of the study or the side effects? 
 
It is unlikely you will suffer any detrimental effects if you enter the study as it only involves small changes in your 
routine care. The three extra blood samples to be taken after your anti-platelet treatment may require 3 extra 
needle pricks; therefore there is a possibility of bruising and slight discomfort. We will however endeavour to keep 
the discomfort to a minimum. All three anti-platelet agents are used as part of routine care for people with your 
condition.  
Prasugrel is licenced for use in patients with your condition. Currently we use this agent in certain groups 
only in place of clopidogrel. If we treat you with prasugrel as part of the trial, we may then switch you back to 
clopidogrel if this is the hospital’s standard anti-platelet agent for you. 
Prasugrel is associated with reduced angina and heart attacks in patients with your condition (which is good), it is 
also associated with an increase in major (including fatal) bleeding. In clinical trials these major bleeds almost 
always occurred in the late follow up phase (weeks or months) and therefore if you are treated initially with this 
agent as part of the trial it is very unlikely that you will suffer from this complication any more than if you were 
treated initially with clopidogrel. 
 
 
Confidentiality 
 
All information about you that is collected during the course of this research will be kept strictly confidential. Your 
medical notes will need to be seen by members of the research team so they can collect information about you 
needed for this research study. The confidentiality of your medical notes will be respected at all times. 
 
Each participant will be allocated a study code, which will be known only to the researcher. All personal and 
medical details will be stored in accordance with the Data Protection Act (1998). All data will be kept on an 
encrypted, and password protected computerised storage system.  
 
 
What will happen to the results of the research study? 
 
This study is being carried out as part of an on-going program of research working towards better outcomes for 
patients. The results of this study will be submitted to medical journals for peer review and publication or 
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presented at meetings. Again your identity will not be disclosed. Each patient should they wish will receive a 
feedback sheet which will summarise the results of the study; however individualised results will not be available.  
 
 
Who reviewed and approved this study? 
 
This study was reviewed by the Coventry and Warwickshire Research Ethics Committee who gave 
approval for the research team to conduct this study. 
 
 
Contact for further information 
 
Research Team: 
Principal Investigator: Dr James M. Cotton, Consultant Cardiologist 
Tel:    
Co-Investigators:  Ms Nazish Khan, Principal Pharmacist Cardiac Services 
Tel:  Bleep  
Dr Vincent Amoah, Cardiology Research Fellow 
Tel:  Bleep  
 
Thank you again for reading this leaflet and considering taking part in this study 
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Appendix 13. Consent form 
  
Consent form 
Study Title 
 
Pharmacokinetics and Pharmacodynamics of Platelet P2Y12 Inhibitors in Patients Undergoing 
Percutaneous Coronary Intervention (PCI) for Acute Myocardial Infarction: 
A Pilot Study 
Name of Principal Investigator: Dr James M. Cotton 
Tele.   (Secretary)   
E-mail.     
         Please initial box 
1. I confirm that I have read and understand the information sheet 
 dated…………     (version ………) for the above study and have had the 
 opportunity to ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
 withdraw at any time; without giving a reason, without effecting my 
 treatment or my legal rights. 
 
3. I understand that relevant sections of my medical notes and data collected during  
the study, may be looked at by authorised members of research team at New 
 cross hospital, from regulatory authorities or from the NHS trust, where it is 
 relevant to my taking in his research. I give permission for these individuals 
 to have access to my records.  
 
4. I understand that the project using the samples I give will include a variety 
 of test aimed at understanding the effect of a major heart attack on the 
 digestive system and if this influences the absorption and activity of platelet 
 inhibitory agents. I also understand the results of these investigations are  
unlikely to have any implications for me personally at this time.  
 
5. I agree that samples I have given and the information gathered about me can 
be stored and possibly used for future projects in cardiovascular medicine, if 
these projects are approved by the local research ethics committee. 
 
6. I understand that I will not benefit financially if this research leads to the 
development of a new treatment or medical test. 
 
7. I agree to take part in the above study. 
     Thank you for agreeing to participate in this research 
 
Name of patient  Date  Signature 
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Name of person taking consent  
(if different from researcher) 
 Date  Signature 
 
Each individual who signs this document must PERSONALLY date his or her signature. 
 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical notes  
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Appendix 15. Research Ethics Committee Approval Letter 2015 
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Appendix 16. Presentations, Publications and Abstracts 
 
The work included in this thesis has been presented at an international 
meeting.  I have also been invited to present on antiplatelet/antithrombotic 
therapies at local, regional and national meetings. 
Appendix 16.1 Presentations 
Title  Forum Month/Year 
An update of the new NICE Atrial 
Fibrillation Guidelines 2014 
 
UKCPA – Cardiac Group 
Introduction to Cardiology 
September 
2014 
Advances in Cardiac Disease 
Management 
 
Association of Pharmacy 
Technicians UK  
May 2014 
Variations in ACS Management in the 
UK 
 
Interventional Cardiology 
Pharmacists Group 
December 
2013 
Anti-platelet Therapies – An Update Midlands Cardiothoracic Nurse 
Practitioner Forum 
November 
2013 
Management of Acute Coronary 
Syndromes 
 
UKCPA – Cardiac Group 
Introduction to Cardiology 
September 
2013 
Advances in Anti-platelet Therapy Society of Cardiothoracic 
Surgeons – Annual Conference 
 
March 2013 
 
Appendix 16.2 Publications arising from this thesis 
The work from this thesis has resulted in the following publications: 
 
Khan N and Cox A.  Advances in Antiplatelet Therapies.  BJ Clin Pharm (2014);Jul:1–5 
 
Khan N. Advances in Cardiac Disease Management.  The Journal of the Association 
of Pharmacy Technicians UK (2014) 
 
Khan N.  Developments and risk analysis in anticoagulation.  British Journal of Cardiac 
Nursing (2015) DOI: http://dx.doi.org/10.12968/bjca.2015.10.2.66  
 
Khan N.  Risks and benefits of antiplatelet therapies.  British Journal of Cardiac 
Nursing (2015)  DOI: http://dx.doi.org/10.12968/bjca.2015.10.5.236 
 
Khan N, Cox AR, Cotton J. Pharmacokinetics and pharmacodynamics of oral P2Y12 
 
 
 
 
 
 
276 
inhibitors during the acute phase of a myocardial infarction: A systematic review. 
PROSPERO (2015): CRD42015023393. Available to view via:  
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015023393 
  
Khan N, Cox AR, Cotton J. Pharmacokinetics and pharmacodynamics of oral P2Y12 
inhibitors during the acute phase of a myocardial infarction: A systematic review.  
Thrombosis Research (2016) DOI: 10.1016/j.thromres.2016.05.019 
Appendix 16.3 Abstracts presented following collation of results 
The results and outcomes from chapters 5 to 8 have been presented at a 
national cardiovascular meeting:  
 
British Cardiovascular Society Annual Conference – June 2016 
 
The degree and time course of platelet inhibition following the administration of 
oral antiplatelet agents in patients presenting with ST-elevation MI. 
 
Khan N1, Amoah A1, Wrigley B1, Munir S1, Khogali S1, Martins J1, Smallwood A1, Vickers 
J2, Nevill AM2, Cotton J1 
Department of Cardiology, The Heart and Lung Centre, The Royal Wolverhampton 
Hospitals NHS Trust, UK1, School of Applied Science, Research Institute for Healthcare 
Science, University of Wolverhampton, UK2 
 
 
British Cardiovascular Society Annual Conference – June 2016 
 
Marked differences in the pharmacodynamics of modern P2Y12 inhibitors in 
patients undergoing treatment for ST segment elevation Myocardial infarction and 
Non ST segment Elevation MI. 
 
Amoah A1, Khan N1, Wrigley B1, Munir S1, Khogali S1, Martins J1, Smallwood A1, Vickers 
J2, Nevill AM2, Cotton J1 
Department of Cardiology, The Heart and Lung Centre, The Royal Wolverhampton 
Hospitals NHS Trust, UK1,  School of Applied Science, Research Institute for Healthcare 
Science, University of Wolverhampton, UK2 
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Appendix 16.4 Work in Progress -  publications in preparation: 
 
 
Khan N, Nightingale P, Newman C, Buckingham M, Nevill AM, Chen R, Cotton J. 
   
Oral P2Y12 Inhibitors Administration and Outcomes in STEMI patients 
Undergoing PPCI -  A Single Tertiary Centre Retrospective Observational 
Analysis. 
 
Amoah A, Khan N, Wrigley B, Munir S, Khogali S, Smallwood A, Vickers J, Nevill AM, 
Cotton J. 
 
Marked heterogeneity in the pharmacodynamics of modern P2Y12 inhibitors 
depending on acute coronary syndrome presentation. 
 
Khan N, Amoah A, Wrigley B, Munir S, Khogali S, Martins J, Smallwood A, Nevill AM, 
Cotton J. 
 
The degree and time course of platelet inhibition following the administration of oral 
antiplatelet agents in patients presenting with ST-elevation MI. 
 
Khan N, Amoah A, Wrigley B, Munir S, Khogali S, Smallwood A, Cornes M, Nevill AM, 
Cotton J. 
 
Gastrointestinal absorption as an important determinant of the onset of action and clinical 
efficacy of ticagrelor. 
 
Khan N, Nightingale P, Newman C, Buckingham M, Cotton J. 
 
The impact of ethnicity, age and gender on call to balloon times and subsequent clinical 
outcomes. 
Khan N, Nightingale P, Newman C, Buckingham M, Cotton J. 
 
A single centre retrospective observational review of the antiplatelet strategies utlised in 
patients who present following an out of hospital cardiac arrest; patterns of use and 
clinical outcomes. 
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